Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 115
Encontrada(s) 2 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Scheeren Brum, Wagner|||0000-0002-9777-0559
  • Molfetta, Guglielmo Di
  • Benedet, Andréa Lessa
  • Arslan, Burak
  • Jonaitis, Erin Mc Mullen
  • Langhough, Rebecca E.
  • Cody, Karly Alex
  • Wilson, Rachael E.
  • Carlsson, Cynthia M.
  • Vanmechelen, Eugeen|||0000-0002-9466-5366
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Rahmouni, Nesrine
  • Tissot, Cécile
  • Stevenson, Jenna
  • Servaes, Stijn|||0000-0002-4431-957X
  • Therriault, Joseph
  • Pascoal, Tharick|||0000-0001-9057-8014
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Johnson, Sterling C.
  • Jeromin, Andreas
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
IMPORTANCE Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests. OBJECTIVE To determine the utility of a novel and commercially available immunoassay for plasma p-tau217 to detect AD pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across 3 selected cohorts. DESIGN, SETTING, AND PARTICIPANTS This cohort study examined data from 3 single-center observational cohorts: cross-sectional and longitudinal data from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (visits October 2017-August 2021) and Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort (visits February 2007-November 2020) and cross-sectional data from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort (baseline visits March 2009-November 2021). Participants included individuals with and without cognitive impairment grouped by amyloid and tau (AT) status using PET or CSF biomarkers. Data were analyzed from February to June 2023. EXPOSURES Magnetic resonance imaging, Aβ positron emission tomography (PET), tau PET, cerebrospinal fluid (CSF) biomarkers (Aβ42/40 and p-tau immunoassays), and plasma p-tau217 (ALZpath pTau217 assay). MAIN OUTCOMES AND MEASURES Accuracy of plasma p-tau217 in detecting abnormal amyloid and tau pathology, longitudinal p-tau217 change according to baseline pathology status. RESULTS The study included 786 participants (mean [SD] age, 66.3 [9.7] years; 504 females [64.1%] and 282 males [35.9%]). High accuracy was observed in identifying elevated Aβ (area under the curve [AUC], 0.92-0.96; 95% CI, 0.89-0.99) and tau pathology (AUC, 0.93-0.97; 95% CI, 0.84-0.99) across all cohorts. These accuracies were comparable with CSF biomarkers in determining abnormal PET signal. The detection of abnormal Aβ pathology using a 3-range reference yielded reproducible results and reduced confirmatory testing by approximately 80%. Longitudinally, plasma p-tau217 values showed an annual increase only in Aβ-positive individuals, with the highest increase observed in those with tau positivity. CONCLUSIONS AND RELEVANCE This study found that a commercially available plasma p-tau217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the preclinical stage.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multiple health behaviour change primary care intervention for smoking cessation, physical activity and healthy diet in adults 45 to 75 years old (EIRA study), a hybrid effectiveness-implementation cluster randomised trial

  • Zabaleta del Olmo, Edurne|||0000-0002-5072-8548
  • Casajuana Closas, Marc|||0000-0001-5653-996X
  • López Jiménez, Tomàs|||0000-0001-8255-4936
  • Pombo, Haizea
  • Pons-Vigués, Mariona|||0000-0002-7929-3701
  • Pujol Ribera, Enriqueta|||0000-0002-9475-0755
  • Cabezas Peña, Carmen|||0000-0002-4291-0454
  • Llobera, Joan
  • Martí-Lluch, Ruth|||0000-0002-7320-9521
  • Vicens, Caterina
  • Motrico, Emma|||0000-0002-0720-567X
  • Gómez-Gómez, Irene|||0000-0001-8014-6955
  • Maderuelo-Fernandez, Jose-Angel|||0000-0001-7544-8684
  • Recio Rodríguez, José I.|||0000-0002-3772-8746
  • Masluk, Barbara
  • Contreras-Martos, Sara
  • Jacques-Aviñó, Constanza|||0000-0001-8506-780X
  • Aznar-Lou, Ignacio|||0000-0002-6780-5968
  • Gil-Girbau, Montserrat|||0000-0002-4396-6492
  • Clavería, Ana|||0000-0001-9552-1260
  • Magallon Botaya, Rosa|||0000-0002-5494-6550
  • Bellón Saameño, Juan Ángel|||0000-0002-4268-4979
  • Ramos, Rafel|||0000-0001-7970-5537
  • Sánchez Pérez, Álvaro
  • Moreno-Peral, Patricia|||0000-0003-4130-9090
  • Leiva, Alfonso|||0000-0001-5306-8533
  • González-Formoso, Clara
  • Bolíbar, Bonaventura|||0000-0003-4653-9805
This study aimed to evaluate the effectiveness of a) a Multiple Health Behaviour Change (MHBC) intervention on reducing smoking, increasing physical activity and adherence to a Mediterranean dietary pattern in people aged 45-75 years compared to usual care; and b) an implementation strategy. A cluster randomised effectiveness-implementation hybrid trial-type 2 with two parallel groups was conducted in 25 Spanish Primary Health Care (PHC) centres (3062 participants): 12 centres (1481 participants) were randomised to the intervention and 13 (1581 participants) to the control group (usual care). The intervention was based on the Transtheoretical Model and focused on all target behaviours using individual, group and community approaches. PHC professionals made it during routine care. The implementation strategy was based on the Consolidated Framework for Implementation Research (CFIR). Data were analysed using generalised linear mixed models, accounting for clustering. A mixed-methods data analysis was used to evaluate implementation outcomes (adoption, acceptability, appropriateness, feasibility and fidelity) and determinants of implementation success. 14.5% of participants in the intervention group and 8.9% in the usual care group showed a positive change in two or all the target behaviours. Intervention was more effective in promoting dietary behaviour change (31.9% vs 21.4%). The overall adoption rate by professionals was 48.7%. Early and final appropriateness were perceived by professionals as moderate. Early acceptability was high, whereas final acceptability was only moderate. Initial and final acceptability as perceived by the participants was high, and appropriateness moderate. Consent and recruitment rates were 82.0% and 65.5%, respectively, intervention uptake was 89.5% and completion rate 74.7%. The global value of the percentage of approaches with fidelity ≥50% was 16.7%. Eight CFIR constructs distinguished between high and low implementation, five corresponding to the Inner Setting domain. Compared to usual care, the EIRA intervention was more effective in promoting MHBC and dietary behaviour change. Implementation outcomes were satisfactory except for the fidelity to the planned intervention, which was low. The organisational and structural contexts of the centres proved to be significant determinants of implementation effectiveness. , . Registered 2 May 2017, "retrospectively registered". The online version contains supplementary material available at 10.1186/s12889-021-11982-4.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown. We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A+) or negative (A-) according to CSF Aβ/Aβ ratio. Plasma pTau, pTau, Aβ and Aβ were measured in the fully-automated LUMIPULSE platform. We used linear regression to compare plasma biomarkers concentrations between A + and A- groups, evaluated Spearman's correlation between plasma and CSF and performed ROC analyses to assess their diagnostic accuracy to detect brain amyloidosis as determined by CSF Aβ/Aβ ratio. We analyzed the potential of pTau to predict amyloidosis in CSF. Plasma pTau and pTau concentration were higher in A + than A- while the plasma Aβ/Aβ ratio was lower in A + compared to A-. pTau and the Aβ/Aβ ratio showed moderate correlation between plasma and CSF (Rho = 0.66 and 0.69, respectively). The areas under the ROC curve to discriminate A + from A- participants were 0.94 (95% CI 0.92-0.97) for pTau, and 0.88 (95% CI 0.84-0.92) for both pTau and Aβ/Aβ. Chronic kidney disease (CKD) was related to increased plasma biomarker concentrations, but ratios were less affected. Plasma pTau had the highest fold change (x4.2) and showed high predictive capability in discriminating A + from A-, having 4-7% misclassification rate. The global accuracy of plasma pTau using a two-threshold approach was robust in symptomatic groups, exceeding 90%. The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Alfabetización en salud mental en adolescentes españoles y su relación con las características sociodemográficas, Mental health literacy in spanish adolescents and its relationship with sociodemographic characteristics

  • Amado Rodríguez, Isaac Daniel|||0000-0001-9863-9256
  • Casañas, Rocio|||0000-0003-2783-8818
  • Mas-Expósito, Laia
  • Lalucat-Jo, Lluís
  • Roldán Merino, Juan Francisco|||0000-0002-7895-6083
  • Fernández San Martín, María Isabel|||0000-0001-9190-7182
FUNDAMENTOS: Diferentes estudios identifican la alfabetización en salud y/o salud mental (ASM) como factores protectores contra el desarrollo de un problema de salud mental. El objetivo de este trabajo fue determinar el grado de alfabetización en salud mental de la población adolescente de Barcelona, así como su relación con variables sociodemográficas y educativas. MÉTODOS: Se realizó un estudio transversal en Barcelona durante el curso 2017-2018. Participaron 1.032 jóvenes entre trece y diecisiete años. Se recogieron las siguientes variables: sexo; edad; nacionalidad; nivel socioeconómico (RDHpc); y nota media escolar. La ASM se midió mediante los test de conocimientos EMHL (reconocimiento de problemas mentales y conocimientos en salud mental; rango 0-10 cada parte), estigma (CAMI: rango 10-50, y RIBS: rango 4-20) y búsqueda de ayuda (GHSQ: rango de 1 a 7). Se realizó análisis de regresión lineal múltiple ajustando el efecto de variables sociodemográficas sobre la puntuación de cada escala. RESULTADOS: La puntuación media (desviación típica) del EMHL test fue de 7,28 (1,27) y 4,24 (1,14), respectivamente, obteniendo mayor puntuación las chicas, RDHpc altas, nota excelente y con nacionalidad española. La mayor diferencia de puntuación en EMHL, ajustando por el resto de variables, correspondió a los adolescentes con nota media excelente y con índice RDHpc elevado (respecto a la categoría basal, beta=0,72 y 0,52, respectivamente). La puntuación media del estigma fue 27,6 (4,47) para CAMI y 8,83 (3,36) para RIBS. Las variables relacionadas con una mayor diferencia de puntuación respecto a la categoría basal y ajustado por el resto de variables fueron: sexo (chico=1,54) y nota académica (excelente=-2,38) para CAMI, y nacionalidad (extranjera=0,82) y nota académica (excelente=-1,30) para RIBS. La puntuación media de RIBS fue 8,83 (3,36), siendo la mayor diferencia de puntuación respecto a la categoría basal la nacionalidad extranjera (beta=0,82) y tener una nota de excelente (1,30). La búsqueda de ayuda fue mayor en padres/madres y amigos, con diferencias según sexo y nacionalidad. CONCLUSIONES: El nivel de alfabetización de salud mental es medio-bajo. Mientras que género, nacionalidad y resultados académicos son los factores que se relacionan con conocimientos y estigma, el nivel socioeconómico se relaciona únicamente con conocimientos en salud mental., BACKGROUND: Different studies identify mental health literacy as a protective factor for developing a mental health problem. The aim of this paper was to determine the degree of mental health literacy of the adolescent population of Barcelona, and its relationship with socio-demographic and educational variables. METHODS: A cross-sectional study was carried out in Barcelona during the 2017-2018 academic year. A total of 1,032 young people between thirteen and seventeen years of age participated. The following variables were collected: sex, age, nationality, socioeconomic status (RDHpc) and average school grade. The aim was to determine the degree of mental health literacy (knowledge, stigma and help-seeking) of the adolescent population of Barcelona, and its relationship with socio-demographic and educational variables. Multiple linear regression analysis was performed adjusting for the effect of sociodemographic variables on the score of each scale. RESULTS: The mean score (standard deviation) of the EMHL test was 7.28 (1.27) and 4.24 (1.14) respectively, with higher scores obtained by girls, high RDHpc, excellent score and Spanish nationality. The greatest difference in EMHL scores, adjusting for the rest of the variables, corresponded to adolescents with an excellent mean score and a high RDHpc index (with respect to the baseline category, beta=0.72 and 0.52 respectively). The mean stigma score was 27.6 (4.47) for CAMI and 8.83 (3.36) for RIBS. The variables related to a greater difference in score with respect to the baseline category and adjusted for the rest of the variables were: gender (boy=1.54) and academic grade (excellent=-2.38) for CAMI, and nationality (foreign=0.82) and academic grade (excellent=-1.30) for RIBS. The mean RIBS score was 8.83 (3.36) with the largest difference in score from baseline being foreign nationality (beta=0.82) and having a grade of excellent (1.30). Help-seeking was higher in parents and friends, with differences according to gender and nationality. CONCLUSIONS: The level of mental health literacy is medium-low. While gender, nationality and educational attainment are the factors that are related to knowledge and stigma, socio-economic status is only related to mental health literacy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

ClinPrior, an algorithm for diagnosis and novel gene discovery by network-based prioritization

  • Schlüter, Agatha|||0000-0001-6732-1528
  • Vélez-Santamaría, Valentina
  • Verdura, Edgard|||0000-0003-3856-2060
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Ruiz, Montserrat|||0000-0003-0466-2653
  • Fourcade, Stéphane|||0000-0002-8031-5007
  • Planas-Serra, Laura|||0000-0002-2586-0897
  • Launay, Nathalie|||0000-0002-7498-217X
  • Guilera, Cristina|||0000-0003-0715-9332
  • Martínez, Juan José
  • Homedes-Pedret, Christian
  • Albertí-Aguiló, M. Antonia
  • Zulaika, Miren
  • Martí, Itxaso|||0000-0003-0578-9568
  • Troncoso, Mónica
  • Tomás Vila, Miguel|||0000-0002-8632-3593
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • García-Pérez, M. Asunción
  • Sobrido-Gómez, María-Jesús
  • López-Laso, Eduardo
  • Fons, Carme
  • Del Toro, Mireia|||0000-0002-8163-1853
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Beltran i Agulló, Sergi|||0000-0002-2810-3445
  • González Gutiérrez-Solana, Luis|||0000-0003-2890-4565
  • Pérez-Jurado, Luis Alberto|||0000-0002-1988-3005
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • de Munain, Adolfo López
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Pujol, Aurora|||0000-0002-9606-0600
Whole-exome sequencing (WES) and whole-genome sequencing (WGS) have become indispensable tools to solve rare Mendelian genetic conditions. Nevertheless, there is still an urgent need for sensitive, fast algorithms to maximise WES/WGS diagnostic yield in rare disease patients. Most tools devoted to this aim take advantage of patient phenotype information for prioritization of genomic data, although are often limited by incomplete gene-phenotype knowledge stored in biomedical databases and a lack of proper benchmarking on real-world patient cohorts. We developed ClinPrior, a novel method for the analysis of WES/WGS data that ranks candidate causal variants based on the patient's standardized phenotypic features (in Human Phenotype Ontology (HPO) terms). The algorithm propagates the data through an interactome network-based prioritization approach. This algorithm was thoroughly benchmarked using a synthetic patient cohort and was subsequently tested on a heterogeneous prospective, real-world series of 135 families affected by hereditary spastic paraplegia (HSP) and/or cerebellar ataxia (CA). ClinPrior successfully identified causative variants achieving a final positive diagnostic yield of 70% in our real-world cohort. This includes 10 novel candidate genes not previously associated with disease, 7 of which were functionally validated within this project. We used the knowledge generated by ClinPrior to create a specific interactome for HSP/CA disorders thus enabling future diagnoses as well as the discovery of novel disease genes. ClinPrior is an algorithm that uses standardized phenotype information and interactome data to improve clinical genomic diagnosis. It helps in identifying atypical cases and efficiently predicts novel disease-causing genes. This leads to increasing diagnostic yield, shortening of the diagnostic Odysseys and advancing our understanding of human illnesses. The online version contains supplementary material available at 10.1186/s13073-023-01214-2.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer's disease in a tertiary memory clinic

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola-Infante, J.E.
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau in prospective settings. Aims: To investigate the performance of plasma pTau, measured in consecutive samples with LUMIPULSE, for detecting Alzheimer's disease in a prospective memory clinic setting, along with evaluating its pre-analytical and analytical stability. Methods: We prospectively measured pTau using the LUMIPULSE automated platform in consecutive patient plasma samples collected between May and November 2024 at the Sant Pau Memory Unit (Barcelona). A subset of participants also underwent paired lumbar puncture for CSF AD biomarkers. We compared biomarker concentrations under different short-term storage conditions (4ºC vs -20ºC) and different protocol pipelines, and assessed lot-to-lot variability. In the subset with available CSF biomarkers, logistic regression was used to evaluate the association between plasma pTau217 and the likelihood of a positive (A +) or a negative (A-) CSF amyloid status. Using ROC analysis, in this prospective cohort we evaluated the accuracy of previously established thresholds derived from historical samples. Results: We included 280 participants, divided into two groups: those with (n = 109) and without CSF data (n = 171). Among the subset with CSF, 48% were A +, with a plasma pTau fold-change of 4.5 × compared to A-. We found no differences in plasma pTau concentrations between either short-term storage conditions. The overall coefficients of analytical variation ranged from 1.8% to 3.2%. Plasma pTau concentrations were slightly higher in paired samples of the clinical protocol. Following a two-threshold approach, the need of confirmatory tests (grey zones) after measuring plasma pTau ranged between 45.9% and 18.3% using our previously reported strict or lenient cutoffs (overall accuracy 96.6% and 92.1%, respectively). Conclusions: The robust stability and low lot-to-lot variability of plasma pTau measurement in an automated platform result in high diagnostic performance of this biomarker in the prospective evaluation of patients in a memory clinic setting. These findings support its implementation into clinical routine, offering clinicians an accessible biomarker for AD diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome

  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Aranha, Mateus|||0000-0001-9594-292X
  • Aragón, Irina
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Benejam, Bessy|||0000-0002-6789-8615
  • Fernández, S.
  • Bargalló, Núria|||0000-0001-6284-5402
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Belbin, Olivia|||0000-0002-6109-6371
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Giménez, Sandra|||0000-0001-8031-2319
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Hernandez, Aida S.
Background and Objectives Cerebral hemorrhages are an exclusion criterion and potential adverse effect of antiamyloid agents. It is, therefore, critical to characterize the natural history of cerebral microbleeds in populations genetically predisposed to Alzheimer disease (AD), such as Down syndrome (DS). We aimed to assess microbleed emergence in adults with DS across the AD spectrum, defining their topography and associations with clinical variables, cognitive outcomes, and fluid and neuroimaging biomarkers. Methods This cross-sectional study included participants aged 18 years or older from the Down-Alzheimer Barcelona Neuroimaging Initiative and Sant Pau Initiative on Neurodegeneration with T1-weighted and susceptibility-weighted images. Participants underwent comprehensive assessments, including apolipoprotein E (APOE) genotyping; fluid and plasma determinations of beta-amyloid, tau, and neurofilament light; cognitive outcomes (Cambridge Cognitive Examination and modified Cued Recall Test); and vascular risk factors (hypertension, diabetes mellitus, and dyslipidemia). We manually segmented microbleeds and characterized their topography. Associations between microbleed severity and AD biomarkers were explored using between-group comparisons (none vs 1 vs 2+) and multivariate linear models. Results We included 276 individuals with DS and 158 healthy euploid controls (mean age = 47.8 years, 50.92% female). Individuals with DS were more likely to have microbleeds than controls (20% vs 8.9%, p < 0.001), with more severe presentation (12% with 2+ vs 1.9%). Microbleeds increased with age (12% 20-30 years vs 60% > 60 years) and AD clinical stage (12.42% asymptomatic, 27.9% prodromal, 35.09% dementia) were more common in APOEe4 carriers (26% vs 18.3% noncarriers, p = 0.008), but not associated with vascular risk factors (p > 0.05). Microbleeds were predominantly posterior (cerebellum 33.66%; occipital 14.85%; temporal 21.29%) in participants with DS. Associations with microbleed severity were found for neuroimaging and fluid AD biomarkers, but only hippocampal volumes (standardized β = -0.18 [-0.31, -0.06], p < 0.005) and CSF p-tau-181 concentrations (β = 0.26 [0.12, 0.41], p < 0.005) survived regression controlling for age and disease stage, respectively. Microbleeds had limited effect on cognitive outcomes. Discussion In participants with DS, microbleeds present with a posterior, lobar predominance, are associated with disease severity, but do not affect cognitive performance. These results suggest an interplay between AD pathology and vascular lesions, implicating microbleeds as a risk factor limiting the use of antiamyloid agents in this population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic risk score based on obesity-related genes and progression in weight loss after bariatric surgery, a 60-month follow-up study

  • Mas-Bermejo, Patricia|||0000-0003-4789-9650
  • Azcona-Granada, Natalia
  • Peña, Elionora
  • Lecube, Albert|||0000-0001-9684-0183
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Luna, Alexis|||0000-0003-2351-5819
  • Rigla Cros, Mercedes|||0000-0002-6691-4871
  • Arenas Solà, Concepción|||0000-0002-6489-4934
  • Caixàs i Pedragós, Assumpta|||0000-0001-8472-9189
  • Rosa de la Cruz, Araceli|||0000-0001-6935-3785
Background: Obesity is a polygenic multifactorial disease. Recent genome-wide association studies have identified several common loci associated with obesity-related phenotypes. Bariatric surgery (BS) is the most effective long-term treatment for patients with severe obesity. The huge variability in BS outcomes between patients suggests a moderating effect of several factors, including the genetic architecture of the patients. Objective: To examine the role of a genetic risk score (GRS) based on 7 polymorphisms in 5 obesity-candidate genes (FTO, MC4R, SIRT1, LEP, and LEPR) on weight loss after BS. Setting: University hospital in Spain. Methods: We evaluated a cohort of 104 patients with severe obesity submitted to BS (Roux-en-Y gastric bypass or sleeve gastrectomy) followed up for >60 months (lost to follow-up, 19.23%). A GRS was calculated for each patient, considering the number of carried risk alleles for the analyzed genes. During the postoperative period, the percentage of excess weight loss total weight loss and changes in body mass index were evaluated. Generalized estimating equation models were used for the prospective analysis of the variation of these variables in relation to the GRS. Results: The longitudinal model showed a significant effect of the GRS on the percentage of excess weight loss (P = 1.5 × 10-5), percentage of total weight loss (P = 3.1 × 10-8), and change in body mass index (P = 7.8 × 10-16) over time. Individuals with a low GRS seemed to experience better outcomes at 24 and 60 months after surgery than those with a higher GRS. Conclusion: The use of the GRS in considering the polygenic nature of obesity seems to be a useful tool to better understand the outcome of patients with obesity after BS.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Genome-Wide DNA Methylation in Early-Onset-Dementia Patients Brain Tissue and Lymphoblastoid Cell Lines

  • Ramos-Campoy, Oscar
  • Comas-Albertí, Aina
  • Borrego-Ecija, Sergi
  • Bosch, Beatriz
  • Sandoval, Juan
  • Fort-Aznar, Laura
  • Moreno-Izco, Fermin
  • Fernández-Villullas, Guadalupe
  • Molina-Porcel, Laura
  • Balasa, Mircea
  • Lladó, Albert
  • Sanchez-Valle, Raquel
  • Antonell, Anna
  • Hervás-Marín, David|||0000-0003-0635-4961
[EN] Epigenetics, a potential underlying pathogenic mechanism of neurodegenerative diseases, has been in the scope of several studies performed so far. However, there is a gap in regard to analyzing different forms of early-onset dementia and the use of Lymphoblastoid cell lines (LCLs). We performed a genome-wide DNA methylation analysis on sixty-four samples (from the prefrontal cortex and LCLs) including those taken from patients with early-onset forms of Alzheimer's disease (AD) and frontotemporal dementia (FTD) and healthy controls. A beta regression model and adjusted p-values were used to obtain differentially methylated positions (DMPs) via pairwise comparisons. A correlation analysis of DMP levels with Clariom D array gene expression data from the same cohort was also performed. The results showed hypermethylation as the most frequent finding in both tissues studied in the patient groups. Biological significance analysis revealed common pathways altered in AD and FTD patients, affecting neuron development, metabolism, signal transduction, and immune system pathways. These alterations were also found in LCL samples, suggesting the epigenetic changes might not be limited to the central nervous system. In the brain, CpG methylation presented an inverse correlation with gene expression, while in LCLs, we observed mainly a positive correlation. This study enhances our understanding of the biological pathways that are associated with neurodegeneration, describes differential methylation patterns, and suggests LCLs are a potential cell model for studying neurodegenerative diseases in earlier clinical phases than brain tissue., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects PI17/00670 to A.A., PI20/00448 to R.S.-V. and FI18/00121 to O.R.-C., and co-funded by the European Union. Departament de Salut de la Generalitat de Catalunya (PERIS 2016 2020, SLT002/16/00329 and PERIS 2019 2021, SLT008/18/00061 ); Departament de Recerca i Universitats de la Generalitat de Catalunya, AGAUR group 2021-SGR-01126. The Article Processing Charge will be funded by University of Barcelona.
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Trajectories of antidepressant use and 6-year change in body weight: a prospective population-based cohort study

  • Lassale, Camille
  • Lugon, Gabriela
  • Hernáez, Álvaro
  • Frank, Philipp
  • Marrugat, Jaume
  • Ramos, Rafel
  • Garre-Olmo, Josep
  • Elosua, Roberto
Background: Antidepressant drug treatment may be associated with weight gain, but long-term studies are lacking. Methods: We included 3,127 adults (1,701 women) from the REGICOR study, aged 55.6 (SD = 11.6) years on average in 2003–2006, living in the northeast of Spain. They had data at two time points (baseline and a median of 6.3 years later) on self-reported antidepressant use, body weight and height, and on baseline smoking, physical activity, diet quality, education, civil status, and depressive symptoms assessed with the Patient Health Questionnaire (PHQ-9) at follow-up. We defined four trajectories of antidepressant use as follows: never use, new use at follow-up, initial use discontinued, repeated use at both time points. We used multivariable linear models to estimate the association of these trajectories with the percentage of weight change. In people without obesity at baseline (n = 2,404), we also estimated the association with obesity incidence at follow-up. Results: The average 6-year weight gain was 0.53 kg (1.01% body weight), and 24.5% of the participants gained >5% of body weight. The majority (83.6%) of participants did not report any use of antidepressants, 6.2% initiated during follow-up, 5.1% discontinued it, and 5.1% reported their use at both time points. In multivariable analyses, compared to never users, all trajectories were associated with greater weight gain: +1.78% (0.57, 2.98) for initial use discontinued, +2.08% (0.97, 3.19) for new use at follow-up, and +1.98% (95% CI: 0.75, 3.20) for repeated use. In non-obese participants at baseline (n = 2,404), the odds ratio for becoming obese was 2.06 (1.03, 3.96) for repeated use and non-statistically significant for the other trajectories. Conclusions: In a population-based adult cohort, repeated use of antidepressants was strongly associated with weight gain. New and discontinued use was associated with weight gain, but non-significantly to obesity incidence. Given the global obesity epidemic and the widespread use of antidepressants, weight management and metabolic monitoring should be encouraged and integrated into depression follow-up guidelines alongside antidepressant prescriptions., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Association between different diet quality scores and depression risk: the REGICOR population-based cohort study

  • Lugon, Gabriela
  • Hernáez, Álvaro
  • Jacka, Felice
  • Marrugat, Jaume
  • Ramos , Rafel
  • Garre-Olmo, Josep
  • Elosua Llanos, Roberto
  • Lassale, Camille
Background Our aim was to determine the association between diet quality and depression incidence in the population-based REGICOR cohort study, Catalonia, Spain. Methods Prospective observational study using participants’ baseline (2003–2006), follow-up (2007–2013) and clinical records data. Five diet quality scores were derived from a food frequency questionnaire (FFQ) at baseline: the relative Mediterranean Diet Score (rMED), the Modified Mediterranean Diet Score (ModMDS), a Dietary Approaches to Stop Hypertension (DASH) score, a Healthful Plant-based Diet Index (HPDI) and the World Health Organization Healthy Diet Indicator (WHO-HDI). Participants using pharmacological antidepressant treatment were excluded as a proxy for presence of depression at baseline. At follow-up, the Patient Health Questionnaire (PHQ-9) was applied to assess depressive symptoms (≥ 10 defining depressive disorder). A secondary outcome was depression diagnosis assessed through clinical records. Logistic regression and Cox proportional hazards models were used. Results Main analysis included 3046 adults (50.3% women) with a mean age of 54.7 (SD = 11.6) years. After 6-years follow-up, 184 (6.04%) cases of depressive disorder were identified. There was 16% lower odds of depressive disorder per 1SD increase of rMED (OR = 0.84; 95%CI = 0.71–0.98). Secondary outcome analysis (n = 4789) identified 261 (5.45%) incident cases of clinical depression diagnosis over 12 years follow-up, and 19% lower risk of clinical depression was observed with the WHO-HDI (HR = 0.81; 95%CI = 0.70–0.93). Adjusting for BMI did not attenuate the findings. Conclusions A significant inverse association between diet quality and depression incidence was found in this population-based cohort study, independent of sociodemographic, health and lifestyle. Adherence to a healthy diet could be a complementary intervention for the prevention of depression., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Modification of high-density lipoprotein functions by diet and other lifestyle changes: A systematic review of randomized controlled trials

  • Sanllorente Melenchon, Albert
  • Lassale, Camille
  • Soria Florido, María Trinidad
  • Castañer, Olga
  • Fitó Colomer, Montserrat
  • Hernáez, Álvaro
High-density lipoprotein (HDL) functional traits have emerged as relevant elements that may explain HDL antiatherogenic capacity better than HDL cholesterol levels. These properties have been improved in several lifestyle intervention trials. The aim of this systematic review is to summarize the results of such trials of the most commonly used dietary modifications (fatty acids, cholesterol, antioxidants, alcohol, and calorie restriction) and physical activity. Articles were screened from the Medline database until March 2021, and 118 randomized controlled trials were selected. Results from HDL functions and associated functional components were extracted, including cholesterol efflux capacity, cholesteryl ester transfer protein, lecithin-cholesterol acyltransferase, HDL antioxidant capacity, HDL oxidation status, paraoxonase-1 activity, HDL anti-inflammatory and endothelial protection capacity, HDL-associated phospholipase A2, HDL-associated serum amyloid A, and HDL-alpha-1-antitrypsin. In mainly short-term clinical trials, the consumption of monounsaturated and polyunsaturated fatty acids (particularly omega-3 in fish), and dietary antioxidants showed benefits to HDL functionality, especially in subjects with cardiovascular risk factors. In this regard, antioxidant-rich dietary patterns were able to improve HDL function in both healthy individuals and subjects at high cardiovascular risk. In addition, in randomized trial assays performed mainly in healthy individuals, reverse cholesterol transport with ethanol in moderate quantities enhanced HDL function. Nevertheless, the evidence summarized was of unclear quality and short-term nature and presented heterogeneity in lifestyle modifications, trial designs, and biochemical techniques for the assessment of HDL functions. Such findings should therefore be interpreted with caution. Large-scale, long-term, randomized, controlled trials in different populations and individuals with diverse pathologies are warranted., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Association of physical activity with high-density lipoprotein functionality in a population-based cohort: the REGICOR study, Asociación de la actividad física con la funcionalidad de las lipoproteínas de alta densidad en una cohorte de base poblacional: el estudio REGICOR

  • Viadas, Raúl
  • Toloba, Andrea
  • Fernández, Isabel
  • Sayols Baixeras, Sergi
  • Hernáez, Álvaro
  • Schroeder, Helmut
  • Degano, Irene R.
  • Lassale, Camille
  • Marrugat, Jaume
  • Elosua Llanos, Roberto
Introduction and objectives To determine the dose-response association between current and past leisure-time physical activity (LTPA), total and at different intensities, and high-density lipoprotein (HDL) functionality parameters. Methods Study participants (n = 642) were randomly drawn from a large population-based survey. Mean age of the participants was 63.2 years and 51.1% were women. The analysis included data from a baseline and a follow-up visit (median follow-up, 4 years). LTPA was assessed using validated questionnaires at both visits. Two main HDL functions were assessed: cholesterol efflux capacity and HDL antioxidant capacity, at the follow-up visit. Linear regression and linear additive models were used to assess the linear and nonlinear association between LTPA and HDL functionality. Results Total LTPA at follow-up showed an inverse and linear relationship between 0 and 400 METs x min/d with HDL antioxidant capacity (regression coefficient [beta]: −0.022; 95%CI, −0.030, −0.013), with a plateau above this threshold. The results were similar for moderate (beta: −0.028; 95%CI, −0.049, −0.007) and vigorous (beta: −0.025; 95%CI, −0.043, −0.007), but not for light-intensity LTPA. LTPA at follow-up was not associated with cholesterol efflux capacity. Baseline LTPA was not associated with any of the HDL functionality parameters analyzed. Conclusions Current moderate and vigorous LTPA showed a nonlinear association with higher HDL antioxidant capacity. Maximal benefit was observed with low-intermediate doses of total LTPA (up to 400 METs x min/d). Our results agree with current recommendations for moderate-vigorous LTPA practice and suggest an association between PA and HDL functionality in the general population., Introducción y objetivos Determinar la relación dosis-respuesta entre la actividad física en el tiempo libre (AFTL) actual y pasada, total y según su intensidad, y la funcionalidad de las lipoproteínas de alta densidad (HDL). Métodos Se seleccionó a 642 participantes de un estudio poblacional: la edad media era de 63,2 años y el 51,1% eran mujeres. Se incluyeron datos de la visita inicial y de un seguimiento a 4 años. La AFTL se evaluó mediante cuestionarios validados. Se determinó la capacidad de eflujo de colesterol y antioxidante en el seguimiento. Se utilizaron modelos de regresión lineal y aditivos para evaluar la relación dosis-respuesta. Resultados Se observó una relación inversa y lineal entre la AFTL total actual (entre 0-400 MET x min/día) y la capacidad antioxidante de HDL (coeficiente de regresión [beta]: -0,022; IC95%, -0,030; -0,013), con una meseta por encima de este umbral. Se observaron resultados similares para la AFTL de intensidad moderada (beta: -0,028; IC95%, -0,049; -0,007) y vigorosa (beta: -0,025; IC95%, -0,043; -0,007), pero no para AFTL de intensidad ligera. La AFTL en el seguimiento no se asoció con la capacidad de eflujo de colesterol. La AFTL basal no se asoció con la funcionalidad de HDL. Conclusiones La AFTL de intensidad moderada-vigorosa actual se asocia de forma no lineal con una mayor capacidad antioxidante de las partículas de HDL. Se observa un beneficio máximo con dosis intermedias-bajas de AFTL (0-400 MET x min/día). Nuestros resultados concuerdan con las recomendaciones de práctica de AFTL y sugieren una asociación con la funcionalidad de HDL., info:eu-repo/semantics/acceptedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Relationship between sex, APOE genotype, endocannabinoids and cognitive change in older adults with metabolic syndrome during a 3-year Mediterranean diet intervention

  • Soldevila-Domenech, Natalia
  • Fagundo, Ana Beatriz
  • Cuenca Royo, Aida
  • Forcano Gamazo, Laura
  • Gomis-Gonzalez, Maria
  • Boronat, Anna
  • Pastor, Antoni
  • Castañer, Olga
  • Zomeño, M. Dolores
  • Goday, Alberto
  • Dierssen, Mara
  • Baghizadeh Hosseini, Khashayar
  • Ros Rahola, Emilio
  • Corella Piquer, Dolores
  • Martínez-González, Miguel Ángel
  • Salas Salvadó, Jordi
  • Fernández-Aranda, Fernando
  • Fitó Colomer, Montserrat
  • de la Torre, Rafael
Background The Mediterranean diet (MedDiet) has demonstrated efficacy in preventing age-related cognitive decline and modulating plasma concentrations of endocannabinoids (eCBs) and N-acylethanolamines (NAEs, or eCB-like compounds), which are lipid mediators involved in multiple neurological disorders and metabolic processes. Hypothesizing that eCBs and NAEs will be biomarkers of a MedDiet intervention and will be related to the cognitive response, we investigated this relationship according to sex and apolipoprotein E (APOE) genotype, which may affect eCBs and cognitive performance. Methods This was a prospective cohort study of 102 participants (53.9% women, 18.8% APOE-ɛ4 carriers, aged 65.6 ± 4.5 years) from the PREDIMED-Plus-Cognition substudy, who were recruited at the Hospital del Mar Research Institute (Barcelona). All of them presented metabolic syndrome plus overweight/obesity (inclusion criteria of the PREDIMED-Plus) and normal cognitive performance at baseline (inclusion criteria of this substudy). A comprehensive battery of neuropsychological tests was administered at baseline and after 1 and 3 years. Plasma concentrations of eCBs and NAEs, including 2-arachidonoylglycerol (2-AG), anandamide (AEA), oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and N-docosahexaenoylethanolamine (DHEA), were also monitored. Baseline cognition, cognitive changes, and the association between eCBs/NAEs and cognition were evaluated according to gender (crude models), sex (adjusted models), and APOE genotype. Results At baseline, men had better executive function and global cognition than women (the effect size of gender differences was − 0.49, p = 0.015; and − 0.42, p = 0.036); however, these differences became nonsignificant in models of sex differences. After 3 years of MedDiet intervention, participants exhibited modest improvements in memory and global cognition. However, greater memory changes were observed in men than in women (Cohen’s d of 0.40 vs. 0.25; p = 0.017). In men and APOE-ε4 carriers, 2-AG concentrations were inversely associated with baseline cognition and cognitive changes, while in women, cognitive changes were positively linked to changes in DHEA and the DHEA/AEA ratio. In men, changes in the OEA/AEA and OEA/PEA ratios were positively associated with cognitive changes. Conclusions The MedDiet improved participants’ cognitive performance but the effect size was small and negatively influenced by female sex. Changes in 2-AG, DHEA, the OEA/AEA, the OEA/PEA and the DHEA/AEA ratios were associated with cognitive changes in a sex- and APOE-dependent fashion. These results support the modulation of the endocannabinoid system as a potential therapeutic approach to prevent cognitive decline in at-risk populations., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Blood DNA methylation signature of diet quality and association with cardiometabolic traits

  • Domínguez-Barragán, Jorge
  • Fernández Sanlés, Alba
  • Hernáez, Álvaro
  • Llauradó-Pont, Joana
  • Marrugat, Jaume
  • Robinson, Oliver
  • Tzoulaki, Ioanna
  • Elosua Llanos, Roberto
  • Lassale, Camille
Aims Diet quality might influence cardiometabolic health through epigenetic changes, but this has been little investigated in adults. Our aims were to identify cytosine–phosphate–guanine (CpG) dinucleotides associated with diet quality by conducting an epigenome-wide association study (EWAS) based on blood DNA methylation (DNAm) and to assess how diet-related CpGs associate with inherited susceptibility to cardiometabolic traits: body mass index (BMI), systolic blood pressure (SBP), triglycerides, type 2 diabetes (T2D), and coronary heart disease (CHD). Methods and results Meta-EWAS including 5274 participants in four cohorts from Spain, the USA, and the UK. We derived three dietary scores (exposures) to measure adherence to a Mediterranean diet, to a healthy plant-based diet, and to the Dietary Approaches to Stop Hypertension. Blood DNAm (outcome) was assessed with the Infinium arrays Human Methylation 450K BeadChip and MethylationEPIC BeadChip. For each diet score, we performed linear EWAS adjusted for age, sex, blood cells, smoking and technical variables, and BMI in a second set of models. We also conducted Mendelian randomization analyses to assess the potential causal relationship between diet-related CpGs and cardiometabolic traits. We found 18 differentially methylated CpGs associated with dietary scores (P < 1.08 × 10−7; Bonferroni correction), of which 12 were previously associated with cardiometabolic traits. Enrichment analysis revealed overrepresentation of diet-associated genes in pathways involved in inflammation and cardiovascular disease. Mendelian randomization analyses suggested that genetically determined methylation levels corresponding to lower diet quality at cg02079413 (SNORA54), cg02107842 (MAST4), and cg23761815 (SLC29A3) were causally associated with higher BMI and at cg05399785 (WDR8) with greater SBP, and methylation levels associated with higher diet quality at cg00711496 (PRMT1) with lower BMI, T2D risk, and CHD risk and at cg0557921 (AHRR) with lower CHD risk. Conclusion Diet quality in adults was related to differential methylation in blood at 18 CpGs, some of which related to cardiometabolic health., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Moron-Font, Miriam
  • Clos-Sansalvador, Marta
  • Calle, Alexandra
  • Morancho Retana, Anna
  • Rosell Novel, Anna
  • Monguió-Tortajada, Marta
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
Ingeniería de tejido cardíaco; Exosomas; Infiltración, Enginyeria de teixits cardíacs; Exosomes; Infiltració, Cardiac tissue engineering; Exosomes; Infiltration, The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation., This work was supported in part by grants from Fundació la Marató de TV3 (201516-10, 201502-30), the PERIS (SLT002/16/00234) and SGR programmes (2017-SGR-301 REMAR Group, 2017-SGR-1427 and 2017-SGR-483 ICREC Group) from the Generalitat de Catalunya, the Spanish Ministry of Economy and Competitiveness-MICINN (SAF2017-84324-C2-1-R; PID2019-110137RB-I00; PID2019-107145RB-I00), Instituto de Salud Carlos III (PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, and ICI20/00135), ISCIII-REDinREN (RD16/0009 Feder Funds), Red de Terapia Celular-TerCel (RD16/0011/0006), CIBER Cardiovascular (CB16/11/00403) projects as a part of the Plan Nacional de I + D + I, and it was co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER), AGAUR (2019PROD00122), Sociedad Española de Cardiología, Societat Catalana de Cardiologia, PCMR[C] and EoI Collaborative Projects on Regenerative Medicine 2019, and Institut Català de Salut (ICS). PG is sponsored by the PERIS (SLT002/16/00209) from the Generalitat de Catalunya. AR is supported by the Miguel Servet program (CPII15/00003) and research grants (PI16/00981) from the Instituto de Salud Carlos III, and co-financed by the European Regional Development Fund. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Association of physical activity with high-density lipoprotein functionality in a population-based cohort: the REGICOR study, Asociación de la actividad física con la funcionalidad de las lipoproteínas de alta densidad en una cohorte de base poblacional: el estudio REGICOR

  • Viadas, Raúl
  • Toloba, Andrea
  • Fernández, Isabel
  • Sayols Baixeras, Sergi
  • Hernáez, Álvaro
  • Schroeder, Helmut
  • Degano, Irene R.
  • Lassale, Camille
  • Marrugat, Jaume
  • Elosua Llanos, Roberto
Introduction and objectives To determine the dose-response association between current and past leisure-time physical activity (LTPA), total and at different intensities, and high-density lipoprotein (HDL) functionality parameters. Methods Study participants (n = 642) were randomly drawn from a large population-based survey. Mean age of the participants was 63.2 years and 51.1% were women. The analysis included data from a baseline and a follow-up visit (median follow-up, 4 years). LTPA was assessed using validated questionnaires at both visits. Two main HDL functions were assessed: cholesterol efflux capacity and HDL antioxidant capacity, at the follow-up visit. Linear regression and linear additive models were used to assess the linear and nonlinear association between LTPA and HDL functionality. Results Total LTPA at follow-up showed an inverse and linear relationship between 0 and 400 METs x min/d with HDL antioxidant capacity (regression coefficient [beta]: −0.022; 95%CI, −0.030, −0.013), with a plateau above this threshold. The results were similar for moderate (beta: −0.028; 95%CI, −0.049, −0.007) and vigorous (beta: −0.025; 95%CI, −0.043, −0.007), but not for light-intensity LTPA. LTPA at follow-up was not associated with cholesterol efflux capacity. Baseline LTPA was not associated with any of the HDL functionality parameters analyzed. Conclusions Current moderate and vigorous LTPA showed a nonlinear association with higher HDL antioxidant capacity. Maximal benefit was observed with low-intermediate doses of total LTPA (up to 400 METs x min/d). Our results agree with current recommendations for moderate-vigorous LTPA practice and suggest an association between PA and HDL functionality in the general population., Introducción y objetivos Determinar la relación dosis-respuesta entre la actividad física en el tiempo libre (AFTL) actual y pasada, total y según su intensidad, y la funcionalidad de las lipoproteínas de alta densidad (HDL). Métodos Se seleccionó a 642 participantes de un estudio poblacional: la edad media era de 63,2 años y el 51,1% eran mujeres. Se incluyeron datos de la visita inicial y de un seguimiento a 4 años. La AFTL se evaluó mediante cuestionarios validados. Se determinó la capacidad de eflujo de colesterol y antioxidante en el seguimiento. Se utilizaron modelos de regresión lineal y aditivos para evaluar la relación dosis-respuesta. Resultados Se observó una relación inversa y lineal entre la AFTL total actual (entre 0-400 MET x min/día) y la capacidad antioxidante de HDL (coeficiente de regresión [beta]: -0,022; IC95%, -0,030; -0,013), con una meseta por encima de este umbral. Se observaron resultados similares para la AFTL de intensidad moderada (beta: -0,028; IC95%, -0,049; -0,007) y vigorosa (beta: -0,025; IC95%, -0,043; -0,007), pero no para AFTL de intensidad ligera. La AFTL en el seguimiento no se asoció con la capacidad de eflujo de colesterol. La AFTL basal no se asoció con la funcionalidad de HDL. Conclusiones La AFTL de intensidad moderada-vigorosa actual se asocia de forma no lineal con una mayor capacidad antioxidante de las partículas de HDL. Se observa un beneficio máximo con dosis intermedias-bajas de AFTL (0-400 MET x min/día). Nuestros resultados concuerdan con las recomendaciones de práctica de AFTL y sugieren una asociación con la funcionalidad de HDL., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Relationship between sex, APOE genotype, endocannabinoids and cognitive change in older adults with metabolic syndrome during a 3-year Mediterranean diet intervention

  • Soldevila-Domenech, Natalia
  • Fagundo, Ana Beatriz
  • Cuenca Royo, Aida
  • Forcano Gamazo, Laura
  • Gomis-Gonzalez, Maria
  • Boronat, Anna
  • Pastor, Antoni
  • Castañer, Olga
  • Zomeño, M. Dolores
  • Goday, Alberto
  • Dierssen, Mara
  • Baghizadeh Hosseini, Khashayar
  • Ros Rahola, Emilio
  • Corella Piquer, Dolores
  • Martínez-González, Miguel Ángel
  • Salas Salvadó, Jordi
  • Fernández-Aranda, Fernando
  • Fitó Colomer, Montserrat
  • de la Torre, Rafael
Background The Mediterranean diet (MedDiet) has demonstrated efficacy in preventing age-related cognitive decline and modulating plasma concentrations of endocannabinoids (eCBs) and N-acylethanolamines (NAEs, or eCB-like compounds), which are lipid mediators involved in multiple neurological disorders and metabolic processes. Hypothesizing that eCBs and NAEs will be biomarkers of a MedDiet intervention and will be related to the cognitive response, we investigated this relationship according to sex and apolipoprotein E (APOE) genotype, which may affect eCBs and cognitive performance. Methods This was a prospective cohort study of 102 participants (53.9% women, 18.8% APOE-ɛ4 carriers, aged 65.6 ± 4.5 years) from the PREDIMED-Plus-Cognition substudy, who were recruited at the Hospital del Mar Research Institute (Barcelona). All of them presented metabolic syndrome plus overweight/obesity (inclusion criteria of the PREDIMED-Plus) and normal cognitive performance at baseline (inclusion criteria of this substudy). A comprehensive battery of neuropsychological tests was administered at baseline and after 1 and 3 years. Plasma concentrations of eCBs and NAEs, including 2-arachidonoylglycerol (2-AG), anandamide (AEA), oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and N-docosahexaenoylethanolamine (DHEA), were also monitored. Baseline cognition, cognitive changes, and the association between eCBs/NAEs and cognition were evaluated according to gender (crude models), sex (adjusted models), and APOE genotype. Results At baseline, men had better executive function and global cognition than women (the effect size of gender differences was − 0.49, p = 0.015; and − 0.42, p = 0.036); however, these differences became nonsignificant in models of sex differences. After 3 years of MedDiet intervention, participants exhibited modest improvements in memory and global cognition. However, greater memory changes were observed in men than in women (Cohen’s d of 0.40 vs. 0.25; p = 0.017). In men and APOE-ε4 carriers, 2-AG concentrations were inversely associated with baseline cognition and cognitive changes, while in women, cognitive changes were positively linked to changes in DHEA and the DHEA/AEA ratio. In men, changes in the OEA/AEA and OEA/PEA ratios were positively associated with cognitive changes. Conclusions The MedDiet improved participants’ cognitive performance but the effect size was small and negatively influenced by female sex. Changes in 2-AG, DHEA, the OEA/AEA, the OEA/PEA and the DHEA/AEA ratios were associated with cognitive changes in a sex- and APOE-dependent fashion. These results support the modulation of the endocannabinoid system as a potential therapeutic approach to prevent cognitive decline in at-risk populations., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience

  • Vives Armengol, Joaquim
  • Coll, Ruth
  • Gálvez-Montón, Carolina
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
  • Bayes-Genis, Antoni
Medicament de teràpia avançada; Medicament en investigació; Translacional (regulació), Medicamento de terapia avanzada; Medicamento en investigación; Traslacional (regulación), Advanced therapy medicinal product; Investigational medicinal product; Translational (regulation), A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval., This work was supported by the Spanish Cell Therapy Network (TerCel) [RD16/0011/0006 and RD16/0011/0028]; and CIBER Cardiovascular [CB16/11/00403] projects, as a part of the National R&D&I Plan, and was co-funded by the ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF); the Government of Catalonia: Agency for Management of University and Research Grants (AGAUR) [2017-SGR-483 and 2017-SGR-719], PERIS Program (Health Department) [SLT002/16/00234 and SLT002/16/00209] and CERCA Program; La Caixa Banking Foundation; grants from the Spanish Ministry of Science, Innovation and Universities (MICINN) [SAF2017-84324-C2-1-R]; Institute of Health Carlos III (ISCIII) [PI18/00256, PIC18/00014, ICI19/00039, and PI19/01788], and cofunded by European Union (ERDF/ESF) - A way to build Europe. This work has also been funded by the Sociedad Española de Cardiología and by the Call for Expression of Interest (EoI) for Collaborative Projects on Regenerative Medicine 2019 of Center for Regenerative Medicine of Barcelona (CMR[B]). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Wharton’s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View

  • Muñoz-Domínguez, Noelia
  • Roura, Santiago
  • Vives Armengol, Joaquim
  • Prat-Vidal, Cristina
Gelatina de Wharton; Enginyeria de teixits cardíacs; Infart de miocardi, Gelatina de Wharton; Ingeniería de tejidos cardíacos; Infarto de miocardio, Wharton’s jelly; Cardiac tissue engineering; Myocardial infarction, Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particularly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton’s jelly MSC and derived EV in post-MI management., This work has been developed in the context of ADVANCE(CAT) with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) and the European Community under the Catalonian ERDF operational program (European Regional Development Fund) 2014–2020, Generalitat de Catalunya (Departament de Salut) PERIS Acció Instrumental de Programes de Recerca Orientats (SLT002/16/00234), Spanish Society of Cardiology, Catalan Society of Cardiology, Fundació bancària La Caixa, CIBER Cardiovascular (CB16/11/00403) and by the Spanish Cell Therapy Network (TerCel, expedient numbers: RD16/0011/0006 & RD16/0011/0028). Projects PI19/01788, PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, ICI20/00135 are funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF)—A way to build Europe. Projects SAF2017-84324-C2-1-R and PID2019-110137RB-I00 are funded the Spanish Ministry of Economy and Competitiveness-MICINN. Our laboratories are awarded by the Generalitat de Catalunya’s AGAUR as Consolidated Research Groups (references 2017-SGR-483, 2017-SGR-719 and 2019PROD00122), and by the Catalan Heath Institute.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

  • Yndestad, Synnøve
  • Engebrethsen, Christina
  • Nikolaienko, Oleksii
  • Vintermyr, Olav Karsten
  • Lillestøl, Reidun
  • Llop-Guevara, Alba
  • Herencia Ropero, Andrea
  • Serra, Violeta
Homologous recombination; Primary breast cancer, Recombinació homòloga; Càncer de mama primari, Recombinación homóloga; Cáncer de mama primario, PURPOSE Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to assess the potential for PARPi in a wider group of patients with breast cancer. METHODS HRD status was established using targeted gene panel sequencing (360 genes) and BRCA1 methylation analysis of pretreatment biopsies from 201 patients with primary breast cancer in the phase II PETREMAC trial (ClinicalTrials.gov identifier: NCT02624973). HRD was defined as mutations in BRCA1, BRCA2, BRIP1, BARD1, or PALB2 and/or promoter methylation of BRCA1 (strict definition; HRD-S). In secondary analyses, a wider definition (HRD-W) was used, examining mutations in 20 additional genes. Furthermore, tumor BRCAness (multiplex ligation-dependent probe amplification), PAM50 subtyping, RAD51 nuclear foci to test functional HRD, tumor-infiltrating lymphocyte (TIL), and PD-L1 analyses were performed. RESULTS HRD-S was present in 5% of non-TNBC cases (n = 9 of 169), contrasting 47% of the TNBC tumors (n = 15 of 32). HRD-W was observed in 23% of non-TNBC (n = 39 of 169) and 59% of TNBC cases (n = 19 of 32). Of 58 non-TNBC and 30 TNBC biopsies examined for RAD51 foci, 4 of 4 (100%) non-TNBC and 13 of 14 (93%) TNBC cases classified as HRD-S had RAD51 low scores. In contrast, 4 of 17 (24%) non-TNBC and 15 of 19 (79%) TNBC biopsies classified as HRD-W exhibited RAD51 low scores. Of nine non-TNBC tumors with HRD-S status, only one had a basal-like PAM50 signature. There was a high concordance between HRD-S and either BRCAness, high TIL density, or high PD-L1 expression (each P < .001). CONCLUSION The prevalence of HRD in non-TNBC suggests that therapy targeting HRD should be evaluated in a wider breast cancer patient population. Strict HRD criteria should be implemented to increase diagnostic precision with respect to functional HRD., Supported by unrestricted grants from The K.G. Jebsen Foundation [SKGJ-MED-020 to H.P.E., S.K., P.E.L.], Helse Vest [912008 to P.E.L.], The Norwegian Research Council [273354 to P.E.L.] and The Norwegian Cancer Society [190281-2017 to S.K., 190275-2017 to P.E.L.]. Research funding was provided by Grieg Foundation (to H.P.E. and T.A.), Helse Vest [912252; Clinical researcher fellowship to H.P.E.], Generalitat de Catalunya [PERIS, SLT017/20/000081 to A.H.R.], “la Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 [LCF/TR/CC19/52470003 to A.L.G.], Asociación Española Contra el Cáncer [AECC, INVES20095LLOP to A.L.G.], Generalitat de Catalunya (PERIS Fellowship SLT002/16/00477 to A.L.G.) ERA PerMed [2019-215 to V.S.] and Miguel Servet fellowship (CPII19/00033 to V.S.). Additional funding and study medication was provided by Illumina [grant number 9529854], Pfizer [WI206347] and AstraZeneca [ESR-14-10077] to H.P.E., S.K., P.E.L.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Patients and healthcare professionals’ voice on preventable readmissions

  • Adamuz, Jordi
  • Lorente García, David
  • Ruiz-Martínez, Maria-José
  • Nieto-Ruiz, Carme
  • Colomer-Plana, Maria
  • de la Cueva-Ariza, Laura
  • Juvé Udina, Maria E.
  • Alonso-Fernández, Sergio
Preventable readmissions; Opinion, Readmisiones prevenibles; Opinión, Readmissions evitables; Opinió, This study was supported by the Departament de Salut de la Generalitat de Catalunya, Pla estratègic de recerca i innovació en salut (PERIS) 2016-2020 (SLT002/16/00085), Catalunya, Spain, and School of Nursing, Medicine and Health Science Faculty, University of Barcelona (PREI-18-005-I).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration

  • Senage, Thomas
  • Paul, Anu
  • Le Tourneau, Thierry
  • Fellah-Hebia, Imen
  • Vadori, Marta
  • Bashir, Salam
  • Evangelista Masip, Artur
  • Casós Vásquez, Kelly
  • Blasco Lucas, Arnau
  • Permanyer Buada, Eduard
  • Galiñanes Hernández, Manuel
Outcomes research; Risk factors, Investigación de resultados; Factores de riesgo, Recerca dels resultats; Factors de risc, Bioprosthetic heart valves (BHVs) are commonly used to replace severely diseased heart valves but their susceptibility to structural valve degeneration (SVD) limits their use in young patients. We hypothesized that antibodies against immunogenic glycans present on BHVs, particularly antibodies against the xenoantigens galactose-α1,3-galactose (αGal) and N-glycolylneuraminic acid (Neu5Gc), could mediate their deterioration through calcification. We established a large longitudinal prospective international cohort of patients (n = 1668, 34 ± 43 months of follow-up (0.1–182); 4,998 blood samples) to investigate the hemodynamics and immune responses associated with BHVs up to 15 years after aortic valve replacement. Early signs of SVD appeared in <5% of BHV recipients within 2 years. The levels of both anti-αGal and anti-Neu5Gc IgGs significantly increased one month after BHV implantation. The levels of these IgGs declined thereafter but anti-αGal IgG levels declined significantly faster in control patients compared to BHV recipients. Neu5Gc, anti-Neu5Gc IgG and complement deposition were found in calcified BHVs at much higher levels than in calcified native aortic valves. Moreover, in mice, anti-Neu5Gc antibodies were unable to promote calcium deposition on subcutaneously implanted BHV tissue engineered to lack αGal and Neu5Gc antigens. These results indicate that BHVs manufactured using donor tissues deficient in αGal and Neu5Gc could be less prone to immune-mediated deterioration and have improved durability., This work was supported by the European Union Seventh Framework Program (FP7/2007/2013) under grant agreement no. 603049 for the Translink Consortium. This research was also funded by a European Union H2020 Program grant no. ERC-2016-STG-716220 to V.P-K. and by the Elizabeth and Nicholas Slezak Super Center for Cardiac Research and Medical Engineering (to V.P-K.). This work was supported by an Institut National de la Santé et de la Recherche Médicale translational grant no. 2012-2016 to T.L.T. This work was supported by the Ministerio de Economía y Competitividad-ISCiii (PI15/00181) and the PERIS SLT002/16/00445 funded by the Department of Health of Generalitat de Catalunya (both granted to C.C.), and cofunded by FEDER (European Regional Development Fund), a way to build Europe. This work was supported by an Israel Ministry of Science & Technology PhD fellowship to S.B. We thank L. Adler for her assistance in the affinity purification of anti-Neu5Gc antibodies and IgG subclass analysis. Finally, we thank N. Bovin from the Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, who provided the Bdi-C3 PAA substrate needed to develop the anti-αGal assays.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants

  • Borrego-Écija, Sergi
  • Turon-Sans, Janina
  • Ximelis, Teresa
  • Aldecoa, Iban
  • Molina-Porcel, Laura
  • Povedano, Mónica
  • Gamez Carbonell, Josep
Proteïna TDP-43; Esclerosi lateral amiotròfica; Demència frontotemporal, Proteína TDP-43; Esclerosis lateral amiotrófica; Demencia frontotemporal, TDP-43 protein; Amyotrophic lateral sclerosis; Frontotemporal dementia, Cognitive impairment and behavioral changes in amyotrophic lateral sclerosis (ALS) are now recognized as part of the disease. Whether it is solely related to the extent of TDP-43 pathology is currently unclear. We aim to evaluate the influence of age, genetics, neuropathological features, and concomitant pathologies on cognitive impairment in ALS patients. We analyzed a postmortem series of 104 ALS patients and retrospectively reviewed clinical and neuropathological data. We assessed the burden and extent of concomitant pathologies, the role of APOE ε4 and mutations, and correlated these findings with cognitive status. We performed a logistic regression model to identify which pathologies are related to cognitive impairment. Cognitive decline was recorded in 38.5% of the subjects. Neuropathological features of frontotemporal lobar degeneration (FTLD) were found in 32.7%, explaining most, but not all, cases with cognitive impairment. Extent of TDP-43 pathology and the presence of hippocampal sclerosis were associated with cognitive impairment. Mutation carriers presented a higher burden of TDP-43 pathology and FTLD more frequently than sporadic cases. Most cases (89.4%) presented some degree of concomitant pathologies. The presence of concomitant pathologies was associated with older age at death. FTLD, but also Alzheimer’s disease, were the predominant underlying pathologies explaining the cognitive impairment in ALS patients. In sum, FTLD explained the presence of cognitive decline in most but not all ALS cases, while other non-FTLD related findings can influence the cognitive status, particularly in older age groups., SBE is a recipient of the Rio-Hortega post-residency grant from the Instituto de Salud Carlos III, Spain. This study was partially funded by Fundació Marató de TV3 (grant no. 20141610 to EG and no. 20143710 to RRG) and Fondo Europeo de Desarrollo Regional (FEDER) (PI15/01618 to RRG). AA is funded by Departament de Salut de la Generalitat de Catalunya, Pla estratègic de recerca i innovació en salut (PERIS) 2016–2020 (SLT002/16/00329). JG is recipient of the Instituto de Salud Carlos III-FEDER grants (PI16/01673 and PI19/00593)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Modification of high-density lipoprotein functions by diet and other lifestyle changes: A systematic review of randomized controlled trials

  • Sanllorente Melenchon, Albert
  • Lassale, Camille
  • Soria Florido, María Trinidad
  • Castañer, Olga
  • Fitó Colomer, Montserrat
  • Hernáez, Álvaro
High-density lipoprotein (HDL) functional traits have emerged as relevant elements that may explain HDL antiatherogenic capacity better than HDL cholesterol levels. These properties have been improved in several lifestyle intervention trials. The aim of this systematic review is to summarize the results of such trials of the most commonly used dietary modifications (fatty acids, cholesterol, antioxidants, alcohol, and calorie restriction) and physical activity. Articles were screened from the Medline database until March 2021, and 118 randomized controlled trials were selected. Results from HDL functions and associated functional components were extracted, including cholesterol efflux capacity, cholesteryl ester transfer protein, lecithin-cholesterol acyltransferase, HDL antioxidant capacity, HDL oxidation status, paraoxonase-1 activity, HDL anti-inflammatory and endothelial protection capacity, HDL-associated phospholipase A2, HDL-associated serum amyloid A, and HDL-alpha-1-antitrypsin. In mainly short-term clinical trials, the consumption of monounsaturated and polyunsaturated fatty acids (particularly omega-3 in fish), and dietary antioxidants showed benefits to HDL functionality, especially in subjects with cardiovascular risk factors. In this regard, antioxidant-rich dietary patterns were able to improve HDL function in both healthy individuals and subjects at high cardiovascular risk. In addition, in randomized trial assays performed mainly in healthy individuals, reverse cholesterol transport with ethanol in moderate quantities enhanced HDL function. Nevertheless, the evidence summarized was of unclear quality and short-term nature and presented heterogeneity in lifestyle modifications, trial designs, and biochemical techniques for the assessment of HDL functions. Such findings should therefore be interpreted with caution. Large-scale, long-term, randomized, controlled trials in different populations and individuals with diverse pathologies are warranted., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

  • Bataller Torralba, Alex
  • Garrido, A.
  • Guijarro, Francisca
  • Oñate, Guadalupe
  • Díaz-Beyá, Marina
  • Arnan, Montserrat
  • Salamero, Olga
Risk stratification; Acute myeloid leukemia, Estratificació del risc; Leucèmia mieloide aguda, Estratificación de riesgo; Leucemia mieloide aguda, The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and management of acute myeloid leukemia (AML) have become fundamental guidelines to assess the prognosis and postremission therapy of patients. However, they have been retrospectively validated in few studies with patients included in different treatment protocols. We analyzed 861 patients included in the Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias-12 risk-adapted protocol, which indicates cytarabine-based consolidation for patients allocated to the ELN 2017 favorable-risk group, whereas it recommends allogeneic stem cell transplantation (alloSCT) as a postremission strategy for the ELN 2017 intermediate- and adverse-risk groups. We retrospectively classified patients according to the ELN 2017, with 327 (48%), 109 (16%), and 245 (36%) patients allocated to the favorable-, intermediate-, and adverse-risk group, respectively. The 2- and 5-year overall survival (OS) rates were 77% and 70% for favorable-risk patients, 52% and 46% for intermediate-risk patients, and 33% and 23% for adverse-risk patients, respectively. Furthermore, we identified a subgroup of patients within the adverse group (inv(3)/t(3;3), complex karyotype, and/or TP53 mutation/17p abnormality) with a particularly poor outcome, with a 2-year OS of 15%. Our study validates the ELN 2017 risk stratification in a large cohort of patients treated with an ELN-2017 risk-adapted protocol based on alloSCT after remission for nonfavorable ELN subgroups and identifies a genetic subset with a very poor outcome that warrants investigation of novel strategies., This study was supported (in part) by Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (ISCIII) grants PI16/01027, PI19/1476, and PI20/01621; Health Research and Innovation Strategic Plan (PERIS) grant SLT002/16/00433 and research group support SGR 1395 and SGR 1655 from Generalitat de Catalunya; resident award “Emili Letang” 2019 (Hospital Clínic de Barcelona); and “Beca de Investigación FEHH 2019” (Fundación Española de Hematologia y Hemoterapia).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A Clinical-Genetic Score for Predicting Weight Loss after Bariatric Surgery: The OBEGEN Study

  • Fidilio Meli, Enzamaría
  • Gutiérrez-Carrasquilla, Liliana
  • Vilarrasa, Núria
  • Pellitero, Silvia
  • Vilallonga Puy, Ramón
  • Garcia Ruiz de Gordejuela, Amador
  • Hernández Pascual, Cristina
  • Simó Canonge, Rafael
  • Ciudin Mihai, Andreea
  • Caixàs, Assumpta
Genética; Obesidad; Pérdida de peso, Genetics; Obesity; Weight loss, Genètica; Obesitat; Pèrdua de pes, Around 30% of the patients that undergo bariatric surgery (BS) do not reach an appropriate weight loss. The OBEGEN study aimed to assess the added value of genetic testing to clinical variables in predicting weight loss after BS. A multicenter, retrospective, longitudinal, and observational study including 416 patients who underwent BS was conducted (Clinical.Trials.gov- NCT02405949). 50 single nucleotide polymorphisms (SNPs) from 39 genes were examined. Receiver Operating Characteristic (ROC) curve analysis were used to calculate sensitivity and specificity. Satisfactory response to BS was defined as at nadir excess weight loss >50%. A good predictive model of response [area under ROC of 0.845 (95% CI 0.805–0.880), p < 0.001; sensitivity 90.1%, specificity 65.5%] was obtained by combining three clinical variables (age, type of surgery, presence diabetes) and nine SNPs located in ADIPOQ, MC4R, IL6, PPARG, INSIG2, CNR1, ELOVL6, PLIN1 and BDNF genes. This predictive model showed a significant higher area under ROC than the clinical score (p = 0.0186). The OBEGEN study shows the key role of combining clinical variables with genetic testing to increase the predictability of the weight loss response after BS. This finding will permit us to implement a personalized medicine which will be associated with a more cost-effective clinical practice., This research was supported by grants from the “Pla Estratègic de Recerca i Innovació en Salut” (PERIS) 2016–2020 (SLT002/16/00497), the Instituto de Salud Carlos III (PI PI18/00964), Fondos FEDER “Una manera de hacer Europa”), and Menarini España. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is an initiative of the Instituto Carlos III.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

  • Garrido, A.
  • Hoyos Colell, Montserrat
  • Arnan, Montserrat
  • Vives Polo, Susana
  • Oñate, Guadalupe
  • Bataller Torralba, Alex
  • Salamero, Olga
Prognostic impact; Mutation; Acute myeloid leukemia, Impacte pronòstic; Mutació; Leucèmia mieloide aguda, Impacto pronóstico; Mutación; Leucemia mieloide aguda, The negative prognostic impact of internal tandem duplication of FLT3 (FLT3-ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML-NPM1) is restricted to those with a higher FLT3-ITD allelic ratio (FLT3high; ≥0.5) and considered negligible in those with a wild-type (FLT3WT)/low ITD ratio (FLT3low). Because the comutation of DNMT3A (DNMT3Amut) has been suggested to negatively influence prognosis in AML-NPM1, we analyzed the impact of DNMT3Amut in FLT3-ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML-NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3Amut status did not have a prognostic impact, with comparable overall survival (P = .2). Prognostic stratification established by FLT3-ITD (FLT3WT = FLT3low > FLT3high) was independent of DNMT3Amut status. Measurable residual disease (MRD) based on NPM1 quantitative polymerase chain reaction was available for 94 patients. DNMT3Amut was associated with a higher number of mutated NPM1 transcripts after induction (P = .012) and first consolidation (C1; P < .001). All DNMT3Amut patients were MRD+ after C1 (P < .001) and exhibited significant MRD persistence after C2 and C3 (MRD+ vs MRD−; P = .027 and P = .001, respectively). Finally, DNMT3Amut patients exhibited a trend toward greater risk of molecular relapse (P = .054). In conclusion, DNMT3Amut did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1 despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention., This work was supported in part by the Biomedical Research Institute (IIB Sant-Pau) and the José Carreras Leukemia Research Institute as well as grants from the Catalan Government (PERIS SLT002/16/0043 and AGAUR 2017 SGR 139) and the Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain (PI17/01246, PI20/01621 and CM20/00061).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Prevalence of Peripheral Arterial Disease and Associated Vascular Risk Factors in 65-Years-Old People of Northern Barcelona

  • Goncalves-Martins, Gabriela
  • Gil Sala, Daniel
  • Tello Diaz, Cristina
  • Tenezaca Sari, Ángel Xavier
  • Marrero Eligio de la Puente, Carlos Ernesto
  • Bellmunt Montoya, Sergi
  • Puig, Teresa
Asintomático; Factores de riesgo cardiovascular; Prevalencia, Asimptomàtic; Factors de risc cardiovascular; Prevalença, Asymptomatic; Cardiovascular risk factors; Prevalence, Objective: To determine the prevalence and risk factors associated with peripheral arterial disease (PAD) in Northern Barcelona at 65 years of age. Methods: A single-center, cross-sectional study, including males and females 65 years of age, health care cardholders of Barcelona Nord. PAD was defined as an ankle–brachial index (ABI) < 0.9. Attending subjects were evaluated for a history of common cardiovascular risk factors. A REGICOR score was obtained, as well as a physical examination and anthropometric measurements. Results: From November 2017 to December 2018, 1174 subjects were included: 479 (40.8%) female and 695 (59.2%) male. Overall prevalence of PAD was 6.2% (95% CI: 4.8–7.6%), being 7.9% (95% CI: 5.9–9.9%) in males and 3.8% (95% CI: 2.1–5.5%) in females. An independent strong association was seen in male smokers and diabetes, with ORs pf 7.2 (95% CI: 2.8–18.6) and 1.8 (95% CI: 1.0–3.3), respectively, and in female smokers and hypertension, with ORs of 5.2 (95% CI: 1.6–17.3) and 3.3 (95% CI: 1.2–9.0). Male subjects presented with higher REGICOR scores (p < 0.001). Conclusion: Higher-risk groups are seen in male subjects with a history of smoking and diabetes and female smokers and arterial hypertension, becoming important subgroups for our primary healthcare centers and should be considered for ABI screening programs., This work was logistically supported by the PERIS 2016–2020 medical research grant from Generalitat de Catalunya (Spain). Expedient Number SLT002/16/00441.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

  • Wang, Yifan
  • Bernhardy, Andrea J.
  • Nacson, Joseph
  • Krais, John J.
  • Tan, Yin-Fei
  • Nicolas, Emmanuelle
  • Llop Guevara, Alba
  • Balmaña Gelpí, Judith
  • Serra Elizalde, Violeta
Resistència terapèutica contra el càncer; Càncer d'ovaris, Resistencia terapéutica al cáncer; Cáncer de ovarios, Cancer therapeutic resistance; Ovarian cancer, BRCA1 mutant carcinomas are sensitive to PARP inhibitor (PARPi) therapy; however, resistance arises. BRCA1 BRCT domain mutant proteins do not fold correctly and are subject to proteasomal degradation, resulting in PARPi sensitivity. In this study, we show that cell lines and patient-derived tumors, with highly disruptive BRCT domain mutations, have readily detectable BRCA1 protein expression, and are able to proliferate in the presence of PARPi. Peptide analyses reveal that chemo-resistant cancers contain residues encoded by BRCA1 intron 15. Mechanistically, cancers with BRCT domain mutations harbor BRCA1 gene breakpoints within or adjacent to Alu elements in intron 15; producing partial gene duplications, inversions and translocations, and terminating transcription prior to the mutation-containing BRCT domain. BRCA1 BRCT domain-deficient protein isoforms avoid mutation-induced proteasomal degradation, support homology-dependent DNA repair, and promote PARPi resistance. Taken together, Alu-mediated BRCA1 gene rearrangements are responsible for generating hypomorphic proteins, and may represent a biomarker of PARPi resistance., This work was supported by the US National Institutes of Health (NIH) Grants P50 CA083638 and 5P30 CA006927, as well as R01CA214799, Susan Komen CCRCR17499048, and OC130212 Department of Defense to N.J., and a Pilot Award and Nested Teal Postdoctoral Scholar supported Y.W. (OC140040). We thank Drs. Judith Balmaña, Cristina Saura and Joaquin Arribas for providing materials. PDXs were established thanks to the GHD-Pink program, the FERO Foundation and the Catalan Agency AGAUR [2017 SGR 540]. V.S. is supported by the Instituto de Salud Carlos III (CP14/00228) and ALG by a PERIS fellowship from the Departament de Salut, Generalitat de Catalunya (SLT002/16/00477). Clovis Oncology supplied rucaparib. We are grateful to FCCC Genomics, Cell Culture and Cell Sorting facilities. We thank Hsin Yao Tang at the Wistar Proteomics facility for help with mass spectrometry.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Fungal and Bacterial Loads: Noninvasive Inflammatory Bowel Disease Biomarkers for the Clinical Setting

  • Philippe Sarrabayrouse, Guillaume
  • Elias Vidal, Andrea
  • Yañez Araya, Francisca
  • Bartoli, Chiara
  • Casellas Jordá, Francesc
  • Borruel Sainz, Natalia
  • Herrera de Guise, Claudia Maria
  • Manichanh, Chaysavanh
  • Varela Castro, Encarna
  • Mayorga Ayala, Luis Fernando
Malaltia inflamatòria intestinal; Càrrega microbiana; Predicció, Enfermedad inflamatoria intestinal; Carga microbiana; Predicción, Inflammatory bowel disease; Microbial load; Prediction, Microbiome sequence data have been used to characterize Crohn's disease (CD) and ulcerative colitis (UC). Based on these data, we have previously identified microbiomarkers at the genus level to predict CD and CD relapse. However, microbial load was underexplored as a potential biomarker in inflammatory bowel disease (IBD). Here, we sought to study the use of fungal and bacterial loads as biomarkers to detect both CD and UC and CD and UC relapse. We analyzed the fecal fungal and bacterial loads of 294 stool samples obtained from 206 participants using real-time PCR amplification of the ITS2 region and the 16S rRNA gene, respectively. We combined the microbial data with demographic and standard laboratory data to diagnose ileal or ileocolonic CD and UC and predict disease relapse using the random forest algorithm. Fungal and bacterial loads were significantly different between healthy relatives of IBD patients and nonrelated healthy controls, between CD and UC patients in endoscopic remission, and between UC patients in relapse and non-UC individuals. Microbial load data combined with demographic and standard laboratory data improved the performance of the random forest models by 18%, reaching an average area under the receiver operating characteristic curve (AUC) of 0.842 (95% confidence interval [CI], 0.65 to 0.98), for IBD diagnosis and enhanced CD and UC discrimination and CD and UC relapse prediction. Our findings show that fecal fungal and bacterial loads could provide physicians with a noninvasive tool to discriminate disease subtypes or to predict disease flare in the clinical setting. IMPORTANCE Next-generation sequence data analysis has allowed a better understanding of the pathophysiology of IBD, relating microbiome composition and functions to the disease. Microbiome composition profiling may provide efficient diagnosis and prognosis tools in IBD. However, the bacterial and fungal loads of the fecal microbiota are underexplored as potential biomarkers of IBD. Ulcerative colitis (UC) patients have higher fecal fungal and bacterial loads than patients with ileal or ileocolonic CD. CD patients who relapsed harbor more-unstable fungal and bacterial loads than those of relapsed UC patients. Fecal fungal and bacterial load data improved prediction performance by 18% for IBD diagnosis based solely on clinical data and enhanced CD and UC discrimination and prediction of CD and UC relapse. Combined with existing laboratory biomarkers such as fecal calprotectin and C-reactive protein (CRP), microbial loads may improve the diagnostic accuracy of IBD and of ileal CD and UC disease activity and prediction of UC and ileal CD clinical relapse., This work was funded by Instituto de Salud Carlos III, grant PI17/00614, cofinanced by the European Regional Development Fund (ERDF) and by the PERIS (SLT002/16). F. Casellas has received research funding from AbbVie, Ferring, MSD, Shire, and Zambon and speaker fees from AbbVie, Chiesi, Ferring, Gebro, MSD, Shire, Takeda, and Zambon. S. Vermeire has received grant support from AbbVie, MSD, Pfizer, J&J, and Takeda; received speaker fees from AbbVie, MSD, Takeda, Ferring, Dr. Falk Pharma, Hospira, Pfizer Inc., and Tillots; and served as a consultant for AbbVie, MSD, Takeda, Ferring, Genentech/Roche, Robarts clinical trials, Gilead, Celgene, Prometheus, Avaxia, Prodigest, Shire, Pfizer Inc, Galapagos, Mundipharma, Hospira, Celgene, Second Genome, and Janssen. C. Manichanh has received financial support for research from Danone.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Impact of Mental Health Literacy on Improving Quality of Life Among Adolescents in Barcelona

  • Amado Rodri­guez, Isaac Daniel
  • Casañas, Rocio
  • Juan Parra, Jaume
  • Roldan-Merino, Juan
  • LALUCAT-JO, LLUIS
  • Fernandez-San-Martin, Maria Isabel
Mental health literacy; Adolescents; Health education; School-based intervention, Alfabetització en salut mental; Adolescents; Educació per a la salut; Intervenció escolar, Alfabetización en salud mental; Adolescentes; Educación para la salud, We aim to assess the effect of the Espaijove.net mental health literacy program on adolescents' quality of life (QOL). Additionally, we aim to describe their QOL and mental well-being. Methods: A multicenter, randomized, controlled trial was conducted, with pre- and post-intervention assessments and 6- and 12-month follow-ups. A total of 1032 students aged 13-14 from 18 schools in Barcelona participated in one of the three following mental health literacy (MHL) programs or were placed in a control group (CG): (1) a 1 h awareness session (G1h); (2) a 6 h MHL program (G6h); (3) a 7 h MHL program with stigma reduction (G7h). Measures: (1) Mental well-being: Strengths and Difficulties Questionnaire (SDQ); (2) QOL: EuroQol 5D-5L with its two parts: the EuroQol 5D-5L Index (0-1) and EuroQol 5D-5L visual analog scale (EQ-VAS) (0-100). Analyses were conducted on an intention-to-treat basis, using data imputation methods for missing data. Intervention effects were assessed using multilevel models. Results: Baseline EQ-VAS and EQ-5D-5L index scores were 77.84 (CI = 76.77-78.91) and 0.91 (CI = 0.90-0.92), respectively. Boys reported higher QOL and SDQ scores (p < 0.001), whereas participants of foreign nationality showed lower scores in QOL (EQ-VAS; p = 0.039) and mental well-being (p < 0.001). Post-intervention, all groups (intervention and control), except G6h, showed QOL improvements. However, in the 6-month follow-up, the CG outperformed the other groups. At 12 months, G7h achieved the highest EQ-VAS scores compared to the other groups. Conclusions: MHL-based interventions improved short-term QOL but failed to sustain these improvements over time. Groups with lower QOL and SDQ scores included girls and adolescents of foreign nationality., This research was funded by the folloqing: Instituto de Salud Carlos III. Subprograma de proyectos de investigación en salud (AES 2015), funded under grant code PI15/01613, co-financed by the European Union through the European Regional Development Fund (FEDER). Departament de Salut de la Generalitat de Catalunya dentro del Pla Estratègic de Recerca i Innovació en Salut 2016–2020 (PERIS), SLT002/16/00202. 20º beca Institut Català de la salut (ICS) per a la Capacitació en Investigació i Realització del Doctorat a l’Atenció Primària 2020, IDIAP 7Z20/010. Ajuts XB para la realización de la tesis doctoral para especialista de reciente titulación en Enfermería (promoción 2017–2019) familiar y comunitaria, 6ª convocatoria Gerencia territorial de Barcelona a través de la Unitat Docent Multiprofessional, Barcelona Ciutat, ICS, 2019. 15º Convocatòria d’Ajuts XB. Modul de Recerca. Unitat de Suport a la Recerca Barcelona Ciutat, 2023.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status

  • Ceausu, Andra
  • Rodríguez-Gallego, Esther
  • Peraire, Joaquim
  • López-Dupla, Miguel
  • Viladés, Consuelo
  • Vidal Gonzalez, Judit
  • Domingo, Pere
Immune recovery; HIV; Interleukin 7, Recuperación inmunológica; VIH; Interleucina 7, Recuperació immunològica; VIH; Interleucina 7, A relationship between polymorphisms in genes encoding interleukin 7 (IL-7) and its cellular receptor (IL-7R) and antiretroviral therapy (ART)-associated immune recovery in HIV subjects has been previously reported. However, details of this relationship remain unclear, and the association of these polymorphisms with circulating IL-7/IL-7R levels is scarce. Here, we explored whether IL-7/IL-7R axis was associated with quantitative CD4+ T-cell recovery in HIV-infected subjects. IL-7/IL-7R polymorphisms were assessed by genotyping, and multiple inheritance models were used to estimate both, their association with low pre-ART CD4+ T-cell counts and incomplete immune recovery status after 48 weeks of suppressive ART. Integrated data from genetic variants association and soluble plasma IL-7/IL-7R quantification suggest that IL-7/IL-7R genotype expression could alter the homeostatic balance between soluble and membrane-bound receptors. The haplotype analyses indicates that allele combinations impacts pre-ART circulating CD4+ T-cell counts, immune recovery status and the absolute increment of CD4+ T-cell counts. The knowledge about how IL-7/IL-7R axis is related to quantitative CD4+ T-cell recovery and immune recovery status after initiating ART could be useful regarding T-cell reservoirs investigations in HIV subjects., This work was supported by the Fondo de Investigacion Sanitaria [PI10/02635, PI13/0796, PI14/1693, PI16/00503, PI16/00684, PI19/01337]-ISCIII-FEDER; Programa de Suport als Grups de Recerca AGAUR (2014SGR250, 2017SGR948); Gilead Fellowship Program GLD14/293 and GLD17/00299; The SPANISH AIDS Research Network [RD12/0017/0005, RD16/0025/0002, RD16/0025/0006, RD16/0025/0019, RD16/0025/0020]-ISCIII-FEDER (Spain) and Consejeria de Economia, Innovacion, Ciencia y Empleo, Junta de Andalucia (Proyecto de Investigacion de Excelencia; CTS2593). FV is supported by grants from the Programa de Intensificacion de Investigadores (INT15/226)-ISCIII. YMP and ERM are supported by the Servicio Andaluz de Salud through Programa Nicolas Monardes (C-0013/17 and C-0032/17, respectively). E.R-M was also supported by Programa Miguel Servet ISCIII, FEDER, CPII014/00025. AR is supported by a grant from the Accio Instrumental d'incorporacio de cientifics i tecnolegs (PERIS SLT002/16/00101), Departament de Salut, Generalitat de Catalunya and Agencia Estatal de Investigacion (Acciones de caracter internacional "Europa Investigacion"; EUIN2017-89297), Ministry of Economy and Competitiveness. We are also grateful to GESIDA for "Premio para Jovenes Investigadores 2019" to AR.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Association between different diet quality scores and depression risk: the REGICOR population-based cohort study

  • Lugon, Gabriela
  • Hernáez, Álvaro
  • Jacka, Felice
  • Marrugat, Jaume
  • Ramos , Rafel
  • Garre-Olmo, Josep
  • Elosua Llanos, Roberto
  • Lassale, Camille
Background Our aim was to determine the association between diet quality and depression incidence in the population-based REGICOR cohort study, Catalonia, Spain. Methods Prospective observational study using participants’ baseline (2003–2006), follow-up (2007–2013) and clinical records data. Five diet quality scores were derived from a food frequency questionnaire (FFQ) at baseline: the relative Mediterranean Diet Score (rMED), the Modified Mediterranean Diet Score (ModMDS), a Dietary Approaches to Stop Hypertension (DASH) score, a Healthful Plant-based Diet Index (HPDI) and the World Health Organization Healthy Diet Indicator (WHO-HDI). Participants using pharmacological antidepressant treatment were excluded as a proxy for presence of depression at baseline. At follow-up, the Patient Health Questionnaire (PHQ-9) was applied to assess depressive symptoms (≥ 10 defining depressive disorder). A secondary outcome was depression diagnosis assessed through clinical records. Logistic regression and Cox proportional hazards models were used. Results Main analysis included 3046 adults (50.3% women) with a mean age of 54.7 (SD = 11.6) years. After 6-years follow-up, 184 (6.04%) cases of depressive disorder were identified. There was 16% lower odds of depressive disorder per 1SD increase of rMED (OR = 0.84; 95%CI = 0.71–0.98). Secondary outcome analysis (n = 4789) identified 261 (5.45%) incident cases of clinical depression diagnosis over 12 years follow-up, and 19% lower risk of clinical depression was observed with the WHO-HDI (HR = 0.81; 95%CI = 0.70–0.93). Adjusting for BMI did not attenuate the findings. Conclusions A significant inverse association between diet quality and depression incidence was found in this population-based cohort study, independent of sociodemographic, health and lifestyle. Adherence to a healthy diet could be a complementary intervention for the prevention of depression., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Blood DNA methylation signature of diet quality and association with cardiometabolic traits

  • Domínguez-Barragán, Jorge
  • Fernández Sanlés, Alba
  • Hernáez, Álvaro
  • Llauradó-Pont, Joana
  • Marrugat, Jaume
  • Robinson, Oliver
  • Tzoulaki, Ioanna
  • Elosua Llanos, Roberto
  • Lassale, Camille
Aims Diet quality might influence cardiometabolic health through epigenetic changes, but this has been little investigated in adults. Our aims were to identify cytosine–phosphate–guanine (CpG) dinucleotides associated with diet quality by conducting an epigenome-wide association study (EWAS) based on blood DNA methylation (DNAm) and to assess how diet-related CpGs associate with inherited susceptibility to cardiometabolic traits: body mass index (BMI), systolic blood pressure (SBP), triglycerides, type 2 diabetes (T2D), and coronary heart disease (CHD). Methods and results Meta-EWAS including 5274 participants in four cohorts from Spain, the USA, and the UK. We derived three dietary scores (exposures) to measure adherence to a Mediterranean diet, to a healthy plant-based diet, and to the Dietary Approaches to Stop Hypertension. Blood DNAm (outcome) was assessed with the Infinium arrays Human Methylation 450K BeadChip and MethylationEPIC BeadChip. For each diet score, we performed linear EWAS adjusted for age, sex, blood cells, smoking and technical variables, and BMI in a second set of models. We also conducted Mendelian randomization analyses to assess the potential causal relationship between diet-related CpGs and cardiometabolic traits. We found 18 differentially methylated CpGs associated with dietary scores (P < 1.08 × 10−7; Bonferroni correction), of which 12 were previously associated with cardiometabolic traits. Enrichment analysis revealed overrepresentation of diet-associated genes in pathways involved in inflammation and cardiovascular disease. Mendelian randomization analyses suggested that genetically determined methylation levels corresponding to lower diet quality at cg02079413 (SNORA54), cg02107842 (MAST4), and cg23761815 (SLC29A3) were causally associated with higher BMI and at cg05399785 (WDR8) with greater SBP, and methylation levels associated with higher diet quality at cg00711496 (PRMT1) with lower BMI, T2D risk, and CHD risk and at cg0557921 (AHRR) with lower CHD risk. Conclusion Diet quality in adults was related to differential methylation in blood at 18 CpGs, some of which related to cardiometabolic health., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comprehensive Constitutional Genetic and Epigenetic Characterization of Lynch-Like Individuals

  • González-Acosta, Maribel
  • Vargas-Parra, Gardenia
  • Navarro, Matilde
  • Balmaña Gelpí, Judith
  • Ramon y Cajal, Teresa
  • Dámaso, Estela
Síndrome de Lynch; Panell de gens del càncer; Epimutació, Síndrome de Lynch; Panel de genes del cáncer; Epimutación, Lynch syndrome; Cancer genes panel; Epimutation, The causal mechanism for cancer predisposition in Lynch-like syndrome (LLS) remains unknown. Our aim was to elucidate the constitutional basis of mismatch repair (MMR) deficiency in LLS patients throughout a comprehensive (epi)genetic analysis. One hundred and fifteen LLS patients harboring MMR-deficient tumors and no germline MMR mutations were included. Mutational analysis of 26 colorectal cancer (CRC)-associated genes was performed. Pathogenicity of MMR variants was assessed by splicing and multifactorial likelihood analyses. Genome-wide methylome analysis was performed by the Infinium Human Methylation 450K Bead Chip. The multigene panel analysis revealed the presence of two MMR gene truncating mutations not previously found. Of a total of 15 additional MMR variants identified, five -present in 6 unrelated individuals- were reclassified as pathogenic. In addition, 13 predicted deleterious variants in other CRC-predisposing genes were found in 12 probands. Methylome analysis detected one constitutional MLH1 epimutation, but no additional differentially methylated regions were identified in LLS compared to LS patients or cancer-free individuals. In conclusion, the use of an ad-hoc designed gene panel combined with pathogenicity assessment of variants allowed the identification of deleterious MMR mutations as well as new LLS candidate causal genes. Constitutional epimutations in non-LS-associated genes are not responsible for LLS., This work was funded by the Spanish Ministry of Economy and Competitiveness and cofunded by FEDER funds -a way to build Europe- (grants SAF2012-33636, SAF2015-68016-R and SAF2016-80888-R), CIBERONC, RTICC Network (RD12/0036/0031 and RD12/0036/0008), the Spanish Association Against Cancer (AECC) (080253), the Government of Catalonia (grant 2014SGR338, 2017SGR1282 and PERIS SLT002/16/0037), Fundación Mutua Madrileña (grant AP114252013). We thank CERCA Programme for institutional support. ED was supported by a grant from the Spanish Ministry of Economy and Competitiveness. The AECC fellowship to MG-A. AF was supported by a grant from the Catalonian Health Department (SLT002/16/00409). FM was supported by CIBERONC. The Mexican National Council for Science and Technology (CONACyT) fellowship to GV.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer

  • Roman-Canal, Berta
  • Gatius, Sònia
  • Bonnin, Sarah
  • Ruiz-Miró, Maria
  • González, Esperanza
  • Gil Moreno, Antonio
  • Colas Ortega, Eva
  • Moiola, Cristian Pablo
Taqman OpenArray technology; Lung cancer diagnosis; Biomarkers, Tecnología Taqman OpenArray; Diagnóstico de cáncer de pulmón; Biomarcadores, Tecnologia Taqman OpenArray; Diagnòstic del càncer de pulmó; Biomarcadors, Lung cancer is the leading cause of cancer-related deaths among men and women in the world, accounting for the 25% of cancer mortality. Early diagnosis is an unmet clinical issue. In this work, we focused to develop a novel approach to identify highly sensitive and specific biomarkers by investigating the use of extracellular vesicles (EVs) isolated from the pleural lavage, a proximal fluid in lung cancer patients, as a source of potential biomarkers. We isolated EVs by ultracentrifuge method from 25 control pleural fluids and 21 pleural lavages from lung cancer patients. Analysis of the expression of EV-associated miRNAs was performed using Taqman OpenArray technology through which we could detect 288 out of the 754 miRNAs that were contained in the OpenArray. The differential expression analysis yielded a list of 14 miRNAs that were significantly dysregulated (adj. p-value < 0.05 and logFC lower or higher than 3). Using Machine Learning approach we discovered the lung cancer diagnostic biomarkers; miRNA-1-3p, miRNA-144-5p and miRNA-150-5p were found to be the best by accuracy. Accordance with our finding, these miRNAs have been related to cancer processes in previous studies. This results opens the avenue to the use of EV-associated miRNA of pleural fluids and lavages as an untapped source of biomarkers, and specifically, identifies miRNA-1-3p, miRNA-144-5p and miRNA 150-5p as promising biomarkers of lung cancer diagnosis., The sample collection was supported by IRBLleida BIOBANK (B.0000682) and Plataforma biobancos PT17/0015/0027.EC hold a postdoctoral fellowship from the Departament de Salut of the Generalitat de Catalunya (SLT002/16/00274). This study was supported by: “Discovery, validation and implementation of biomarkers for Precision Oncology” (ISCIII PIE15/00029), CIBERONC (CB16/12/00231 and CB16/12/00328), Grups consolidats de la Generalitat de Catalunya (2017SGR1368 and 2017SGR1661) and Asociación Española contra el Cancer (GCTRA1804MATI).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa

  • Cantero Perez, Jon
  • Grau Exposito, Judit
  • Serra Peinado, Carla
  • Rosero, Daniela A.
  • Luque Ballesteros, Laura
  • Astorga Gamaza, Antonio
  • Castellví Vives, Josep
  • Mañalich Barrachina, Laura
  • Centeno Mediavilla, Maria Cristina
  • Falcó Ferrer, Vicenç
  • Buzón Gómez, María José
  • Genesca Ferrer, Meritxell
HIV viral reservoirs; Cervical mucosa; TRM, Reservorios virales de VIH; Mucosa cervical; TRM, Reservoris virals del VIH; Mucosa cervical; TRM, HIV viral reservoirs are established very early during infection. Resident memory T cells (TRM) are present in tissues such as the lower female genital tract, but the contribution of this subset of cells to the pathogenesis and persistence of HIV remains unclear. Here, we show that cervical CD4+TRM display a unique repertoire of clusters of differentiation, with enrichment of several molecules associated with HIV infection susceptibility, longevity and self-renewing capacities. These protein profiles are enriched in a fraction of CD4+TRM expressing CD32. Cervical explant models show that CD4+TRM preferentially support HIV infection and harbor more viral DNA and protein than non-TRM. Importantly, cervical tissue from ART-suppressed HIV+ women contain high levels of viral DNA and RNA, being the TRM fraction the principal contributor. These results recognize the lower female genital tract as an HIV sanctuary and identify CD4+TRM as primary targets of HIV infection and viral persistence. Thus, strategies towards an HIV cure will need to consider TRM phenotypes, which are widely distributed in tissues., This work was primarily supported by grants from the Spanish "Ministerio de Economia y Competitividad, Instituto de Salud Carlos III" (ISCIII, PI14/01235 and PI17/01470) and a fellowship award from the Dexeus foundation for women's health research to M.G., grants R21AI118411 and SAF2015-67334-R (from the Spanish Secretariat of Science and Innovation and FEDER funds) to M.J.B and grants from the ISCIII (PI14/01058 and PI17/00164) to J.G.P. M.G., M.J.B., and. J.G.P. are supported by the Spanish AIDS network Red Tematica Cooperativa de Investigacion en SIDA (RD16/0025/0007) M.G. is currently supported by the "Pla estrategic de recerca i innovacio en salut" (PERIS, SLT002/16/00353), from the Catalan government, while the Miguel Servet program from the ISCIII supports M.J.B. (CP17/00179) and J.G.P. (CP15/00014).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Vigilancia epidemiológica intensificada de arbovirosis: primer caso de dengue autóctono en Cataluña (España), zona Metropolitana Norte de Barcelona, 2018-2019, Intensified epidemiological surveillance of arbovirosis: First case of native dengue fever in Catalonia (Spain), Northern Metropolitan Area of Barcelona, 2018-2019

  • Valerio, Lluís
  • Roure, Silvia
  • Benitez Diaz, Rosa Maria
  • Fernández-Rivas, Gema
  • Rivaya, Belén
  • Expósito, Carme
  • Salvador Velez, Fernando M
Arbovirosis; Vigilància epidemiològica; Espanya, Arbovirosis; Vigilancia epidemiológica; España, Arbovirosis; Epidemiologic surveillance; Spain, Objetivo Valorar los resultados obtenidos por una red de vigilancia epidemiológica y asistencial de arbovirosis compuesta por médicos y profesionales de enfermería de hospital y atención primaria (AP) formados en su identificación, confirmación diagnóstica y manejo clínico. Emplazamiento Zona Sanitaria Metropolitana Norte de Barcelona (1.400.000 habitantes; Cataluña, España) durante un año natural. Participantes Diecisiete médicos (7 de AP y 10 hospitalarios) más 4 enfermeros/as de AP. Tipo de estudio Estudio observacional prospectivo. Mediciones principales Se definieron variables demográficas, epidemiológicas (caso autóctono/importado, sospechoso/probable/confirmado) y asistenciales (síntomas, perfil serológico, periodo virémico). Resultados De los 34 pacientes identificados cumplían criterios de estudio 26 (76,5%) casos; de ellos, se confirmó alguna arbovirosis en 14 (53,8%): 13 fiebres dengues más 1 chikungunya. No se registraron casos de fiebre de zika. Existían antecedentes de viaje a zonas endémicas (23; 88,4%), pero no en 3 casos (11,6%), en los que se consideró la posibilidad de una transmisión autóctona; de ellos, se confirmó un caso de dengue. La incidencia estimada de arbovirosis fue de 0,4 (IC 95%: 0,33-0,51) casos × 10.000 hab./año, que, comparada con la incidencia estimada en la misma área geográfica durante el periodo 2009-2013 (0,19 casos × 10.000 hab./año; IC 95%: 0,07-0,31), mostró un incremento significativo (p = 0,044). Los pacientes en periodo de viremia al momento de la primera visita médica fueron 11 (42,3%). Conclusiones Un programa de vigilancia epidemiológica intensificada definido a nivel de AP y hospitalario es capaz de detectar significativamente más casos de arbovirosis importadas y transmitidas autóctonamente. Posiblemente asistimos a un aumento en la incidencia de arbovirosis importadas, por lo que las medidas encaminadas a su identificación y confirmación deben reforzarse., Objective To evaluate the results obtained by a surveillance network on arbovirosis composed by doctors and nurses located at hospitals and Primary Care trained in their identification, diagnostic confirmation and clinical management. Location North Metropolitan Area of Barcelona (1,400,000 inhabitants; Catalonia; Spain) during a calendar year. Participants Seven Primary Care and 10 hospital physicians plus 4 Primary Care nurses. Type of study A prospective observational study. Main measurements Demographic, epidemiological (autochthonous/imported, suspect/probable/confirmed case) and healthcare variables (symptoms, serological profile, viral period) were defined. Results Of the 34 patients identified, 26 (76.5%) met study criteria. Among them, any arbovirosis was confirmed in 14 (53.8%): 13 dengue plus 1 chikungunya fever. There were no cases of Zika fever. There was a history of travel to endemic areas 23 (88.4%), but not in 3 cases (11.6%) in which the possibility of an indigenous transmission was considered; of them, a case of dengue was confirmed. The estimated incidence of arbovirosis was 0.4 (95% CI: 0.33-0.51) cases × 10,000 hab/year which, when compared to the estimated incidence in the same geographical area during the period 2009-2013 (0.19 cases × 10,000 hab/year; 95% CI: 0.07-0.31), a significant increase was found ( P = .044). Patients within viremia period at the time of their first medical visit were 11 (42.3%). Conclusions An intensified epidemiological surveillance program defined at Primary Care and hospital levels is able to detect significantly more cases of imported and autochthonous arbovirosis. Possibly we are witnessing an increase in the incidence of imported arbovirosis and, thus, measures aimed at their identification and confirmation should be reinforced., La Plataforma Integral para control de las arbovirosis en Cataluña (PICAT) es un proyecto realizado con el apoyo del Departamento de Salud de la Generalitat de Catalunya y ha sido financiada mediante una beca del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, cod. exp. SLT002/16/00466.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Trajectories of antidepressant use and 6-year change in body weight: a prospective population-based cohort study

  • Lassale, Camille
  • Lugon, Gabriela
  • Hernáez, Álvaro
  • Frank, Philipp
  • Marrugat, Jaume
  • Ramos, Rafel
  • Garre-Olmo, Josep
  • Elosua, Roberto
Background: Antidepressant drug treatment may be associated with weight gain, but long-term studies are lacking. Methods: We included 3,127 adults (1,701 women) from the REGICOR study, aged 55.6 (SD = 11.6) years on average in 2003–2006, living in the northeast of Spain. They had data at two time points (baseline and a median of 6.3 years later) on self-reported antidepressant use, body weight and height, and on baseline smoking, physical activity, diet quality, education, civil status, and depressive symptoms assessed with the Patient Health Questionnaire (PHQ-9) at follow-up. We defined four trajectories of antidepressant use as follows: never use, new use at follow-up, initial use discontinued, repeated use at both time points. We used multivariable linear models to estimate the association of these trajectories with the percentage of weight change. In people without obesity at baseline (n = 2,404), we also estimated the association with obesity incidence at follow-up. Results: The average 6-year weight gain was 0.53 kg (1.01% body weight), and 24.5% of the participants gained >5% of body weight. The majority (83.6%) of participants did not report any use of antidepressants, 6.2% initiated during follow-up, 5.1% discontinued it, and 5.1% reported their use at both time points. In multivariable analyses, compared to never users, all trajectories were associated with greater weight gain: +1.78% (0.57, 2.98) for initial use discontinued, +2.08% (0.97, 3.19) for new use at follow-up, and +1.98% (95% CI: 0.75, 3.20) for repeated use. In non-obese participants at baseline (n = 2,404), the odds ratio for becoming obese was 2.06 (1.03, 3.96) for repeated use and non-statistically significant for the other trajectories. Conclusions: In a population-based adult cohort, repeated use of antidepressants was strongly associated with weight gain. New and discontinued use was associated with weight gain, but non-significantly to obesity incidence. Given the global obesity epidemic and the widespread use of antidepressants, weight management and metabolic monitoring should be encouraged and integrated into depression follow-up guidelines alongside antidepressant prescriptions., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Low doses of LPS exacerbate the inflammatory response and trigger death on TLR3-primed human monocytes

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
TLR sensing of pathogens triggers monocyte activation to initiate the host innate immune response to infection. Monocytes can dynamically adapt to different TLR agonists inducing different patterns of inflammatory response, and the sequence of exposure to TLRs can dramatically modulate cell activation. Understanding the interactions between TLR signalling that lead to synergy, priming and tolerance to TLR agonists may help explain how prior infections and inflammatory conditioning can regulate the innate immune response to subsequent infections. Our goal was to investigate the role of MyD88-independent/dependent TLR priming on modulating the monocyte response to LPS exposure. We stimulated human blood monocytes with agonists for TLR4 (LPS), TLR3 (poly(I:C)) and TLR7/8 (R848) and subsequently challenged them to low doses of endotoxin. The different TLR agonists promoted distinct inflammatory signatures in monocytes. Upon subsequent LPS challenge, LPS- and R848-primed monocytes did not enhance the previous response, whereas poly(I:C)-primed monocytes exhibited a significant inflammatory response concomitant with a sharp reduction on cell viability. Our results show that TLR3-primed monocytes are prompted to cell death by apoptosis in the presence of low endotoxin levels, concurrent with the production of high levels of TNFα and IL6. Of note, blocking of TNFR I/II in those monocytes did reduce TNFα production but did not abrogate cell death. Instead, direct signalling through TLR4 was responsible of such effect. Collectively, our study provides new insights on the effects of cross-priming and synergism between TLR3 and TLR4, identifying the selective induction of apoptosis as a strategy for TLR-mediated host innate response.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacological modulation of SAMHD1 activity by CDK4/6 inhibitors improves anticancer therapy

  • Castellví, Marc
  • Felip, Eudald|||0000-0002-3812-1313
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Badia, Roger|||0000-0003-3982-7577
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Pujantell, Maria|||0000-0002-9471-5853
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Teruel, Iris|||0000-0002-5563-6562
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
Sterile alpha motif and histidine-aspartic acid domain-containing protein 1 (SAMHD1) is a dNTP triphosphohydrolase involved in the regulation of the intracellular dNTP pool, linked to viral restriction, cancer development and autoimmune disorders. SAMHD1 function is regulated by phosphorylation through a mechanism controlled by cyclin-dependent kinases and tightly linked to cell cycle progression. Recently, SAMHD1 has been shown to decrease the efficacy of nucleotide analogs used as chemotherapeutic drugs. Here, we demonstrate that SAMHD1 can enhance or decrease the efficacy of various classes of anticancer drug, including nucleotide analogues, but also anti-folate drugs and CDK inhibitors. Importantly, we show that selective CDK4/6 inhibitors are pharmacological activators of SAMHD1 that act by inhibiting its inactivation by phosphorylation. Combinations of a CDK4/6 inhibitor with nucleoside or folate antimetabolites potently enhanced drug efficacy, resulting in highly synergic drug combinations (CI < 0.04). Mechanistic analyses reveal that cell cycle-controlled modulation of SAMHD1 function is the central process explaining changes in anticancer drug efficacy, therefore providing functional proof of the potential of CDK4/6 inhibitors as a new class of adjuvants to boost chemotherapeutic regimens. The evaluation of SAMHD1 expression in cancer tissues allowed for the identification of cancer types that would benefit from the pharmacological modulation of SAMHD1 function. In conclusion, these results indicate that the modulation of SAMHD1 function may represent a promising strategy for the improvement of current antimetabolite-based treatments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ev-associated miRNAs from peritoneal lavage are a source of biomarkers in endometrial cancer

  • Roman-Canal, Berta|||0000-0002-6784-0077
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Gatius, Sònia
  • Bonnin, Sarah|||0000-0001-5159-2518
  • Ruiz-Miró, María
  • González, Esperanza
  • González-Tallada, Xavier
  • Llordella, Ivanna
  • Hernández, Isabel|||0000-0001-8119-393X
  • Porcel, José M.|||0000-0002-2734-8061
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Ponomarenko, Julia|||0000-0002-1477-9444
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Colás Ortega, Eva|||0000-0003-0302-4828
Endometrial cancer (EC) is the sixth most common cancer in women worldwide and is responsible for more than 89,000 deaths every year. Mortality is associated with presence of poor prognostic factors at diagnosis, i.e., diagnosis at an advanced stage, with a high grade and/or an aggressive histology. Development of novel approaches that would permit us to improve the clinical management of EC patients is an unmet need. In this study, we investigate a novel approach to identify highly sensitive and specific biomarkers of EC using extracellular vesicles (EVs) isolated from the peritoneal lavage of EC patients. EVs of peritoneal lavages of 25 EC patients were isolated and their miRNA content was compared with miRNAs of EVs isolated from the ascitic fluid of 25 control patients. Expression of the EV-associated miRNAs was measured using the Taqman OpenArray technology that allowed us to detect 371 miRNAs. The analysis showed that 114 miRNAs were significantly dysregulated in EC patients, among which eight miRNAs, miRNA-383-5p, miRNA-10b-5p, miRNA-34c-3p, miRNA-449b-5p, miRNA-34c-5p, miRNA-200b-3p, miRNA-2110, and miRNA-34b-3p, demonstrated a classification performance at area under the receiver operating characteristic curve (AUC) values above 0.9. This finding opens an avenue for the use of EV-associated miRNAs of peritoneal lavages as an untapped source of biomarkers for EC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

APP-derived peptides reflect neurodegeneration in frontotemporal dementia

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Subirana, Andrea
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Vanderstichele, Hugo
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Antonell, Anna|||0000-0002-3286-8459
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Objective: We aimed to investigate the relationship between cerebrospinal fluid levels (CSF) of amyloid precursor protein (APP)-derived peptides related to the amyloidogenic pathway, cortical thickness, neuropsychological performance, and cortical gene expression profiles in frontotemporal lobar degeneration (FTLD)-related syndromes, Alzheimer's disease (AD), and healthy controls. Methods: We included 214 participants with CSF available recruited at two centers: 93 with FTLD-related syndromes, 57 patients with AD, and 64 healthy controls. CSF levels of amyloid β (Aβ)1-42, Aβ1-40, Aβ1-38, and soluble β fragment of APP (sAPPβ) were centrally analyzed. We compared CSF levels of APP-derived peptides between groups and, we studied the correlation between CSF biomarkers, cortical thickness, and domain-specific cognitive composites in each group. Then, we explored the relationship between cortical thickness, CSF levels of APP-derived peptides, and regional gene expression profile using a brain-wide regional gene expression data in combination with gene set enrichment analysis. Results: The CSF levels of Aβ1-40, Aβ1-38, and sAPPβ were lower in the FTLD-related syndromes group than in the AD and healthy controls group. CSF levels of all APP-derived peptides showed a positive correlation with cortical thickness and the executive cognitive composite in the FTLD-related syndromes group but not in the healthy control or AD groups. In the cortical regions where we observed a significant association between cortical thickness and CSF levels of APP-derived peptides, we found a reduced expression of genes related to synaptic function. Interpretation: APP-derived peptides in CSF may reflect FTLD-related neurodegeneration. This observation has important implications as Aβ1-42 levels are considered an indirect biomarker of cerebral amyloidosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status

  • Ceausu, Andra
  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Peraire, Joaquim|||0000-0001-7808-5479
  • López-Dupla, M.
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Vidal-Gonzalez, J.
  • Perpiñán, C.
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Veloso, S.
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Castellano, Alfonso J.
  • Ruiz-Mateos, E.
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Vidal, Francisco|||0000-0001-8089-4945
  • Rull, A.
A relationship between polymorphisms in genes encoding interleukin 7 (IL-7) and its cellular receptor (IL-7R) and antiretroviral therapy (ART)-associated immune recovery in HIV subjects has been previously reported. However, details of this relationship remain unclear, and the association of these polymorphisms with circulating IL-7/IL-7R levels is scarce. Here, we explored whether IL-7/IL-7R axis was associated with quantitative CD4 T-cell recovery in HIV-infected subjects. IL-7/IL-7R polymorphisms were assessed by genotyping, and multiple inheritance models were used to estimate both, their association with low pre-ART CD4 T-cell counts and incomplete immune recovery status after 48 weeks of suppressive ART. Integrated data from genetic variants association and soluble plasma IL-7/IL-7R quantification suggest that IL-7/IL-7R genotype expression could alter the homeostatic balance between soluble and membrane-bound receptors. The haplotype analyses indicates that allele combinations impacts pre-ART circulating CD4 T-cell counts, immune recovery status and the absolute increment of CD4 T-cell counts. The knowledge about how IL-7/IL-7R axis is related to quantitative CD4 T-cell recovery and immune recovery status after initiating ART could be useful regarding T-cell reservoirs investigations in HIV subjects.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Validation of cancer diagnoses in electronic health records, Results from the information system for research in primary care (SIDIAP) in northeast spain

  • Recalde, Martina|||0000-0003-2256-618X
  • Manzano-Salgado, Cyntia B.
  • Díaz, Yesika|||0000-0002-3727-7340
  • Puente, Diana|||0000-0003-4725-537X
  • Garcia Gil, M. Del Mar
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Ribes-Puig, Josefa
  • Galceran, Jaume|||0000-0002-1584-7293
  • Posso, Margarita|||0000-0002-5053-257X
  • Macià Guilà, Francesc|||0000-0002-6090-5894
  • Duarte Salles, Talita|||0000-0002-8274-0357
Background: Electronic health records are becoming an increasingly valuable resource for epidemiology but their data quality needs to be quantified. We aimed to validate twenty-five types of incident cancer cases in the Information System for Research in Primary Care (SIDIAP) in Catalonia with the population-based cancer registries of Girona and Tarragona as the gold-standard. Methods: We calculated the sensitivity, positive predictive values (PPV), and the timedifference between the date of diagnosis entered into the SIDIAP and into the registries. We added hospital discharge cancer diagnoses to the SIDIAP to assess sensitivity changes. Results: We identified 27,046 incident cancer diagnoses in the SIDIAP from 2009-2015 among the 949,841 residents of Girona and Tarragona. The cancer types with the highest sensitivity were breast (89%, 95% CI: 88-90%), colorectal (81%, 95% CI: 80-82%), and prostate (81%, 95% CI: 80-83%). Trachea, bronchus and lung cancers had the highest PPV (76%, 95% CI: 74%-78%) followed by stomach (72%, 95% CI: 68-75%) and pancreas (71%, 95% CI: 67-75%). Most cancer diagnoses were reported with less than three months of difference between the SIDIAP and the registries. More cases were registered first in the registries than in the SIDIAP. By adding cancer diagnoses based on hospital discharge data, sensitivity increased for all cancers, especially for gallbladder and biliary tract for which the sensitivity increased by 21%. Conclusion: The SIDIAP includes 76% of the cancer diagnoses in the cancer registries but includes a considerable number of cases that are not in the registries. The SIDIAP reports most of the cancer diagnoses within a three-month period difference from the date of diagnosis in the cancer registries. Our results support the use of the SIDIAP cancer diagnoses for epidemiological research when cancer is the outcome of interest. We recommend adding hospital discharge data to the SIDIAP to increase data quality, particularly for less frequent cancer types.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efectividad de una intervención educativa multidisciplinar en pacientes con fractura de fémur, estudio SWEET HOME, Effectiveness of a multidisciplinary educational intervention in patients with hip fracture

  • Sanclemente-Boli, Teresa
  • Ponce-Ruiz, Sandra
  • Álvarez-Lorenzo, Consuelo
  • Zuriguel Pérez, Esperanza|||0000-0002-0622-8423
  • Tapia Melenchon, Raquel|||0000-0002-4936-7511
  • Ramentol-Sintas, Marc
  • Villar-Casares, María del Mar
  • Teixidor Serra, Jordi|||0000-0003-1280-9088
  • Molero-García, Vicente
  • Sánchez Raya, Judith|||0000-0002-9356-7211
  • Lalueza-Broto, Pilar
  • Ginés Puertas, Alejandro
  • Garrido-Clua, Miriam
  • Mestre Torres, Jaume|||0000-0001-6612-221X
Antecedentes y objetivo: La fractura de fémur (FF) es una lesión frecuente en personas de edad avanzada. El objetivo fue evaluar la efectividad de una intervención educativa multidisciplinar en pacientes con FF para favorecer el regreso al domicilio y disminuir las complicaciones hospitalarias. Material y método: Estudio cuasiexperimental con medidas repetidas al ingreso, al alta, a los 30 días y al año de seguimiento. Se incluyeron pacientes ≥ 65 años con FF ingresados en la unidad de ortogeriatría entre febrero de 2016 y enero de 2017. La intervención educativa constó de dos actuaciones coordinadas: una educación sanitaria durante la hospitalización y un soporte multimodal durante la transición al domicilio. Resultados: Se incluyeron 67 pacientes (77,6% mujeres; edad 84,19 ± 7,78 años). Regresaron al domicilio el 70,1%, doblando la cifra de los años 2014-2015. Hubo un 8,5% de reingresos a los 30 días y al año. Al año, el nivel de dependencia fue cercano al nivel prefractura (Barthel: 86,67 ± 19,31; 94,33 ± 14,66), la movilidad mejoró respecto al alta (Parker: 4,73 ± 1,84; 6,73 ± 2,76; Timed Up and Go test: 38,29 ± 21,27; 21,91 ± 10,97) y el rendimiento cognitivo no empeoró de forma significativa. La percepción de pacientes, cuidadores y profesionales fue que la educación sanitaria mejoró la autonomía del paciente. La satisfacción con el proceso asistencial fue alta. Conclusiones: Este estudio aporta como novedad, a los beneficios ya descritos en los modelos asistenciales ortogeriátricos, el incremento del número de pacientes que regresan al domicilio en condiciones de seguridad., Background and objective: Hip fracture is a common injury among elderly patients. The main goal of our study was to assess the effectiveness of a multidisciplinary educational intervention aimed at hip fracture patients to promote home discharges and reduce in-hospital complications. Material and method: A quasi-experimental study was performed by taking repeated measurements at hospital admission, at hospital discharge, and at both 30 days and one year of discharge. Patients aged ≥ 65 years with hip fracture who were admitted to the Orthogeriatric Service between February 2016 and January 2017 were included in the study. The educational intervention consisted in two coordinated actions: patient education administered during their hospitalization and multimodal support provided during their discharge home. Results: A total of 67 patients were included in the study (77.6% of whom were women; 84.19 ± 7,78 years old). Of these, 70.1% were discharged home, which doubles the figures recorded in the 2014-2015 period. The rate of readmission at 30 days and one year of the discharge was 8.5%. At the one-year follow-up, the patient's dependence to perform basic activities of daily living was nearer to the pre-fracture level (Barthel: 86.67 ± 19.31; 94.33 ± 14.66), their mobility had improved in comparison with the time of discharge (Parker: 4.73 ± 1.84; 6.73 ± 2.76; Timed Up and Go Test: 38.29 ± 21.27; 21.91 ± 10.97), and their cognitive function had not worsened significantly. The patient education measures improved the patients' autonomy as perceived by the patients, the caregivers, and the healthcare providers. Satisfaction with the healthcare received was high. Conclusions: As a novelty to the already described benefits in orthogeriatric care models, this study would contribute by proving an increase of the number of patients discharged home in a safe condition.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Metabolic syndrome and risk of cancer, A study protocol of case-control study using data from the Information System for the Development of Research in Primary Care (SIDIAP) in Catalonia

  • Puente, Diana|||0000-0003-4725-537X
  • López Jiménez, Tomàs|||0000-0001-8255-4936
  • Cos Claramunt, Francesc Xavier|||0000-0003-3943-479X
  • Ortega, Yolanda
  • Duarte Salles, Talita|||0000-0002-8274-0357
Background Metabolic syndrome (MS) is defined by the clustering of specific metabolic disorders in one subject. MS is highly prevalent globally and currently considered a growing public health concern. MS comprises obesity, hypertension, dyslipidaemia and insulin resistance. Mechanisms linking MS with cancer are poorly understood, and it is as yet unknown if MS confers a greater risk than the risk entailed by each of its separate components. The main objective of this study is to compare the association between MS and 14 site-specific cancer against the association between one or two individual components of MS and cancer. The secondary objective is to evaluate the time elapsed since the diagnosis of MS and the subsequent onset of cancer within the 2006-2017 period by sex. Methods and analysis A case-control study will be conducted for the main objective and a cohort of patients with MS will be followed for the evaluation of the second objective. Incident cases of fourteen types of cancer in patients ≥40 years of age diagnosed prospectively will be selected from electronic primary care records in the Information System for Research in Primary Care (SIDIAP database; www.sidiap.org). The SIDIAP database includes anonymous data from 6 million people (80% of the Catalan population) registered in 286 primary healthcare centres. Each matched control (four controls for each case) will have the same inclusion date, the same sex and age (±1 year) than the paired case. Logistic regression and a descriptive analysis and Kaplan-Meier analysis will be performed, in accordance with the objectives. Ethics and dissemination The protocol of the study was approved by the IDIAP Jordi Gol Clinical Research Ethics Committee (protocol P17/212). The study's findings will be published in a peer-reviewed journal and disseminated at national and international conferences and oral presentations to researchers, clinicians and policy makers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification and characterization of new RNASEH1 mutations associated with PEO syndrome and multiple mitochondrial DNA deletions

  • Carreño Gago, Lidia
  • Blázquez-Bermejo, Cora
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Cámara, Yolanda|||0000-0003-2458-6942
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Martí, R.
  • Torres-Torronteras, J.
  • García Arumí, Elena|||0000-0003-1848-005X
Mitochondrial DNA (mtDNA) depletion and deletion syndrome encompasses a group of disorders caused by mutations in genes involved in mtDNA replication and maintenance. The clinical phenotype ranges from fatal infantile hepatocerebral forms to mild adult onset progressive external ophthalmoplegia (PEO). We report the case of a patient with PEO and multiple mtDNA deletions, with two new homozygous mutations in RNASEH1. The first mutation (c.487T.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Metabolites related to purine catabolism and risk of type 2 diabetes incidence, modifying effects of the TCF7L2-rs7903146 polymorphism

  • Papandreou, Christopher|||0000-0002-6803-507X
  • Li, Jun
  • Liang, Liming|||0000-0001-8261-3174
  • Bulló, Mònica|||0000-0002-0218-7046
  • Zheng, Yan
  • Ruiz-Canela, Miguel|||0000-0002-7684-2787
  • Yu, Edward
  • Guasch-Ferré, Marta
  • Razquín, Cristina|||0000-0003-3480-2645
  • Clish, Clary|||0000-0001-8259-9245
  • Corella, Dolores|||0000-0002-2366-4104
  • Estruch, Ramón|||0000-0003-1260-4445
  • Ros, Emilio|||0000-0002-2573-1294
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Arós, Fernando
  • Serra-Majem, Luís|||0000-0002-9658-9061
  • Rosique, Nuria
  • Martínez-González, Miguel A.
  • Hu, Frank B..
  • Salas-Salvadó, Jordi|||0000-0003-2700-7459
Studies examining associations between purine metabolites and type 2 diabetes (T2D) are limited. We prospectively examined associations between plasma levels of purine metabolites with T2D risk and the modifying effects of transcription factor-7-like-2 (TCF7L2) rs7903146 polymorphism on these associations. This is a case-cohort design study within the PREDIMED study, with 251 incident T2D cases and a random sample of 694 participants (641 non-cases and 53 overlapping cases) without T2D at baseline (median follow-up: 3.8 years). Metabolites were semi-quantitatively profiled with LC-MS/MS. Cox regression analysis revealed that high plasma allantoin levels, including allantoin-to-uric acid ratio and high xanthine-to-hypoxanthine ratio were inversely and positively associated with T2D risk, respectively, independently of classical risk factors. Elevated plasma xanthine and inosine levels were associated with a higher T2D risk in homozygous carriers of the TCF7L2-rs7903146 T-allele. The potential mechanisms linking the aforementioned purine metabolites and T2D risk must be also further investigated.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer's disease cerebrospinal fluid

  • Lleó, Alberto|||0000-0002-2568-5478
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Chiva, Cristina
  • Balateu Paños, Daniel
  • Colom-Cadena, Martí|||0000-0002-8514-4534
  • Gómez, Gemma
  • Muñoz, Laia|||0000-0003-0578-3094
  • Querol-Vilaseca, Marta|||0000-0002-8589-1636
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Tainta, Mikel|||0000-0003-0624-1211
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Spires Jones, Tara
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Martínez Lage, Pablo
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Bayés, Àlex|||0000-0002-5265-6306
  • Belbin, Olivia|||0000-0002-6109-6371
A biomarker of synapse loss, an early event in Alzheimer's disease (AD) pathophysiology that precedes neuronal death and symptom onset, would be a much-needed prognostic biomarker. With direct access to the brain interstitial fluid, the cerebrospinal fluid (CSF) is a potential source of synapse-derived proteins. In this study, we aimed to identify and validate novel CSF biomarkers of synapse loss in AD. Discovery: Combining shotgun proteomics of the CSF with an exhaustive search of the literature and public databases, we identified 251 synaptic proteins, from which we selected 22 for further study. Verification: Twelve proteins were discarded because of poor detection by Selected Reaction Monitoring (SRM). We confirmed the specific expression of 9 of the remaining proteins (Calsyntenin-1, GluR2, GluR4, Neurexin-2A, Neurexin-3A, Neuroligin-2, Syntaxin-1B, Thy-1, Vamp-2) at the human synapse using Array Tomography microscopy and biochemical fractionation methods. Exploration: Using SRM, we monitored these 9 synaptic proteins (20 peptides) in a cohort of CSF from cognitively normal controls and subjects in the pre-clinical and clinical AD stages (n 80). Compared with controls, peptides from 8 proteins were elevated 1.3 to 1.6-fold (p < 0.04) in prodromal AD patients. Validation: Elevated levels of a GluR4 peptide at the prodromal stage were replicated (1.3-fold, p 0.04) in an independent cohort (n 60). Moreover, 7 proteins were reduced at preclinical stage 1 (0.6 to 0.8-fold, p < 0.04), a finding that was replicated (0.7 to 0.8-fold, p < 0.05) for 6 proteins in a third cohort (n 38). In a cross-cohort meta-analysis, 6 synaptic proteins (Calsyn-tenin-1, GluR4, Neurexin-2A, Neurexin-3A, Syntaxin-1B and Thy-1) were reduced 0.8-fold (p < 0.05) in preclinical AD, changes that precede clinical symptoms and CSF markers of neurodegeneration. Therefore, these proteins could have clinical value for assessing disease progression, especially in preclinical stages of AD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effectiveness of a psychoeducation group intervention conducted by primary healthcare nurses in patients with depression and physical comorbidity : study protocol for a randomized, controlled trial

  • Casañas, Rocio|||0000-0003-2783-8818
  • Martín Royo, Jaume
  • Fernández San Martín, María Isabel|||0000-0001-9190-7182
  • Raya Tena, Antonia
  • Mendioroz Peña, Jacobo|||0000-0002-8883-2180
  • Sauch Valmaña, Glòria
  • Masa-Font, Roser
  • Casajuana Closas, Marc|||0000-0001-5653-996X
  • Fernandez Linares, Eva María
  • Cols-Sagarra, Cèlia
  • González-Tejón, Susana
  • Foguet-Boreu, Quintí|||0000-0002-6069-5305
  • Martín Lopez, Luis Miguel
Background: Depressive disorders are the third leading cause of consultation in primary care, mainly in patients with chronic physical illnesses. Studies have shown the effectiveness of group psychoeducation in reducing symptoms in depressive individuals. Our primary aim is to evaluate the effectiveness of an intervention based on a psychoeducational program, carried out by primary care nurses, to improve the remission/response rate of depression in patients with chronic physical illness. Secondarily, to assess the cost-effectiveness of the intervention, its impact on improving control of the physical pathology and quality of life, and intervention feasibility. Methods/design: A multicenter, randomized, clinical trial, with two groups and one-year follow-up evaluation. Economic evaluation study. Subjects: We will assess 504 patients (252 in each group) aged.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications

  • Franch-Expósito, Sebastià|||0000-0002-4542-1701
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Vila-Casadesús, Maria|||0000-0001-6597-7953
  • Hernández-Illán, Eva
  • Esteban-Fabró, Roger
  • Díaz-Gay, Marcos|||0000-0003-0658-0467
  • Lozano, Juan José
  • Castells, Antoni|||0000-0001-8431-2033
  • Llovet, Josep Maria
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Camps Polo, Jordi|||0000-0003-2929-4228
Somatic copy number alterations (CNAs) are a hallmark of cancer, but their role in tumorigenesis and clinical relevance remain largely unclear. Here, we developed CNApp, a web-based tool that allows a comprehensive exploration of CNAs by using purity-corrected segmented data from multiple genomic platforms. CNApp generates genome-wide profiles, computes CNA scores for broad, focal and global CNA burdens, and uses machine learning-based predictions to classify samples. We applied CNApp to the TCGA pan-cancer dataset of 10,635 genomes showing that CNAs classify cancer types according to their tissue-of-origin, and that each cancer type shows specific ranges of broad and focal CNA scores. Moreover, CNApp reproduces recurrent CNAs in hepatocellular carcinoma and predicts colon cancer molecular subtypes and microsatellite instability based on broad CNA scores and discrete genomic imbalances. In summary, CNApp facilitates CNA-driven research by providing a unique framework to identify relevant clinical implications. CNApp is hosted at . In most cases, human cells contain two copies of each of their genes, yet sometimes this can change, an effect called copy number alteration (CNA). Cancer is a genetic disease and thus, studying the DNA from tumor samples is crucial to improving diagnosis and choosing the right treatment. Most tumors contain cells with CNAs; however, the impact of CNAs in cancer progression is poorly understood. CNAs can be studied by examining the genome of tumor cells and finding which regions display an unusual number of copies. It may also be possible to gather information about different cancer types by analyzing the CNAs in a tumor, but this approach requires the analysis of large amounts of data. To aid the analysis of CNAs in cancer cells, Franch-Expósito, Bassaganyas et al. have created an online tool called CNApp, which is able to identify and count CNAs in genomic data and link them to features associated with different cancers. The hope is that a better understanding of the effect of CNAs in cancer could help better diagnose cancers, and improve outcomes for patients. Potentially, this could also predict what type of treatment would work better for a specific tumor. Besides, by using a machine-learning approach, the tool can also make predictions about specific cancer subtypes in order to facilitate clinical decisions. Franch-Expósito, Bassaganyas et al. tested CNApp using previously existing cancer data from 33 different cancer types to show how CNApp can help the interpretation of CNAs in cancer. Moreover, CNApp can also use CNAs to identify different types of bowel (colorectal) cancer in a way that could help doctors to make decisions about treatment. Together these findings show that CNApp provides an adaptable and accessible research tool for the study of cancer genomics, which could provide opportunities to inform medical procedures.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer's disease

  • Siedlecki-Wullich, Dolores|||0000-0002-9099-9406
  • Català-Solsona, Judit|||0000-0002-2927-9135
  • Fábregas Ordóñez, Cristina
  • Hernández, Isabel|||0000-0001-8119-393X
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lleó, Alberto|||0000-0002-2568-5478
  • Boada, Mercè|||0000-0003-2617-3009
  • Saura Antolín, Carlos|||0000-0003-3692-5657
  • Rodríguez Álvarez, José|||0000-0001-8582-8082
  • Miñano Molina, Alfredo Jesús|||0000-0002-7761-5682
Several evidences suggest that failure of synaptic function occurs at preclinical stages of Alzheimer's disease (AD) preceding neuronal loss and the classical AD pathological hallmarks. Nowadays, there is an urgent need to identify reliable biomarkers that could be obtained with non-invasive methods to improve AD diagnosis at early stages. Here, we have examined plasma levels of a group of miRNAs related to synaptic proteins in a cohort composed of cognitive healthy controls (HC), mild cognitive impairment (MCI) and AD subjects. Plasma and brain levels of miRNAs were analysed in two different cohorts including 38 HC, 26 MCI, 56 AD dementia patients and 27 frontotemporal dementia (FTD) patients. D'Agostino and Pearson and Shapiro-Wilk tests were used to evaluate data normality. miRNA levels between groups were compared using a two-sided nonparametric Mann-Whitney test and sensitivity and specificity was determined by receiver operating characteristic curve analysis. Significant upregulation of miR-92a-3p, miR-181c-5p and miR-210-3p was found in the plasma of both MCI and AD subjects. MCI patients that progress to AD showed higher plasma levels of these miRNAs. By contrast, no changes in miR-92a-3p, miR-181c-5p or miR-210-3p levels were observed in plasma obtained from a cohort of FTD. Our study shows that plasma miR-92a-3p, miR-181c-5p and miR-210-3p constitute a specific molecular signature potentially useful as a potential biomarker for AD. The online version of this article (10.1186/s13195-019-0501-4) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Childhood maltreatment and risk for suicide attempts in major depression, a sex-specific approach

  • Goldberg, Ximena|||0000-0001-9681-5826
  • Serra Blasco, Maria|||0000-0001-5793-9906
  • Vicent Gil, Muriel|||0000-0001-7534-5095
  • Aguilar, Eva|||0000-0003-1877-1471
  • Ros, Laura
  • Arias, Barbara|||0000-0001-9181-2132
  • Courtet, Philippe|||0000-0002-6519-8586
  • Palao, Diego|||0000-0002-3323-6568
  • Cardoner, Narcís|||0000-0001-9633-0888
Background : Childhood maltreatment increases the risk of suicide attempts in the general population, possibly having similar effects among patients with major depressive disorder (MDD). The few studies that have addressed this association have been restricted to specific populations (e.g. treatment-resistant depression, personality disorders) and have rarely taken sex into account. Objective : To examine the impact of childhood maltreatment on suicide attempts among MDD patients above and beyond other risk factors and potential confounders, while considering potential sex-specific effects. Methods : The study assessed 165 patients with a principal diagnosis of MDD. Neurological alterations, psychiatric comorbidities, and drug abuse were reasons for exclusion. Logistic regressions using the whole sample, and divided by sex, were run to test the association between childhood maltreatment and history of suicide attempts, controlling for symptom severity, comorbidities, and treatment-resistant depression. Results : There was a significant and clinically relevant association between childhood maltreatment and history of suicide attempts in the total sample. Patients with childhood maltreatment were 3.01 times more likely to present a history of suicide attempts than patients without childhood maltreatment. A family history of psychiatric disorders also contributed to the variance of attempted suicide, but its interaction with childhood maltreatment was not statistically significant. When testing the model separately, the effect of childhood maltreatment on suicide attempts remained for females, whereas for males, age of MDD onset and Childhood Trauma Questionnaire minimization-denial scale were predictive variables. Conclusions : Childhood maltreatment is a clear predictor of suicidal behaviour among MDD patients, and this effect remains significant after controlling for potential confounders. Also, the sex of patients emerges as a relevant factor that may model the mechanisms underlying the prediction of suicide attempts. Since suicide is the main cause of premature death among MDD patients, interventions targeting childhood maltreatment should be included in preventive and clinical strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Age-related metabolic changes limit efficacy of deoxynucleoside-based therapy in thymidine kinase 2-deficient mice

  • Blázquez-Bermejo, Cora
  • Molina-Granada, David|||0000-0002-8260-7775
  • Vila-Julià, Ferran
  • Jiménez-Heis, Daniel
  • Zhou, Xiaoshan
  • Torres-Torronteras, Javier|||0000-0002-6092-9458
  • Karlsson, Anna
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Cámara, Yolanda|||0000-0003-2458-6942
Thymidine kinase 2 (TK2) catalyses the phosphorylation of deoxythymidine (dThd) and deoxycytidine (dCtd) within mitochondria. TK2 deficiency leads to mtDNA depletion or accumulation of multiple deletions. In patients, TK2 mutations typically manifest as a rapidly progressive myopathy with infantile onset, leading to respiratory insufficiency and encephalopathy in the most severe clinical presentations. TK2-deficient mice develop the most severe form of the disease and die at average postnatal day 16. dThd+dCtd administration delayed disease progression and expanded lifespan of a knockin murine model of the disease. We daily administered TK2 knockout mice (Tk2 KO) from postnatal day 4 with equimolar doses of dThd+dCtd, dTMP+dCMP, dThd alone or dCtd alone. We monitored body weight and survival and studied different variables at 12 or 29 days of age. We determined metabolite levels in plasma and target tissues, mtDNA copy number in tissues, and the expression and activities of enzymes with a relevant role in mitochondrial dNTP anabolism or catabolism. dThd+dCtd treatment extended average lifespan of Tk2 KO mice from 16 to 34 days, attenuated growth retardation, and rescued mtDNA depletion in skeletal muscle and other target tissues of 12-day-old mice, except in brain. However, the treatment was ineffective in 29-day-old mice that still died prematurely. Bioavailability of dThd and dCtd markedly decreased during mouse development. Activity of enzymes catabolizing dThd and dCtd increased with age in small intestine. Conversely, the activity of the anabolic enzymes decreased in target tissues during mouse development. We also found that administration of dThd alone had the same impact on survival to that of dThd+dCtd, whereas dCtd alone had no influence on lifespan. dThd+dCtd treatment recruits alternative cytosolic salvage pathways for dNTP synthesis, suggesting that this therapy would be of benefit for any Tk2 mutation. dThd accounts for the therapeutic effect of the combined treatment in mice. During the first weeks after birth, mice experience marked tissue-specific metabolic regulations and ontogenetic changes in dNTP metabolism-related enzymes that limit therapeutic efficacy to early developmental stages. This study was funded by grants from the Spanish Ministry of Industry, Economy and Competitiveness, the Spanish Instituto de Salud Carlos III, the Fundación Inocente, Inocente, AFM Téléthon and the Generalitat de Catalunya. The disclosed funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Adipose stem cells from patients with Crohn's disease show a distinctive DNA methylation pattern

  • Serena, Carolina|||0000-0003-2251-0856
  • Millán Scheiding, Mónica
  • Ejarque, Miriam|||0000-0003-0545-9817
  • Saera-Vila, Alfonso
  • Maymó-Masip, Elsa
  • Núñez Roa, Catalina
  • Monfort-Ferré, Diandra|||0000-0003-3832-4249
  • Terrón-Puig, Margarida
  • Bautista, Michelle
  • Menacho, Margarita
  • Marti-Gallostra, Marc|||0000-0002-0783-6359
  • Espin-Basany, Eloy|||0000-0002-9139-4548
  • Vendrell, Joan|||0000-0002-6994-6115
  • Fernández-Veledo, Sonia|||0000-0003-2906-3788
Crohn's disease (CD) is characterized by persistent inflammation and ulceration of the small or large bowel, and expansion of mesenteric adipose tissue, termed creeping fat (CF). We previously demonstrated that human adipose-derived stem cells (hASCs) from CF of patients with CD exhibit dysfunctional phenotypes, including a pro-inflammatory profile, high phagocytic capacity, and weak immunosuppressive properties. Importantly, these phenotypes persist in patients in remission and are found in all adipose depots explored including subcutaneous fat. We hypothesized that changes in hASCs are a consequence of epigenetic modifications. We applied epigenome-wide profiling with a methylation array (Illumina EPIC/850k array) and gene expression analysis to explore the impact of CD on the methylation signature of hASCs isolated from the subcutaneous fat of patients with CD and healthy controls (n = 7 and 5, respectively; cohort I). Differentially methylated positions (p value cutoff < 1 × 10 -4 and ten or more DMPs per gene) and regions (inclusion threshold 0.2, p value cutoff < 1 × 10 -2 and more than 2 DMRs per gene) were identified using dmpfinder and Bumphunter (minfi), respectively. Changes in the expression of differentially methylated genes in hASCs were validated in a second cohort (n = 10/10 inactive and active CD and 10 controls; including patients from cohort I) and also in peripheral blood mononuclear cells (PBMCs) of patients with active/inactive CD and of healthy controls (cohort III; n = 30 independent subjects). We found a distinct DNA methylation landscape in hASCs from patients with CD, leading to changes in the expression of differentially methylated genes involved in immune response, metabolic, cell differentiation, and development processes. Notably, the expression of several of these genes in hASCs and PBMCs such as tumor necrosis factor alpha (TNFA) and PR domain zinc finger protein 16 (PRDM16) were not restored to normal (healthy) levels after disease remission. hASCs of patients with CD exhibit a unique DNA methylation and gene expression profile, but the expression of several genes are only partially restored in patients with inactive CD, both in hASCs and PBMCs. Understanding how CD shapes the functionality of hASCs is critical for investigating the complex pathophysiology of this disease, as well as for the success of cell-based therapies. Human adipose-stem cells isolated from subcutaneous fat of patients with Crohn's disease exhibit an altered DNA methylation pattern and gene expression profile compared with those isolated from healthy individuals, with immune system, cell differentiation, metabolic and development processes identified as the main pathways affected. Interestingly, the gene expression of several genes involved in these pathways is only partially restored to control levels in patients with inactive Crohn's disease, both in human adipose-stem cells and peripheral blood mononuclear cells. Understanding how Crohn's disease shapes the functionality of human adipose-stem cells is critical for investigating the complex pathophysiology of this disease, as well as for the success of cell-based therapies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Vacunación antineumocócica en adultos de Cataluña, coberturas y grado de adecuación a distintas guías de recomendaciones. Antipneumococcal vaccination in Catalonian adults: Vaccine coverages and adequacy to distinct guideline recommendations

  • Ochoa-Gondar, Olga
  • Vila Córcoles, Ángel|||0000-0002-1644-0188
  • De Diego-Cabanes, Cinta|||0000-0001-7801-067X
  • Satué, Eva
  • Vila-Rovira, Angel
  • Aragón, María|||0000-0002-5990-6953
Objetivos: Conocer las coberturas de vacunación antineumocócica en la población adulta de Cataluñ y analizar el grado de adecuación del estado vacunal según 3 guías distintas de recomendaciones actualmente vigentes. Diseño:Estudio transversal de base poblacional. Ámbito: Atención Primaria de Salud, Comunidad Autónoma de Cataluña. Participantes: Un total de 2.033.465 personas ≥50 años, asignadas al Institut Català de la Salut. Mediciones principales: Se revisó la recepción o no de vacuna antineumocócica polisacárida tricosavalente(VNP23) y/o conjugada tridecavalente(VNC13) a 1/01/2015. Se valoró el grado de adecuación del uso de ambas vacunas según 3 guías distintas de recomendaciones: Ministerio de Sanidad (coincidente con el Departament de Salut de Cataluña), Sociedad Española de Medicina Familiar y Comunitaria (semFYC) y Centers for Disease Control and Prevention (CDC). Resultados: Un total de 789.098 (38,8%) de personas habían recibido la VNP23 y 5.031 (0,2%) la VNC13. La cobertura de VNP23 aumentó significativamente con la edad (4,8% en 50-59años, 35,5% en 60-69 años, 71,9% en 70-79 años y 79,5% en ≥80 años; p<0,001), mientras que la cobertura de VNC13 fue muy baja en todos los grupos etarios. De acuerdo con las 3 guías analizadas, un 46,1% de los sujetos estudiados estaban adecuadamente vacunados según las recomendaciones del Ministerio de Sanidad, un 19,3% según la semFYC y un 4,6% según los CDC., Objectives: To know antipneumococcal vaccination coverages among Catalonian adults and evaluate the adequacy of vaccine use according to 3 distinct current vaccination guidelines. Design: Population-based cross-sectional study. Setting: Primary Health Care. Catalonia, Spain. Participants: A total of 2,033,465 individuals ≥ 50 years-old registered in the Catalonian Health Institute. Main measurements: Vaccination status for the 23-valent pneumococcal polysaccharide vaccine (PPV23) and/or the 13-valent pneumococcal conjugate vaccine (PCV13) was revised at 1/01/2015. Adequacy of vaccination status was determined according to 3 distinct vaccination recommendation guidelines: Spanish Ministry of Health (basically coinciding with Catalonian Health Institute's recommendations), Spanish Society of Family Physicians (semFYC) and Centers for Disease Control and Prevention (CDC). Results: Overall, 789,098 (38.8%) persons had received PPV23 and 5,031 (0.2%) had received PCV13. PPV23 coverage largely increased with increasing age (4.8% in 50-59 years, 35.5% in 60-69 years, 71.9% in 70-79 years and 79.5% in ≥ 80 years; P <.001), whereas PCV13 coverage was very small in all age groups. Considering the 3 analysed vaccine guidelines a 46.1% of the overall study population were adequacy vaccinated according to Spanish Ministry's recommendations, 19.3% according to semFYC's recommendations and 4.6% according to CDC's recommendations. Conclusion: PPV23 coverage among Catalonian adults may be considered as intermediate, but PCV13 coverage is very small. The institutional recommendations (Spanish Ministry) are more followed than corporative (semFYC) or less local (CDC) recommendations in clinical practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA

  • Radua, Joaquim|||0000-0003-1240-5438
  • Vieta, Eduard|||0000-0002-0548-0053
  • Shinohara, Russell
  • Kochunov, Peter
  • Quidé, Yann|||0000-0002-8569-7139
  • Green, Melissa J.
  • Weickert, Cynthia S.
  • Weickert, Thomas
  • Bruggemann, Jason
  • Kircher, Tilo|||0000-0002-2514-2625
  • Nenadić, Igor|||0000-0002-0749-7473
  • Cairns, Murray J.
  • Seal, Marc
  • Schall, Ulrich
  • Henskens, Frans
  • Fullerton, Janice M.|||0000-0003-4014-4490
  • Mowry, Bryan
  • Pantelis, Christos|||0000-0002-9565-0238
  • Lenroot, Rhoshel
  • Cropley, Vanessa
  • Loughland, Carmel
  • Scott, Rodney
  • Wolf, Daniel H.
  • Satterthwaite, Theodore D.|||0000-0001-7072-9399
  • Tan, Yunlong
  • Sim, Kang|||0000-0003-3209-9626
  • Piras, Fabrizio|||0000-0003-3566-5494
  • Spalletta, Gianfranco|||0000-0002-7432-4249
  • Banaj, Nerisa|||0000-0002-6317-8549
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Solanes, Aleix|||0000-0002-2491-200X
  • Albajes-Eizagirre, Anton
  • Canales-Rodriguez, Erick Jorge|||0000-0001-6421-2633
  • Sarro, Salvador
  • Giorgio, Annabella Di
  • Bertolino, Alessandro
  • Stäblein, Michael
  • Oertel, Viola
  • Knöchel, Christian
  • Borgwardt, Stefan
  • du Plessis, Stefan
  • Yun, Je-Yeon|||0000-0002-5531-2410
  • Kwon, Jun Soo|||0000-0002-1060-1462
  • Dannlowski, Udo|||0000-0002-0623-3759
  • Hahn, Tim|||0000-0002-8929-4134
  • Grotegerd, Dominik
  • Alloz, Clara
  • Arango, Celso|||0000-0003-3382-4754
  • Janssen, Joost|||0000-0001-7613-2067
  • Díaz-Caneja, Covadonga M.|||0000-0001-8538-3175
  • Jiang, Wenhao
  • Calhoun, Vince
  • Ehrlich, Stefan|||0000-0003-2132-4445
  • Yang, Kun
  • Cascella, Nicola G.
  • Takayanagi, Yoichiro
  • Sawa, Akira
  • Tomyshev, Alexander
  • Lebedeva, Irina
  • Kaleda, Vasily
  • Kirschner, Matthias
  • Hoschl, Cyril
  • Tomecek, David
  • Skoch, Antonin
  • van Amelsvoort, Therese
  • Bakker, Geor
  • James, Anthony|||0000-0002-2742-8328
  • Preda, Adrian
  • Weideman, Andrea
  • Stein, Dan J.|||0000-0001-7218-7810
  • Howells, Fleur
  • Uhlmann, Anne|||0000-0002-1753-7811
  • Temmingh, Henk
  • López-Jaramillo, Carlos
  • Díaz-Zuluaga, Ana M..
  • Fortea, Lydia|||0000-0001-6778-2316
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Solana, Elisabeth|||0000-0001-7973-2439
  • Llufriu, Sara|||0000-0003-4273-9121
  • Jahanshad, Neda|||0000-0003-4401-8950
  • Thompson, Paul
  • Turner, Jessica A.
  • van Erp, Theo
A common limitation of neuroimaging studies is their small sample sizes. To overcome this hurdle, the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium combines neuroimaging data from many institutions worldwide. However, this introduces heterogeneity due to different scanning devices and sequences. ENIGMA projects commonly address this heterogeneity with random-effects meta-analysis or mixed-effects mega-analysis. Here we tested whether the batch adjustment method, ComBat, can further reduce site-related heterogeneity and thus increase statistical power. We conducted random-effects meta-analyses, mixed-effects mega-analyses and ComBat mega-analyses to compare cortical thickness, surface area and subcortical volumes between 2897 individuals with a diagnosis of schizophrenia and 3141 healthy controls from 33 sites. Specifically, we compared the imaging data between individuals with schizophrenia and healthy controls, covarying for age and sex. The use of ComBat substantially increased the statistical significance of the findings as compared to random-effects meta-analyses. The findings were more similar when comparing ComBat with mixed-effects mega-analysis, although ComBat still slightly increased the statistical significance. ComBat also showed increased statistical power when we repeated the analyses with fewer sites. Results were nearly identical when we applied the ComBat harmonization separately for cortical thickness, cortical surface area and subcortical volumes. Therefore, we recommend applying the ComBat function to attenuate potential effects of site in ENIGMA projects and other multi-site structural imaging work. We provide easy-to-use functions in R that work even if imaging data are partially missing in some brain regions, and they can be trained with one data set and then applied to another (a requirement for some analyses such as machine learning).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Yeast Ppz1 protein phosphatase toxicity involves the alteration of multiple cellular targets

  • Velázquez, Diego|||0000-0002-5987-2570
  • Albacar, Marcel|||0000-0002-2612-2888
  • Zhang, Chunyi
  • Calafí, Carlos
  • López Malo, María
  • Torres Torronteras, Javier
  • Martí, Ramón
  • Kovalchuk, Sergey I.
  • Pinson, Benoit
  • Jensen, Ole N.
  • Daignan-Fornier, Bertrand
  • Casamayor Gracia, Antonio|||0000-0003-2788-7329
  • Ariño Carmona, Joaquín|||0000-0002-6774-2987
Control of the protein phosphorylation status is a major mechanism for regulation of cellular processes, and its alteration often lead to functional disorders. Ppz1, a protein phosphatase only found in fungi, is the most toxic protein when overexpressed in Saccharomyces cerevisiae. To investigate the molecular basis of this phenomenon, we carried out combined genome-wide transcriptomic and phosphoproteomic analyses. We have found that Ppz1 overexpression causes major changes in gene expression, affecting ~ 20% of the genome, together with oxidative stress and increase in total adenylate pools. Concurrently, we observe changes in the phosphorylation pattern of near 400 proteins (mainly dephosphorylated), including many proteins involved in mitotic cell cycle and bud emergence, rapid dephosphorylation of Snf1 and its downstream transcription factor Mig1, and phosphorylation of Hog1 and its downstream transcription factor Sko1. Deletion of HOG1 attenuates the growth defect of Ppz1-overexpressing cells, while that of SKO1 aggravates it. Our results demonstrate that Ppz1 overexpression has a widespread impact in the yeast cells and reveals new aspects of the regulation of the cell cycle.
Dipòsit Digital de Documents de la UAB
Publication

Body mass index and waist circumference in relation to the risk of 26 types of cancer, a prospective cohort study of 3.5 million adults in Spain

  • Recalde, Martina|||0000-0003-2256-618X
  • Davila-Batista, Veronica|||0000-0001-8888-395X
  • Díaz, Yesika|||0000-0002-3727-7340
  • Leitzmann, Michael
  • Romieu, Isabelle
  • Freisling, Heinz
  • Duarte Salles, Talita|||0000-0002-8274-0357
A high body mass index (BMI) has been associated with increased risk of several cancers; however, whether BMI is related to a larger number of cancers than currently recognized is unclear. Moreover, whether waist circumference (WC) is more strongly associated with specific cancers than BMI is not well established. We aimed to investigate the associations between BMI and 26 cancers accounting for non-linearity and residual confounding by smoking status as well as to compare cancer risk estimates between BMI and WC. Prospective cohort study with population-based electronic health records from Catalonia, Spain. We included 3,658,417 adults aged ≥ 18 years and free of cancer at baseline between 2006 and 2017. Our main outcome measures were cause-specific hazard ratios (HRs) with 99% confidence intervals (CIs) for incident cancer at 26 anatomical sites. After a median follow-up time of 8.3 years, 202,837 participants were diagnosed with cancer. A higher BMI was positively associated with risk of nine cancers (corpus uteri, kidney, gallbladder, thyroid, colorectal, breast post-menopausal, multiple myeloma, leukemia, non-Hodgkin lymphoma) and was positively associated with three additional cancers among never smokers (head and neck, brain and central nervous system, Hodgkin lymphoma). The respective HRs (per 5 kg/m 2 increment) ranged from 1.04 (99%CI 1.01 to 1.08) for non-Hodgkin lymphoma to 1.49 (1.45 to 1.53) for corpus uteri cancer. While BMI was negatively associated to five cancer types in the linear analyses of the overall population, accounting for non-linearity revealed that BMI was associated to prostate cancer in a U-shaped manner and to head and neck, esophagus, larynx, and trachea, bronchus and lung cancers in an L-shaped fashion, suggesting that low BMIs are an approximation of heavy smoking. Of the 291,305 participants with a WC measurement, 27,837 were diagnosed with cancer. The 99%CIs of the BMI and WC point estimates (per 1 standard deviation increment) overlapped for all cancers. In this large Southern European study, a higher BMI was associated with increased risk of twelve cancers, including four hematological and head and neck (only among never smokers) cancers. Furthermore, BMI and WC showed comparable estimates of cancer risk associated with adiposity. Supplementary information accompanies this paper at 10.1186/s12916-020-01877-3.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The DNA methylation landscape of human cancer organoids available at the American type culture collection

  • Joshi, Ricky S.|||0000-0003-4463-0453
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Piñeyro, David|||0000-0001-5633-3339
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Arribas, Carles
  • Esteller, M.|||0000-0003-4490-6093
One caveat in cancer research is the dependence of certain experimental systems that might not really reflect the properties of the primary tumours. The recent irruption of 3D cultured cells termed organoids could render a better representation of the original tumour sample. However, every laboratory has its own protocol and tissue-provider to establish these cancer models, preventing further dissemination and validation of the obtained data. To address this problem, the Human Cancer Models Initiative (HCMI) has selected the American Type Culture Collection (ATCC) to make available organoid models to the scientific community. In this regard, no epigenetic information is available for these samples and, overall, the DNA methylation profiles of human cancer organoids are largely unknown. Herein, we provide the DNA methylation landscape of 25 human cancer organoids available at the ATCC using a microarray that interrogates more than 850,000 CpG sites. We observed that the studied organoids retain the epigenetic setting of their original primary cancer type; that exhibit a DNA methylation landscape characteristic of transformed tissues excluding an overgrowth of normal-matched cells; and that are closer to the DNA methylation profiles of the corresponding primary tumours than to established 2D cell lines. Most importantly, the obtained DNA methylation results are freely available to everyone for further data mining. Thus, our findings support from the epigenetic standpoint that the ATCC human cancer organoids recapitulate many of the features of the disorder in the patient and are excellent tools to be shared among investigators for further tumour biology research.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE-ε4 in middle-age cognitively unimpaired individuals from the ALFA study

  • Vilor Tejedor, Natalia
  • Operto, Gregory
  • Evans, T. E.
  • Falcon, Carles
  • Crous-Bou, Marta|||0000-0003-1493-4288
  • Minguillón, Carolina
  • Cacciaglia, Raffaele
  • Milà-Alomà, Marta
  • Grau-Rivera, Oriol|||0000-0002-4730-5341
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Garrido-Martín, Diego
  • Moran, S.|||0000-0003-4192-8983
  • Esteller, M.|||0000-0003-4490-6093
  • Adams, Hieab H. H.|||0000-0003-3687-2508
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Guigó, Roderic|||0000-0002-5738-4477
  • Gispert, Juan Domingo|||0000-0002-6155-0642
Background: Current evidence supports the involvement of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism, and the ε4 allele of APOE gene in hippocampal-dependent functions. Previous studies on the association of Val66Met with whole hippocampal volume included patients of a variety of disorders. However, it remains to be elucidated whether there is an impact of BDNF Val66Met polymorphism on the volumes of the hippocampal subfield volumes (HSv) in cognitively unimpaired (CU) individuals, and the interactive effect with the APOE-ε4 status. Methods: BDNF Val66Met and APOE genotypes were determined in a sample of 430 CU late/middle-aged participants from the ALFA study (ALzheimer and FAmilies). Participants underwent a brain 3D-T1-weighted MRI scan, and volumes of the HSv were determined using Freesurfer (v6.0). The effects of the BDNF Val66Met genotype on the HSv were assessed using general linear models corrected by age, gender, education, number of APOE-ε4 alleles and total intracranial volume. We also investigated whether the association between APOE-ε4 allele and HSv were modified by BDNF Val66Met genotypes. Results: BDNF Val66Met carriers showed larger bilateral volumes of the subiculum subfield. In addition, HSv reductions associated with APOE-ε4 allele were significantly moderated by BDNF Val66Met status. BDNF Met carriers who were also APOE-ε4 homozygous showed patterns of higher HSv than BDNF Val carriers. Conclusion: To our knowledge, the present study is the first to show that carrying the BDNF Val66Met polymorphisms partially compensates the decreased on HSv associated with APOE-ε4 in middle-age cognitively unimpaired individuals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A novel hypomorphic splice variant in EIF2B5 gene is associated with mild ovarioleukodystrophy

  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Schlüter, Agatha|||0000-0001-6732-1528
  • Verdura, Edgard|||0000-0003-3856-2060
  • Ruiz, Montserrat|||0000-0003-0466-2653
  • Martínez, Juan José
  • Gourlaouen, Isabelle
  • Ka, Chandran
  • Lobato, Ricardo
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Le Gac, Gérald|||0000-0003-3236-7280
  • Fourcade, Stéphane|||0000-0002-8031-5007
  • Pujol, Aurora|||0000-0002-9606-0600
To identify the genetic cause in an adult ovarioleukodystrophy patient resistant to diagnosis. We applied whole-exome sequencing (WES) to a vanishing white matter disease patient associated with premature ovarian failure at 26 years of age. We functionally tested an intronic variant by RT-PCR on patient's peripheral blood mononuclear cells (PBMC) and by minigene splicing assay. WES analysis identified two novel variants in the EIF2B5 gene: c.725A.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone

  • Estellés, Teresa
  • Zhu, Nuole|||0000-0002-0015-9455
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Subirana, Andrea
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Belbin, Olivia|||0000-0002-6109-6371
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
Cerebrospinal fluid (CSF) Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio are markers of amyloid pathology, but previous studies suggest that their levels might be influenced by additional pathophysiological processes. To compare Aβ1-42 and the Aβ1-42/Aβ1-40 ratio in CSF in different neurodegenerative disorders and study their association with other biomarkers (tTau, pTau181, and NfL) and with cognitive and functional progression. We included all participants from the Sant Pau Initiative on Neurodegeneration (SPIN) with CSF Aβ1-42 and Aβ1-42/Aβ1-40. Participants had diagnoses of Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal lobar degeneration-related syndromes, non-neurodegenerative conditions, or were cognitively normal. We classified participants as "positive" or "negative" according to each marker. We compared CSF levels of tTau, pTau181, and NfL between concordant and discordant groups through ANCOVA and assessed differences in cognitive (MMSE, FCSRT) and functional (GDS, CDR-SOB) progression using Cox regression and linear-mixed models. In the 1791 participants, the agreement between Aβ1-42 and Aβ1-42/Aβ1-40 was 78.3%. The Aβ1-42/Aβ1-40 ratio showed a stronger correlation with tTau and pTau181 than Aβ1-42 and an agreement with tTau and pTau181 of 73.1% and 77.1%, respectively. Participants with a low Aβ1-42/Aβ1-40 ratio showed higher tTau and pTau181 and worse cognitive and functional prognosis, regardless of whether they were positive or negative for Aβ1-42. The results were consistent across stages, diagnostic categories, and use of different cutoffs. Although Aβ1-42 and Aβ1-42/Aβ1-40 are considered markers of the same pathophysiological pathway, our findings provide evidence favoring the use of the Aβ1-42/Aβ1-40 ratio in clinical laboratories in the context of AD. The online version contains supplementary material available at 10.1186/s13195-022-00967-z.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cognitive decline in amyotrophic lateral sclerosis, Neuropathological substrate and genetic determinants

  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Ximelis, Teresa
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Povedano, Mónica
  • Rubio, Miguel Angel|||0000-0002-0495-6240
  • Gamez, Josep|||0000-0003-3127-7486
  • Cano, Antonio
  • Paré-Curell, Martí|||0000-0002-0627-5350
  • Bajo, Lorena
  • Sotoca Fernández, Javier|||0000-0003-3400-1434
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Balasa, Mircea|||0000-0002-1795-4228
  • Antonell, Anna|||0000-0002-3286-8459
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Gelpi, Ellen|||0000-0003-2948-4187
Cognitive impairment and behavioral changes in amyotrophic lateral sclerosis (ALS) are now recognized as part of the disease. Whether it is solely related to the extent of TDP-43 pathology is currently unclear. We aim to evaluate the influence of age, genetics, neuropathological features, and concomitant pathologies on cognitive impairment in ALS patients. We analyzed a postmortem series of 104 ALS patients and retrospectively reviewed clinical and neuropathological data. We assessed the burden and extent of concomitant pathologies, the role of APOE ε4 and mutations, and correlated these findings with cognitive status. We performed a logistic regression model to identify which pathologies are related to cognitive impairment. Cognitive decline was recorded in 38.5% of the subjects. Neuropathological features of frontotemporal lobar degeneration (FTLD) were found in 32.7%, explaining most, but not all, cases with cognitive impairment. Extent of TDP-43 pathology and the presence of hippocampal sclerosis were associated with cognitive impairment. Mutation carriers presented a higher burden of TDP-43 pathology and FTLD more frequently than sporadic cases. Most cases (89.4%) presented some degree of concomitant pathologies. The presence of concomitant pathologies was associated with older age at death. FTLD, but also Alzheimer's disease, were the predominant underlying pathologies explaining the cognitive impairment in ALS patients. In sum, FTLD explained the presence of cognitive decline in most but not all ALS cases, while other non-FTLD related findings can influence the cognitive status, particularly in older age groups.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evaluation of biochemical and hematological parameters in adults with Down syndrome

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Garzón, Diana
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Fortea, Juan|||0000-0002-1340-638X
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
Down syndrome (DS) is the most common worldwide cause of intellectual disability of genetic origin and the most common chromosomal disorder affecting live-born infants. In addition to intellectual disability, individuals with DS have other comorbidities and complex medical conditions. The increase in the life expectancy of patients with DS requires expanding the knowledge about their clinical characteristics and related laboratory parameters. Several studies exploring laboratory tests in DS patients exist, but their focus is limited to specific areas of metabolism. Therefore, our main goal was to describe the biochemical and hematological findings in a DS cohort and to compare the values to those of a control population. A total of 248 DS individuals and 84 control subjects were enrolled. DS individuals had a higher frequency of several clinical conditions compared to control individuals and presented with significant differences with respect to the controls in both biochemical and hematological parameters. We found age- and sex-related differences in several of the parameters. A good understanding of the differences in our cohort might be of aid in the clinical follow-up of adults with DS, especially considering that the lifespan of DS individuals may reach 60 years of age in developed countries.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Complex multiple risk intervention to promote healthy behaviours in people between 45 to 75 years attended in primary health care (EIRA study), study protocol for a hybrid trial

  • Zabaleta del Olmo, Edurne|||0000-0002-5072-8548
  • Pombo, Haizea
  • Pons-Vigués, Mariona|||0000-0002-7929-3701
  • Casajuana Closas, Marc|||0000-0001-5653-996X
  • Pujol Ribera, Enriqueta|||0000-0002-9475-0755
  • López Jiménez, Tomàs|||0000-0001-8255-4936
  • Cabezas Peña, Carmen|||0000-0002-4291-0454
  • Martín-Borràs, Carme
  • Serrano-Blanco, Antoni|||0000-0001-6123-0633
  • Rubio-Valera, Maria|||0000-0003-2856-1697
  • Llobera, Joan
  • Leiva, Alfonso|||0000-0001-5306-8533
  • Vicens, Caterina
  • Vidal, Clara
  • Campíñez Navarro, Manuel
  • Martín-Álvarez, Remedios
  • Maderuelo-Fernandez, Jose-Angel|||0000-0001-7544-8684
  • Recio, José-Ignacio
  • Garcia-Ortiz, Luis|||0000-0001-6555-8302
  • Motrico, Emma|||0000-0002-0720-567X
  • Bellón Saameño, Juan Ángel|||0000-0002-4268-4979
  • Moreno-Peral, Patricia|||0000-0003-4130-9090
  • Martín-Cantera, Carlos|||0000-0003-0656-8126
  • Clavería, Ana|||0000-0001-9552-1260
  • Aldecoa-Landesa, Susana
  • Magallon Botaya, Rosa|||0000-0002-5494-6550
  • Bolíbar, Bonaventura|||0000-0003-4653-9805
Health promotion is a key process of current health systems. Primary Health Care (PHC) is the ideal setting for health promotion but multifaceted barriers make its integration difficult in the usual care. The majority of the adult population engages two or more risk behaviours, that is why a multiple intervention might be more effective and efficient. The primary objectives are to evaluate the effectiveness, the cost-effectiveness and an implementation strategy of a complex multiple risk intervention to promote healthy behaviours in people between 45 to 75 years attended in PHC. This study is a cluster randomised controlled hybrid type 2 trial with two parallel groups comparing a complex multiple risk behaviour intervention with usual care. It will be carried out in 26 PHC centres in Spain. The study focuses on people between 45 and 75 years who carry out two or more of the following unhealthy behaviours: tobacco use, low adherence to the Mediterranean dietary pattern or insufficient physical activity level. The intervention is based on the Transtheoretical Model and it will be made by physicians and nurses in the routine care of PHC practices according to the conceptual framework of the "5A's". It will have a maximum duration of 12 months and it will be carried out to three different levels (individual, group and community). Incremental cost per quality-adjusted life year gained measured by the tariffs of the EuroQol-5D questionnaire will be estimated. The implementation strategy is based on the "Consolidated Framework for Implementation Research", a set of discrete implementation strategies and an evaluation framework. EIRA study will determine the effectiveness and cost-effectiveness of a complex multiple risk intervention and will provide a better understanding of implementation processes of health promotion interventions in PHC setting. It may contribute to increase knowledge about the individual and structural barriers that affect implementation of these interventions and to quantify the contextual factors that moderate the effectiveness of implementation. , .Retrospectively registered on May 2, 2017.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

  • Pallarès, Victor|||0000-0002-9851-0345
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Chillón, M. Carmen|||0000-0003-1624-6059
  • Barragán, Eva
  • Prieto Conde, M. Isabel
  • Llop, Marta
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Montesinos, Pau|||0000-0002-3275-5593
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Brunet, Salut|||0000-0003-0491-1672
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • González-Díaz, Marcos
  • Sierra, Jorge|||0000-0002-7966-0356
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
In recent years, several attempts have been made to identify novel prognostic markers in patients with intermediate-risk acute myeloid leukemia (IR-AML), to implement risk-adapted strategies. The non-receptor tyrosine kinases are proteins involved in regulation of cell growth, adhesion, migration and apoptosis. They associate with metastatic dissemination in solid tumors and poor prognosis. However, their role in haematological malignancies has been scarcely studied. We hypothesized that PTK2/FAK, PTK2B/PYK2, LYN or SRC could be new prognostic markers in IR-AML. We assessed PTK2, PTK2B, LYN and SRC gene expression in a cohort of 324 patients, adults up to the age of 70, classified in the IR-AML cytogenetic group. Univariate and multivariate analyses showed that PTK2B, LYN and PTK2 gene expression are independent prognostic factors in IR-AML patients. PTK2B and LYN identify a patient subgroup with good prognosis within the cohort with non-favorable FLT3/NPM1 combined mutations. In contrast, PTK2 identifies a patient subgroup with poor prognosis within the worst prognosis cohort who display non-favorable FLT3/NPM1 combined mutations and underexpression of PTK2B or LYN. The combined use of these markers can refine the highly heterogeneous intermediate-risk subgroup of AML patients, and allow the development of risk-adapted post-remission chemotherapy protocols to improve their response to treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Medication-Related Problems in Older People with Multimorbidity in Catalonia, A Real-World Data Study with 5 Years' Follow-Up

  • Troncoso-Mariño, Amelia|||0000-0002-1064-0912
  • Roso-Llorach, Albert|||0000-0002-9264-0405
  • López Jiménez, Tomàs|||0000-0001-8255-4936
  • Villén, Noemí
  • Amado, Ester
  • Fernández-Bertolín, Sergio|||0000-0002-0029-6564
  • Carrasco-Ribelles, Lucía Amalia|||0000-0001-9263-1747
  • Borras, Josep M.|||0000-0001-7330-6308
  • Violán, Concepció|||0000-0003-3309-5360
Aging, multimorbidity, and polypharmacy are associated with medication-related problems (MRPs). This study aimed to assess the association that multimorbidity and mortality have with MRPs in older people over time. We followed multimorbid, older (65-99 years) people in Catalonia from 2012 to 2016, using longitudinal data and Cox models to estimate adjusted hazard ratios (HR). We reviewed electronic health records to collect explanatory variables and MRPs (duplicate therapy, drug-drug interactions, potentially inappropriate medications (PIM), and contraindicated drugs in chronic kidney disease (CKD) or liver disease). There were 723,016 people (median age: 74 years; 58.9% women) who completed follow-up. We observed a significant (p < 0.001) increase in the proportion with at least one MRP (2012: 66.9% to 2016: 75.5%); contraindicated drugs in CKD (11.1 to 18.5%) and liver disease (3.9 to 5.3%); and PIMs (62.5 to 71.1%), especially drugs increasing fall risk (67.5%). People with ≥10 diseases had more MRPs (in 2016: PIMs, 89.6%; contraindicated drugs in CKD, 34.4%; and in liver disease, 9.3%). All MRPs were independently associated with mortality, from duplicate therapy (HR 1.06; 95% confidence interval (CI) 1.04-1.08) to interactions (HR 1.60; 95% CI 1.54-1.66). Ensuring safe pharmacological treatment in elderly, multimorbid patient remains a challenge for healthcare systems.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4 + Diffuse Large B-Cell Lymphoma Cells

  • Falgàs, Aïda|||0000-0002-5040-2265
  • Pallarès, Victor|||0000-0002-9851-0345
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Núñez, Yáiza|||0000-0001-7268-2125
  • Sierra, Jorge|||0000-0002-7966-0356
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Álamo, Patricia|||0000-0003-0510-5701
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
Around 40-50% of diffuse large-B cell lymphoma (DLBCL) patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many ongoing clinical trials for DLBCL patients involve microtubule targeting agents (MTAs), however, their anticancer activity is limited by severe side effects. Therefore, we chose to improve the therapeutic window of the MTA monomethyl auristatin E developing a nanoconjugate, T22-AUR, that selectively targets the CXCR4 receptor, which is overexpressed in many DLBCL cells (CXCR4 +) and associated with poor prognosis. The T22-AUR specificity towards CXCR4 receptor was performed by flow cytometry in different DLBCL cell lines and running biodistribution assays in a subcutaneous mouse model bearing CXCR4 + DLBCL cells. Moreover, we determined T22-AUR cytotoxicity using cell viability assays, cell cycle analysis, DAPI staining and immunohistochemistry. Finally, the T22-AUR antineoplastic effect was evaluated in vivo in an extranodal CXCR4 + DLBCL mouse model whereas the toxicity analysis was assessed by histopathology in non-infiltrated mouse organs and by in vitro cytotoxic assays in human PBMCs. We demonstrate that the T22-AUR nanoconjugate displays CXCR4-dependent targeting and internalization in CXCR4 + DLBCL cells in vitro as well as in a subcutaneous DLBCL mouse model. Moreover, it shows high cytotoxic effect in CXCR4 + DLBCL cells, including induction of G2/M mitotic arrest, DNA damage, mitotic catastrophe and apoptosis. Furthermore, the nanoconjugate shows a potent reduction in lymphoma mouse dissemination without histopathological alterations in non-DLBCL infiltrated organs. Importantly, T22-AUR also exhibits lack of toxicity in human PBMCs. T22-AUR exerts in vitro and in vivo anticancer effect on CXCR4 + DLBCL cells without off-target toxicity. Thus, T22-AUR promises to become an effective therapy for CXCR4 + DLBCL patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

AMYQ, An index to standardize quantitative amyloid load across PET tracers

  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Aranha, Mateus|||0000-0001-9594-292X
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carrió, Ignasi|||0000-0003-1135-5352
  • Camacho, Valle|||0000-0003-0748-0847
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Positron emission tomography (PET) amyloid quantification methods require magnetic resonance imaging (MRI) for spatial registration and a priori reference region to scale the images. Furthermore, different tracers have distinct thresholds for positivity. We propose the AMYQ index, a new measure of amyloid burden, to overcome these limitations. We selected 18F-amyloid scans from ADNI and Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) with the corresponding T1-MRI. A subset also had neuropathological data. PET images were normalized, and the AMYQ was calculated based on an adaptive template. We compared AMYQ with the Centiloid scale on clinical and neuropathological diagnostic performance. AMYQ was related with amyloid neuropathological burden and had excellent diagnostic performance to discriminate controls from patients with Alzheimer's disease (AD) (area under the curve [AUC] = 0.86). AMYQ had a high agreement with the Centiloid scale (intraclass correlation coefficient [ICC] = 0.88) and AUC between 0.94 and 0.99 to discriminate PET positivity when using different Centiloid cutoffs. AMYQ is a new MRI-independent index for standardizing and quantifying amyloid load across tracers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effectiveness of an Intervention Aimed at Improving Information for Patients with High Cardiovascular Risk, INFORISK Clinical Trial

  • Brotons, Carlos|||0000-0001-9388-6581
  • Moral Peláez, Irene|||0000-0002-3842-8796
  • Fernández, Diana
  • Puig Palma, Mireia|||0000-0001-6676-8432
  • Vilella, Teresa|||0000-0002-5281-4386
  • Puig Reixach, Maria Teresa|||0000-0003-1402-7653
  • Cuixart Costa, Lluís|||0000-0003-3073-514X
  • Férriz, Gemma
  • Pedro-Pijoan, Anna Maria|||0000-0001-5348-6612
  • Codinachs, Roger|||0000-0002-2888-1562
  • Rodríguez, Mónica
  • Fuentes, Rubén
Background: The concept of global cardiovascular risk is not usually well understood by patients in consultation. Methods: This was a multicenter, prospective, randomized, open clinical trial of one-year duration to evaluate the effectiveness in reducing global cardiovascular risk with an intervention aimed at high-risk patients to improve information on the cardiovascular risk compared to the usual care. The intervention was focused on providing information about cardiovascular risk in a more understandable way, explaining the best practices to reduce cardiovascular risk, and tailoring information to the individual. Results: Four-hundred and sixty-four subjects participated in the study; 59.3% were men, and the mean age was 61.0 (SD 8.0) years. Significant reductions in systolic blood pressure (SBP) (-3.12 mmHg), body mass index (BMI) (-0.34 kg/m 2), abdominal circumference (-1.24 cm), and REGICOR cardiovascular risk (-0.63) were observed in the intervention group. Overall, no differences in cardiovascular risk score were observed between groups at the end of follow-up. Conclusions: Providing an easy-to-understand assessment of the cardiovascular risk motivated high-risk patients to adopt a healthier lifestyle and improved cardiovascular risk after one year in the intervention group. Clinicians should assess a patient's baseline understanding of their CV risk using tools other than absolute risk before making treatment recommendations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effects of a psychosocial intervention at one-year follow-up in a PREDIMED-plus sample with obesity and metabolic syndrome

  • Mallorquí-Bagué, Núria|||0000-0003-1434-3162
  • Lozano Madrid, María|||0000-0003-3833-317X
  • Vintró Alcaraz, Cristina|||0000-0001-9453-8810
  • Forcano, Laura|||0000-0002-8478-1451
  • Díaz-López, Andrés|||0000-0002-7500-5629
  • Galera, Ana
  • Fernández-Carrión, Rebeca
  • Granero, Roser|||0000-0001-6308-3198
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Corella, Dolores|||0000-0002-2366-4104
  • Pintó, Xavier|||0000-0002-2216-2444
  • Cuenca-Royo, Aida|||0000-0001-8551-5457
  • Bulló, Mònica|||0000-0002-0218-7046
  • Salas-Salvadó, Jordi|||0000-0003-2700-7459
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
This study examines if overweight/obesity are related to higher impulsivity, food addiction and depressive symptoms, and if these variables could be modified after 1 year of a multimodal intervention (diet, physical activity, psychosocial support). 342 adults (55-75 years) with overweight/obesity and metabolic syndrome (MetS) from the PREDIMED-Plus Cognition study were randomized to the intervention or to the control group (lifestyle recommendations). Cognitive and psychopathological assessments were performed at baseline and after 1-year follow-up. At baseline, higher impulsivity was linked to higher food addiction and depressive symptoms, but not to body mass index (BMI). Food addiction not only predicted higher BMI and depressive symptoms, but also achieved a mediational role between impulsivity and BMI/depressive symptoms. After 1 year, patients in both groups reported significant decreases in BMI, food addiction and impulsivity. BMI reduction and impulsivity improvements were higher in the intervention group. Higher BMI decrease was achieved in individuals with lower impulsivity. Higher scores in food addiction were also related to greater post-treatment impulsivity. To conclude, overweight/obesity are related to higher impulsivity, food addiction and depressive symptoms in mid/old age individuals with MetS. Our results also highlight the modifiable nature of the studied variables and the interest of promoting multimodal interventions within this population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome

  • Lleó, Alberto|||0000-0002-2568-5478
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Montal, Victor|||0000-0002-5714-9282
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Benejam, Bessy|||0000-0002-6789-8615
  • Fernández, Susana|||0000-0002-9777-1156
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Garzón, Diana
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Camacho, Valle|||0000-0003-0748-0847
  • Medrano-Martorell, Santiago|||0000-0002-6586-7284
  • Belbin, Olivia|||0000-0002-6109-6371
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blesa, Rafael|||0000-0003-4026-2884
  • Blennow, Kaj|||0000-0002-1890-4193
  • Fortea, Juan|||0000-0002-1340-638X
  • Zetterberg, Henrik|||0000-0003-3930-4354
Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73-0.87] and 0.92 [95% CI 0.89-0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS. Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology. Here, the authors investigated whether plasma ptau181 could be a potential biomarker of AD in individuals with Down syndrome (DS) and find plasma p-tau181 can detect AD in DS adults.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration

  • Cervantes González, Alba|||0000-0003-1006-6719
  • Irwin, David J.|||0000-0002-5599-5098
  • Alcolea, Daniel|||0000-0002-3819-3245
  • McMillan, Corey T.|||0000-0002-7581-6405
  • Chen-Plotkin, Alice
  • Wolk, David
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Querol-Vilaseca, Marta|||0000-0002-8589-1636
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lee, Edward B.
  • Trojanowski, John Q.|||0000-0002-9239-8794
  • Grossman, Murray|||0000-0002-7447-6218
  • Lleó, Alberto|||0000-0002-2568-5478
  • Belbin, Olivia|||0000-0002-6109-6371
Synapse degeneration is an early event in pathological frontotemporal lobar degeneration (FTLD). Consequently, a surrogate marker of synapse loss could be used to monitor early pathologic changes in patients with underlying FTLD. The aim of this study was to evaluate the relationship of antemortem cerebrospinal fluid (CSF) levels of 8 synaptic proteins with postmortem global tau and TDP-43 burden and cognitive performance and to assess their diagnostic capacity in a neuropathological FTLD cohort. We included patients with a neuropathological confirmation of FTLD-Tau (n = 24, mean age-at-CSF 67 years ± 11), FTLD-TDP (n = 25, 66 years ± 9) or AD (n = 25, 73 years ± 6) as well as cognitively normal controls (n = 35, 69 years ± 7) from the Penn FTD Center and ADRC. We used a semi-quantitative measure of tau and TDP-43 inclusions to quantify pathological burden across 16 brain regions. Statistical methods included Spearman rank correlations, one-way analysis of covariance, ordinal regression, step-wise multiple linear regression and receiver-operating characteristic curves. CSF calsyntenin-1 and neurexin-2a were correlated in all patient groups (r = .55 to.88). In FTLD-TDP, we observed low antemortem CSF levels of calsyntenin-1 and neurexin-2a compared to AD (.72-fold, p = .001,.77-fold, p = .04, respectively) and controls (.80-fold, p = .02,.78-fold, p = .02, respectively), which were inversely associated with post-mortem global TDP-43 burden (regression r 2 = .56, p = .007 and r 2 = .57, p = .006, respectively). A multimarker panel including calsyntenin-1 was associated with TDP-43 burden (r 2 = .69, p = .003) and MMSE score (r 2 = .19, p = .03) in FTLD. A second multimarker synaptic panel, also including calsyntenin-1, was associated with MMSE score in FTLD-tau (r 2 = .49, p = .04) and improved diagnostic performance to discriminate FTLD-Tau and FTLD-TDP neuropathologic subtypes (AUC = .83). These synaptic panels have potential in the differential diagnosis of FTLD neuropathologic subtypes and as surrogate markers of cognitive performance in future clinical trials targeting TDP-43 or tau. The online version contains supplementary material available at 10.1186/s13024-022-00534-y.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Barriers, facilitators, and proposals for improvement in the implementation of a collaborative care program for depression, a qualitative study of primary care physicians and nurses

  • Aragonès, Enric|||0000-0002-5245-4667
  • López-Cortacans, Germán|||0000-0001-6910-3284
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Tomé-Pires, Catarina|||0000-0001-7347-4950
  • Porta-Casteràs, Daniel|||0000-0002-3921-3607
  • Palao, Diego|||0000-0002-3323-6568
Primary care plays a central role in the treatment of depression. Nonetheless, shortcomings in its management and suboptimal outcomes have been identified. Collaborative care models improve processes for the management of depressive disorders and associated outcomes. We developed a strategy to implement the INDI collaborative care program for the management of depression in primary health care centers across Catalonia. The aim of this qualitative study was to evaluate a trial implementation of the program to identify barriers, facilitators, and proposals for improvement. One year after the implementation of the INDI program in 18 public primary health care centers we performed a qualitative study in which the opinions and experiences of 23 primary care doctors and nurses from the participating centers were explored in focus groups. We performed thematic content analysis of the focus group transcripts. The results were organized into three categories: facilitators, barriers, and proposals for improvement as perceived by the health care professionals involved. The most important facilitator identified was the perception that the INDI collaborative care program could be a useful tool for reorganizing processes and improving the management of depression in primary care, currently viewed as deficient. The main barriers identified were of an organizational nature: heavy workloads, lack of time, high staff turnover and shortages, and competing demands. Additional obstacles were inertia and resistance to change among health care professionals. Proposals for improvement included institutional buy-in to guarantee enduring support and the organizational changes needed for successful implementation. The INDI program is perceived as a useful, viable program for improving the management of depression in primary care. Uptake by primary care centers and health care professionals, however, was poor. The identification and analysis of barriers and facilitators will help refine the strategy to achieve successful, widespread implementation. ClinicalTrials.gov identifier: ; Registered 18th September, 2017.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

  • Oñate, Guadalupe|||0000-0003-2180-2371
  • Bataller, Alex|||0000-0002-6085-2745
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Arnan, Montserrat
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Coll, Rosa|||0000-0003-0560-1254
  • Tormo, Mar|||0000-0001-9622-1649
  • Sampol, Antonia|||0000-0001-7465-6203
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Salamero, Olga|||0000-0003-3237-0025
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Bargay, Joan|||0000-0002-6739-3916
  • Aljarilla, Alba
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Sierra, Jorge|||0000-0002-7966-0356
  • Pratcorona, Marta|||0000-0001-6375-596X
The negative prognostic impact of internal tandem duplication of FLT3 (FLT3- ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML- NPM1) is restricted to those with a higher FLT3 -ITD allelic ratio (FLT3 high ; ≥0.5) and considered negligible in those with a wild-type (FLT3 WT)/low ITD ratio (FLT3 low). Because the comutation of DNMT3A (DNMT3A mut) has been suggested to negatively influence prognosis in AML- NPM1, we analyzed the impact of DNMT3A mut in FLT3 -ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML- NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3A mut status did not have a prognostic impact, with comparable overall survival (P =.2). Prognostic stratification established by FLT3 -ITD (FLT3 WT = FLT3 low.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia, validation in a risk-adapted protocol

  • Bataller, Alex|||0000-0002-6085-2745
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Guijarro, Francesca|||0000-0001-6376-0929
  • Oñate, Guadalupe|||0000-0003-2180-2371
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Arnan, Montserrat
  • Tormo, Mar|||0000-0001-9622-1649
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Queipo de Llano, María Paz
  • Coll, Rosa|||0000-0003-0560-1254
  • Gallardo, David|||0000-0003-1615-4592
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Salamero, Olga|||0000-0003-3237-0025
  • Sampol, Antonia|||0000-0001-7465-6203
  • Merchan, Brayan M.|||0000-0002-6733-6006
  • Bargay, Joan|||0000-0002-6739-3916
  • Castaño-Díez, Sandra|||0000-0001-9044-4665
  • Esteban Corredera, Daniel|||0000-0001-8897-3170
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Rivero, Andrea|||0000-0002-4233-5031
  • Mozas, Pablo|||0000-0001-9528-4971
  • López Guerra, Mónica|||0000-0002-5545-0178
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Costa, Dolors|||0000-0002-8276-3292
  • Rozman, Maria|||0000-0002-2641-1110
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Colomer, Dolors|||0000-0001-7486-8484
  • Brunet, Salut|||0000-0003-0491-1672
  • Sierra, Jorge|||0000-0002-7966-0356
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and management of acute myeloid leukemia (AML) have become fundamental guidelines to assess the prognosis and postremission therapy of patients. However, they have been retrospectively validated in few studies with patients included in different treatment protocols. We analyzed 861 patients included in the Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias-12 risk-adapted protocol, which indicates cytarabine-based consolidation for patients allocated to the ELN 2017 favorable-risk group, whereas it recommends allogeneic stem cell transplantation (alloSCT) as a postremission strategy for the ELN 2017 intermediate- and adverse-risk groups. We retrospectively classified patients according to the ELN 2017, with 327 (48%), 109 (16%), and 245 (36%) patients allocated to the favorable-, intermediate-, and adverse-risk group, respectively. The 2- and 5-year overall survival (OS) rates were 77% and 70% for favorable-risk patients, 52% and 46% for intermediate-risk patients, and 33% and 23% for adverse-risk patients, respectively. Furthermore, we identified a subgroup of patients within the adverse group (inv(3)/t(3;3), complex karyotype, and/or TP53 mutation/17p abnormality) with a particularly poor outcome, with a 2-year OS of 15%. Our study validates the ELN 2017 risk stratification in a large cohort of patients treated with an ELN-2017 risk-adapted protocol based on alloSCT after remission for nonfavorable ELN subgroups and identifies a genetic subset with a very poor outcome that warrants investigation of novel strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model

  • Pallarès, Victor|||0000-0002-9851-0345
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Aviñó, Ana|||0000-0003-3047-738X
  • Núñez, Yáiza|||0000-0001-7268-2125
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Serna, Naroa|||0000-0001-5682-8198
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sierra, Jorge|||0000-0002-7966-0356
  • Cedó, Lídia|||0000-0003-4354-3411
  • Eritja, Ramon|||0000-0001-5383-9334
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
Current therapy in acute myeloid leukemia (AML) is based on chemotherapeutic drugs administered at high doses, lacking targeting selectivity and displaying poor therapeutic index because of severe adverse effects. Here, we develop a novel nanoconjugate that combines a self-assembled, multivalent protein nanoparticle, targeting the CXCR4 receptor, with an Oligo-Ara-C prodrug, a pentameric form of Ara-C, to highly increase the delivered payload to target cells. This 13.4 nm T22-GFP-H6-Ara-C nanoconjugate selectively eliminates CXCR4 AML cells, which are protected by its anchoring to the bone marrow (BM) niche, being involved in AML progression and chemotherapy resistance. This nanoconjugate shows CXCR4-dependent internalization and antineoplastic activity in CXCR4 AML cells in vitro. Moreover, repeated T22-GFP-H6-Ara-C administration selectively eliminates CXCR4 leukemic cells in BM, spleen and liver. The leukemic dissemination blockage induced by T22-GFP-H6-Ara-C is significantly more potent than buffer or Oligo-Ara-C-treated mice, showing no associated on-target or off-target toxicity and, therefore, reaching a highly therapeutic window. In conclusion, T22-GFP-H6-Ara-C exploits its 11 ligands-multivalency to enhance target selectivity, while the Oligo-Ara-C prodrug multimeric form increases 5-fold its payload. This feature combination offers an alternative nanomedicine with higher activity and greater tolerability than current intensive or non-intensive chemotherapy for AML patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

  • Zhu, Nuole|||0000-0002-0015-9455
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Montal, Victor|||0000-0002-5714-9282
  • Estellés, Teresa
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Muñoz, Laia|||0000-0003-0578-3094
  • Belbin, Olivia|||0000-0002-6109-6371
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Astrocytes play an essential role in neuroinflammation and are involved in the pathogenesis of neurodenegerative diseases. Studies of glial fibrillary acidic protein (GFAP), an astrocytic damage marker, may help advance our understanding of different neurodegenerative diseases. In this study, we investigated the diagnostic performance of plasma GFAP (pGFAP), plasma neurofilament light chain (pNfL) and their combination for frontotemporal dementia (FTD) and Alzheimer's disease (AD) and their clinical utility in predicting disease progression. Methods: pGFAP and pNfL concentrations were measured in 72 FTD, 56 AD and 83 cognitively normal (CN) participants using the Single Molecule Array technology. Of the 211 participants, 199 underwent cerebrospinal (CSF) analysis and 122 had magnetic resonance imaging. We compared cross-sectional biomarker levels between groups, studied their diagnostic performance and assessed correlation between CSF biomarkers, cognitive performance and cortical thickness. The prognostic performance was investigated, analyzing cognitive decline through group comparisons by tertile. Results: Unlike pNfL, which was increased similarly in both clinical groups, pGFAP was increased in FTD but lower than in AD (all P < 0.01). Combination of both plasma markers improved the diagnostic performance to discriminate FTD from AD (area under the curve [AUC]: combination 0.78; pGFAP 0.7; pNfL 0.61, all P < 0.05). In FTD, pGFAP correlated with cognition, CSF and plasma NfL, and cortical thickness (all P < 0.05). The higher tertile of pGFAP was associated with greater change in MMSE score and poor cognitive outcome during follow-up both in FTD (1.40 points annually, hazard ratio [HR] 3.82, P < 0.005) and in AD (1.20 points annually, HR 2.26, P < 0.005). Conclusions: pGFAP and pNfL levels differ in FTD and AD, and their combination is useful for distinguishing between the two diseases. pGFAP could also be used to track disease severity and predict greater cognitive decline during follow-up in patients with FTD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of Apolipoprotein e ϵ4 Allele with Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults with down Syndrome

  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernandez, S.
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Muñoz, Laia|||0000-0003-0578-3094
  • Padilla, Concepción|||0000-0003-4102-6787
  • Aranha, Mateus|||0000-0001-9594-292X
  • Estellés, Teresa
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Belbin, Olivia|||0000-0002-6109-6371
  • Camacho, Valle|||0000-0003-0748-0847
  • Wilson, Liam Reese
  • Annus, Tiina
  • Osorio, R.S.
  • Videla, S.
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Holland, Anthony|||0000-0003-4107-130X
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Zaman, Shahid
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Importance: Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS). Previous studies have suggested that the APOE ϵ4 allele plays a role in the risk and age at onset of dementia in DS; however, data on in vivo biomarkers remain scarce. Objective: To investigate the association of the APOE ϵ4 allele with clinical and multimodal biomarkers of AD in adults with DS. Design, Setting, and Participants: This dual-center cohort study recruited adults with DS in Barcelona, Spain, and in Cambridge, UK, between June 1, 2009, and February 28, 2020. Included individuals had been genotyped for APOE and had at least 1 clinical or AD biomarker measurement; 2 individuals were excluded because of the absence of trisomy 21. Participants were either APOE ϵ4 allele carriers or noncarriers. Main Outcomes and Measures: Participants underwent a neurological and neuropsychological assessment. A subset of participants had biomarker measurements: Aβ1-42, Aβ1-40, phosphorylated tau 181 (pTau181) and neurofilament light chain (NfL) in cerebrospinal fluid (CSF), pTau181, and NfL in plasma; amyloid positron emission tomography (PET); fluorine 18-labeled-fluorodeoxyglucose PET; and/or magnetic resonance imaging. Age at symptom onset was compared between APOE ϵ4 allele carriers and noncarriers, and within-group local regression models were used to compare the association of biomarkers with age. Voxelwise analyses were performed to assess topographical differences in gray matter metabolism and volume. Results: Of the 464 adults with DS included in the study, 97 (20.9%) were APOE ϵ4 allele carriers and 367 (79.1%) were noncarriers. No differences between the 2 groups were found by age (median [interquartile range], 45.9 [36.4-50.2] years vs 43.7 [34.9-50.2] years; P =.56) or sex (51 male carriers [52.6%] vs 199 male noncarriers [54.2%]). APOE ϵ4 allele carriers compared with noncarriers presented with AD symptoms at a younger age (mean [SD] age, 50.7 [4.4] years vs 52.7 [5.8] years; P =.02) and showed earlier cognitive decline. Locally estimated scatterplot smoothing curves further showed between-group differences in biomarker trajectories with age as reflected by nonoverlapping CIs. Specifically, carriers showed lower levels of the CSF Aβ1-42 to Aβ1-40 ratio until age 40 years, earlier increases in amyloid PET and plasma pTau181, and earlier loss of cortical metabolism and hippocampal volume. No differences were found in NfL biomarkers or CSF total tau and pTau181. Voxelwise analyses showed lower metabolism in subcortical and parieto-occipital structures and lower medial temporal volume in APOE ϵ4 allele carriers. Conclusions and Relevance: In this study, the APOE ϵ4 allele was associated with earlier clinical and biomarker changes of AD in DS. These results provide insights into the mechanisms by which APOE increases the risk of AD, emphasizing the importance of APOE genotype for future clinical trials in DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide

  • Esquirol, Albert|||0000-0002-6062-5980
  • Pascual, Maria Jesus
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Herruzo, Beatriz
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Pérez, Ariadna
  • Torio, Alberto
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Cuesta, Marian
  • Martino Bofarull, Rodrigo|||0000-0001-5143-4042
  • Sierra, Jorge|||0000-0002-7966-0356
One hundred and sixty-one patients underwent haploidentical stem cell transplantation (haploSCT) with thiotepa, busulfan, and fludarabine conditioning followed by post-transplantation cyclophosphamide (PTCy) (on days +3 and +4) and tacrolimus as graft-versus-host disease prophylaxis. Forty-two percent of patients had a high or very high revised Disease Risk Index (rDRI), 55% had an European Society for Blood and Marrow Transplantation risk score (EBMT-RS) ≥4, and 36% had an age-adjusted Hematopoietic Cell Transplant Comorbidity Index (HCT-CI-age) score ≥3. Each of these was considered an unfavorable score. Using the pretransplantation unfavorable scores that had an independent impact on each transplantation outcome studied in multivariate analysis allowed for better stratification of patient outcomes. Thus, the 3-year overall survival (OS) in patients with 0, 1, 2, and 3 unfavorable scores was 86%, 56%, 36%, and 24%, respectively. Nonrelapse mortality (NRM) was negatively impacted by the EBMT-RS and the HCT-CI-age score (3-year NRM in patients with 0, 1, and 2 unfavorable scores was 12%, 33%, and 43%, respectively), whereas the EBMT-RS and the rDRI had an impact on the 3-year relapse incidence (8%, 18%, and 41% in patients with 0, 1, and 2 unfavorable scores, respectively). In conclusion, our study shows that combining 2 or 3 of these well-defined pretransplantation scores improves the ability to predict transplantation outcomes in the setting of haploSCT with PTCy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clonal Spread and Intra- and Inter-Species Plasmid Dissemination Associated With Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales During a Hospital Outbreak in Barcelona, Spain

  • Marí-Almirall, Marta
  • Ferrando, Núria
  • José Fernández, Mariana
  • Cosgaya, Clara
  • Viñes, Joaquim|||0000-0003-0709-5236
  • Rubio, Elisa|||0000-0002-2556-8837
  • Cuscó, Anna|||0000-0002-9574-5755
  • Muñoz, Laura
  • Pellice, Martina
  • Vergara, Andrea|||0000-0002-5046-4490
  • Campo, Irene
  • Rodríguez-Serna, Laura
  • Santana, Gemina
  • del Río, Ana
  • Francino, Olga|||0000-0002-9022-3835
  • Ciruela, Pilar|||0000-0003-0842-7220
  • Ballester, Frederic
  • Marco, Francesc|||0000-0002-1863-6379
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Soriano Viladomiu, Alex|||0000-0002-9374-0811
  • Pitart, Cristina|||0000-0002-3083-7915
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Roca, Ignasi|||0000-0002-1800-1576
Objectives: The study aimed to characterize the clonal spread of resistant bacteria and dissemination of resistance plasmids among carbapenem-resistant Enterobacterales at a tertiary hospital in Catalonia, Spain. Methods: Isolates were recovered from surveillance rectal swabs and diagnostic samples. Species identification was by matrix-assisted laser desorption ionization-time time of flight mass spectrometry (MALDI-TOF MS). Molecular typing was performed by pulsed-field gel electrophoresis (PFGE) and multi-locus sequence typing (MLST). Antimicrobial susceptibility was assessed by gradient-diffusion and carriage of bla genes was detected by PCR. Plasmid typing, conjugation assays, S1-PFGE studies and long-read sequencing were used to characterize resistance plasmids. Results: From July 2018 to February 2019, 125 Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales were recovered from 101 inpatients from surveillance (74.4%) or clinical samples (25.6%), in a tertiary hospital in Barcelona. Clonality studies identified a major clone of Klebsiella pneumoniae belonging to sequence type ST15 and additional isolates of K. pneumoniae, Escherichia coli and Enterobacter sp. from different STs. All isolates but one carried the bla allelic variant. The bla gene was located in an IncFIIk plasmid of circa 106 Kb in a non-classical Tn 4401 element designated NTE-pMC-2-1. Whole-genome sequencing revealed different rearrangements of the 106 Kb plasmid while the NTE-pMC-2-1 module was highly conserved. Conclusion: We report a hospital outbreak caused by the clonal dissemination of KPC-producing ST15 K. pneumoniae but also the intra- and inter-species transmission of the bla gene associated with plasmid conjugation and/or transposon dissemination. To our knowledge, this is the first report of an outbreak caused by KPC-producing Enterobacterales isolated from human patients in Catalonia and highlights the relevance of surveillance studies in the early detection and control of antibiotic resistant high-risk clones.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acute lymphoblastic leukemia necessitates GSH-dependent ferroptosis defenses to overcome FSP1-epigenetic silencing

  • Pontel, Lucas B.|||0000-0001-8384-3422
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Morellato, Agustín E.
  • Santos, Juliana|||0000-0003-4148-9570
  • Roué, Gaël|||0000-0003-0245-2257
  • Esteller, M|||0000-0003-4490-6093
Ferroptosis is a form of cell death triggered by phospholipid hydroperoxides (PLOOH) generated from the iron-dependent oxidation of polyunsaturated fatty acids (PUFAs). To prevent ferroptosis, cells rely on the antioxidant glutathione (GSH), which serves as cofactor of the glutathione peroxidase 4 (GPX4) for the neutralization of PLOOHs. Some cancer cells can also limit ferroptosis through a GSH-independent axis, centered mainly on the ferroptosis suppressor protein 1 (FSP1). The significance of these two anti-ferroptosis pathways is still poorly understood in cancers from hematopoietic origin. Here, we report that blood-derived cancer cells are selectively sensitive to compounds that block the GSH-dependent anti-ferroptosis axis. In T- and B- acute lymphoblastic leukemia (ALL) cell lines and patient biopsies, the promoter of the gene coding for FSP1 is hypermethylated, silencing the expression of FSP1 and creating a selective dependency on GSH-centered anti-ferroptosis defenses. In-trans expression of FSP1 increases the resistance of leukemic cells to compounds targeting the GSH-dependent anti-ferroptosis pathway. FSP1 over-expression also favors ALL-tumor growth in an in vivo chick chorioallantoic membrane (CAM) model. Hence, our results reveal a metabolic vulnerability of ALL that might be of therapeutic interest
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

DNA methylation biomarkers of myocardial infarction and cardiovascular disease

  • Fernández-Sanlés, Alba
  • Sayols-Baixeras, Sergi
  • Subirana, I.
  • Sentí, Mariano
  • Pérez-Fernández, S.
  • de Castro Moura, Manuel
  • Esteller, M|||0000-0003-4490-6093
  • Marrugat, Jaume|||0000-0003-3320-554X
  • Elosua, Roberto|||0000-0001-8235-0095
Background: The epigenetic landscape underlying cardiovascular disease (CVD) is not completely understood and the clinical value of the identified biomarkers is still limited. We aimed to identify differentially methylated loci associated with acute myocardial infarction (AMI) and assess their validity as predictive and causal biomarkers. Results: We designed a case-control, two-stage, epigenome-wide association study on AMI (n = 391, n = 204). DNA methylation was assessed using the Infinium MethylationEPIC BeadChip. We performed a fixed-effects meta-analysis of the two samples. 34 CpGs were associated with AMI. Only 12 of them were available in two independent cohort studies (n ~ 1800 and n ~ 2500) with incident coronary and cardiovascular disease (CHD and CVD, respectively). The Infinium HumanMethylation450 BeadChip was used in those two studies. Four of the 12 CpGs were validated in association with incident CHD: AHRR-mapping cg05575921, PTCD2-mapping cg25769469, intergenic cg21566642 and MPO-mapping cg04988978. We then assessed whether methylation risk scores based on those CpGs improved the predictive capacity of the Framingham risk function, but they did not. Finally, we aimed to study the causality of those associations using a Mendelian randomization approach but only one of the CpGs had a genetic influence and therefore the results were not conclusive. Conclusions: We have identified 34 CpGs related to AMI. These loci highlight the relevance of smoking, lipid metabolism, and inflammation in the biological mechanisms related to AMI. Four were additionally associated with incident CHD and CVD but did not provide additional predictive information.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neural correlates of episodic memory in adults with Down syndrome and Alzheimer's disease

  • Benejam, Bessy|||0000-0002-6789-8615
  • Aranha, Mateus|||0000-0001-9594-292X
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Videla, Sebastián|||0000-0001-5049-1379
  • Bartrés-Faz, David|||0000-0001-6020-4118
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Background: Adults with Down syndrome are at an ultra-high risk of developing early-onset Alzheimer's disease. Episodic memory deficits are one of the earliest signs of the disease, but their association with regional brain atrophy in the population with Down syndrome has not been explored. We aimed to investigate the neuroanatomical correlates of episodic memory in adults with Down syndrome and symptomatic Alzheimer's disease. Methods: Single-center, cross-sectional study. A total of 139 adults with Down syndrome (85 asymptomatic and 54 with symptomatic Alzheimer's disease) were included in the study (mean age 43.6 ± 10.9 years, 46% female). Episodic memory was assessed using the modified Cued Recall Test. Immediate (trial 1 free immediate recall, trial 3 free immediate recall, total free immediate recall score, and total immediate score) and delayed scores (free delayed recall score and total delayed score) were examined. Cortical thickness from magnetic resonance imaging was determined with surface-based morphometry using the FreeSurfer 6.0 software package. The clusters of reduced cortical thickness were compared between symptomatic and asymptomatic participants to create a cortical atrophy map. Then, the correlation between cortical thickness and the modified Cued Recall Test subscores were separately assessed in symptomatic and asymptomatic subjects, controlling for age, sex, and severity of intellectual disability. Results: Compared with asymptomatic participants, those with symptomatic Alzheimer's disease showed a pattern of cortical atrophy in posterior parieto-temporo-occipital cortices. In symptomatic subjects, trial 1 immediate free recall significantly correlated with cortical atrophy in lateral prefrontal regions. Trial 3 free immediate recall and total free immediate recall were associated with the most widespread cortical atrophy. Total immediate score was related to posterior cortical atrophy, including lateral parietal and temporal cortex, posterior cingulate cortex, precuneus, and medial temporal lobe areas. Delayed memory scores were associated with cortical atrophy in temporoparietal and medial temporal lobe regions. No significant relationships were observed between episodic memory measures and cortical atrophy in asymptomatic subjects. Conclusions: Different episodic memory measures were associated with cortical atrophy in specific brain regions in adults with Down syndrome and Alzheimer's disease. These results overlap with those described in sporadic Alzheimer's disease and further support the similarities between Down syndrome-associated Alzheimer's disease and that in the general population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Systematic Collaborative Reanalysis of Genomic Data Improves Diagnostic Yield in Neurologic Rare Diseases

  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Matalonga, Leslie
  • Pujadas, Montserrat
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Tonda, Raúl
  • Artuch, R.|||0000-0002-3422-9685
  • Gallano, Pia|||0000-0001-8104-2197
  • Garrabou, Glòria|||0000-0001-8973-9933
  • González, Juan R.|||0000-0003-3267-2146
  • Grinberg, Daniel|||0000-0001-9859-2590
  • Guitart, Maria|||0000-0003-2957-7404
  • Laurie, Steven|||0000-0003-3913-5829
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Luengo, Cristina
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Milà, Montserrat
  • Ovelleiro, David|||0000-0002-9415-2229
  • Parra, Genís
  • Pujol, Aurora|||0000-0002-9606-0600
  • Tizzano, Eduardo F.|||0000-0002-7116-6310
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Palau, Francesc|||0000-0002-8635-5421
  • Ribes, Antònia
  • Pérez-Jurado, Luis Alberto|||0000-0002-1988-3005
  • Beltran i Agulló, Sergi|||0000-0002-2810-3445
  • Schlüter, Agatha|||0000-0001-6732-1528
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Cáceres, Alejandro|||0000-0001-8551-6695
  • Nascimento, Andrés
  • García-Cazorla, Àngels
  • Cueto-González, Anna Mª|||0000-0001-7694-6124
  • Marcé-Grau, Anna|||0000-0001-5762-4023
  • Ruiz Nel Lo, Anna
  • Martínez-Monseny, Antonio
  • Sánchez, Aurora|||0000-0003-1167-1451
  • García, Belén
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
  • Gel, Bernat|||0000-0001-8878-349X
  • Fusté, Berta
  • Hernández Ferrer, Carles
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Arjona, César
  • Hernando Davalillo, Cristina
  • Natera de Benito, Daniel
  • Picó Amador, Daniel
  • Gómez-Andrés, David|||0000-0001-5654-7791
  • Yubero, Délia
  • Pelegrí-Sisó, Dolors|||0000-0002-5993-3003
  • Verdura, Edgard|||0000-0003-3856-2060
  • García Arumí, Elena|||0000-0003-1848-005X
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Tobías, Ester|||0000-0002-9968-3651
  • López-Grondona, Fermina
  • Cardellach, Francesc|||0000-0003-3286-3436
  • García García, Francesc Josep|||0000-0001-9021-0324
  • Munell Casadesus, Francina|||0000-0001-8580-2819
  • Tort, Frederic|||0000-0003-2733-1603
  • Aznar, Gemma
  • Olive Cirera, Gemma
  • Tell-Martí, Gemma|||0000-0003-2728-6961
  • Muñoz-Pujol, Gerard|||0000-0002-6863-3993
  • Paramonov, Ida
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Madrigal, Irene|||0000-0002-7229-1199
  • Valenzuela, Irene|||0000-0003-2350-6058
  • Gut, Ivo|||0000-0001-7219-632X
  • Cusco, Ivon|||0000-0003-2104-9332
  • Trotta, Jean-Rémi
  • Cruz, Jordi
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Milisenda, José César|||0000-0003-0151-7872
  • Ma Grau, Josep
  • Garcia-Villoria, Judit
  • Armstrong, Judith|||0000-0003-0588-9307
  • Cantó, Judith
  • Sala-Coromina, Júlia|||0000-0001-5116-6316
  • Rodríguez-Revenga, Laia
  • Alías, Laura|||0000-0003-2193-6185
  • Gort, Laura|||0000-0003-4746-1034
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Costa, Mar
  • Fernández-Callejo, Marcos
  • López Sánchez, Marcos|||0000-0002-1517-5968
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Gut, Marta|||0000-0002-4063-7159
  • Serrano, Mercedes|||0000-0002-2056-2428
  • Raspall-Chaure, Miquel|||0000-0002-3132-3342
  • Del Toro, Mireia|||0000-0002-8163-1853
  • Bayés, Mònica
  • Baena Díez, Neus|||0000-0003-0677-240X
  • Spataro, Nino|||0000-0002-2127-2238
  • Capdevila, Núria|||0000-0003-2080-7381
  • Ugarteburu, Olatz|||0000-0003-4214-3301
  • Muñoz-Cabello, Patricia|||0000-0002-5242-9605
  • Romero Duque, Penélope|||0000-0003-3509-1320
  • Rabionet, Raquel|||0000-0001-5006-8140
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Calvo-Escalona, Rosa|||0000-0001-9572-4228
  • Urreizti, Roser|||0000-0003-3617-7134
  • Bernal, Sara|||0000-0003-4427-0574
  • Boronat Guerrero, Susana|||0000-0001-7096-5578
  • Balcells, Susana|||0000-0003-1211-1907
  • Vendrell, Teresa
Many patients experiencing a rare disease remain undiagnosed even after genomic testing. Reanalysis of existing genomic data has shown to increase diagnostic yield, although there are few systematic and comprehensive reanalysis efforts that enable collaborative interpretation and future reinterpretation. The Undiagnosed Rare Disease Program of Catalonia project collated previously inconclusive good quality genomic data (panels, exomes, and genomes) and standardized phenotypic profiles from 323 families (543 individuals) with a neurologic rare disease. The data were reanalyzed systematically to identify relatedness, runs of homozygosity, consanguinity, single-nucleotide variants, insertions and deletions, and copy number variants. Data were shared and collaboratively interpreted within the consortium through a customized Genome-Phenome Analysis Platform, which also enables future data reinterpretation. Reanalysis of existing genomic data provided a diagnosis for 20.7% of the patients, including 1.8% diagnosed after the generation of additional genomic data to identify a second pathogenic heterozygous variant. Diagnostic rate was significantly higher for family-based exome/genome reanalysis compared with singleton panels. Most new diagnoses were attributable to recent gene-disease associations (50.8%), additional or improved bioinformatic analysis (19.7%), and standardized phenotyping data integrated within the Undiagnosed Rare Disease Program of Catalonia Genome-Phenome Analysis Platform functionalities (18%).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients

  • Lennol, Matthew Paul
  • Sánchez-Domínguez, Irene|||0000-0001-6421-8293
  • Cuchillo-Ibáñez, Inmaculada|||0000-0002-3689-5518
  • Camporesi, Elena
  • Brinkmalm, Gunnar
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Soria, Guadalupe
  • Aguado, Fernando|||0000-0002-0393-1308
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Sáez-Valero, Javier
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer's disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. Results: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. Conclusion: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study

  • Guillén, Núria|||0000-0002-1341-9834
  • Contador, José
  • Buongiorno, Mariateresa
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Culell, Natalia
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Piñol-Ripoll, Gerard
  • Carnes-Vendrell, Anna
  • Ispierto, María Lourdes|||0000-0002-1837-9675
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Puig-Pijoan, Albert|||0000-0002-9848-3711
  • Fernández-Lebrero, Aida|||0000-0002-2097-4430
  • Balasa, Mircea|||0000-0002-1795-4228
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta (Aβ, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (-) or abnormal (+) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and amyloid-PET was analyzed by overall percent agreement (OPA). 236 participants were included (mean age 67.9 years (SD 9.1), MMSE score 24.5 (SD 4.1)). Diagnoses were mild cognitive impairment or dementia due to AD (49%), Lewy body dementia (22%), frontotemporal dementia (10%) and others (19%). Mean time between tests was 5.1 months (SD 4.1). OPA between single CSF biomarkers and amyloid-PET was 74% for , 75% for pTau181, 73% for tTau. The use of biomarker ratios improved OPA: 87% for Aβ/Aβ (n = 155), 88% for pTau181/Aβ (n = 94) and 82% for tTau/Aβ (n = 160). A + T + N + cases showed the highest agreement between CSF biomarkers and amyloid-PET (96%), followed by A-T-N- cases (89%). Aβ/Aβ was a better marker of cerebral amyloid deposition, as identified by amyloid tracers, than Aβ alone. Combined biomarkers in CSF predicted amyloid-PET result better than single biomarkers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development

  • Thambyrajah, Roshana|||0000-0002-3941-760X
  • Maqueda, Maria|||0000-0001-9304-1714
  • Fadlullah, Muhammad Zaki|||0000-0002-3111-8090
  • Proffitt, Martin
  • Neo, Wen Hao|||0000-0002-6827-3027
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Casado Pelaez, Marta|||0000-0002-8428-8384
  • Herrero-Molinero, Patricia
  • Brujas, Carla
  • Castelluccio, Noemi|||0000-0003-2635-4889
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Iglesias, Arnau|||0000-0002-7195-7868
  • Marruecos, Laura|||0000-0002-4206-709X
  • Ruiz-Herguido, Cristina
  • Esteller, M|||0000-0003-4490-6093
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Lacaud, Georges|||0000-0002-5630-2417
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Bigas Salvans, Anna|||0000-0003-4801-6899
Recent findings suggest that Hematopoietic Stem Cells (HSC) and progenitors arise simultaneously and independently of each other already in the embryonic aorta-gonad mesonephros region, but it is still unknown how their different features are established. Here, we uncover IκBα (Nfkbia, the inhibitor of NF-κB) as a critical regulator of HSC proliferation throughout development. IκBα balances retinoic acid signaling levels together with the epigenetic silencer, PRC2, specifically in HSCs. Loss of IκBα decreases proliferation of HSC and induces a dormancy related gene expression signature instead. Also, IκBα deficient HSCs respond with superior activation to in vitro culture and in serial transplantation. At the molecular level, chromatin regions harboring binding motifs for retinoic acid signaling are hypo-methylated for the PRC2 dependent H3K27me3 mark in IκBα deficient HSCs. Overall, we show that the proliferation index in the developing HSCs is regulated by a IκBα-PRC2 axis, which controls retinoic acid signaling.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate

  • Thambyrajah, Roshana|||0000-0002-3941-760X
  • Maqueda, Maria|||0000-0001-9304-1714
  • Neo, Wen Hao|||0000-0002-6827-3027
  • Imbach, Kathleen|||0000-0002-3861-7845
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Grases Mendoza, Daniela|||0000-0002-5981-7248
  • Fadlullah, Zaki
  • Gambera, Stefano|||0000-0003-2998-8502
  • Matteini, Fernando
  • Wang, Xiaonan|||0000-0003-3759-778X
  • Calero-Nieto, Fernando|||0000-0003-3358-8253
  • Esteller, M.|||0000-0003-4490-6093
  • Florian, María Carolina
  • Porta-Pardo, Eduard|||0000-0001-7900-4239
  • Benedito, Rui|||0000-0003-2458-3055
  • Göttgens, Berthold|||0000-0001-6302-5705
  • Lacaud, Georges|||0000-0002-5630-2417
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Bigas Salvans, Anna|||0000-0003-4801-6899
Hematopoietic stem cells (HSCs) develop from the hemogenic endothelium (HE) in the aorta- gonads-and mesonephros (AGM) region and reside within Intra-aortic hematopoietic clusters (IAHC) along with hematopoietic progenitors (HPC). The signalling mechanisms that distinguish HSCs from HPCs are unknown. Notch signaling is essential for arterial specification, IAHC formation and HSC activity, but current studies on how Notch segregates these different fates are inconsistent. We now demonstrate that Notch activity is highest in a subset of, GFI1 +, HSC-primed HE cells, and is gradually lost with HSC maturation. We uncover that the HSC phenotype is maintained due to increasing levels of NOTCH1 and JAG1 interactions on the surface of the same cell (cis) that renders the NOTCH1 receptor from being activated. Forced activation of the NOTCH1 receptor in IAHC activates a hematopoietic differentiation program. Our results indicate that NOTCH1-JAG1 cis-inhibition preserves the HSC phenotype in the hematopoietic clusters of the embryonic aorta.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lower serum ferritin levels are associated with worse cognitive performance in aging

  • Rosell-Díaz, Marisel|||0000-0001-7599-6584
  • Santos-González, Elena
  • Motger Albertí, Anna|||0000-0002-9430-371X
  • Gallardo-Nuell, Laura
  • Arnoriaga-Rodriguez, Maria|||0000-0002-0394-1223
  • Coll-Martínez, Clàudia|||0000-0003-2927-4008
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Garre-Olmo, Josep|||0000-0002-7817-0814
  • Puig, Josep|||0000-0003-2791-6599
  • Ramos, Rafel|||0000-0001-7970-5537
  • Mayneris-Perxachs, Jordi|||0000-0003-3788-3815
  • Fernández-Real Lemos, José Manuel|||0000-0002-7442-9323
Objectives: Iron is important for neurogenesis, synaptic development, and neurotransmitter synthesis. Serum ferritin (SF) is a reliable marker for assessing iron stores. Therefore, we evaluated the cognitive function associated with SF levels. We also assessed brain iron content using R2* Magnetic Resonance Imaging (MRI) and its association with SF levels. Design: Data from three cross-sectional observational studies were used. Aging Imageomics (n = 1030) was conducted on aged subjects. Health Imageomics (n = 971) and IR0NMET (n = 175) were conducted in middle-aged subjects. Setting and participants: Participants were enrolled at Dr. Josep Trueta University Hospital facilities. The three cohorts included a total of 2176 subjects (mean age, 52 years; 48% men). Measurements: SF levels were measured by standard laboratory methods. Total Digits Span (TDS), and Phonemic Verbal Fluency (PVF) were used to assess executive function. Language function was assessed by semantic verbal fluency (SVF), attention by the Symbol Digit Modalities Test, and memory by the Memory Binding Tests - Total Free Recall and Total Delayed Free Recall. MRI was used to assess the iron content of the brain by R2*. Results: In subjects aged 65 years or older, SF levels were associated with increased TDS (β = 0.003, p = 0.02), PVF (β = 0.004, p = 0.01), and SVF (β = 0.004, p = 0.002) scores. After stratification by sex, these findings were significant only in men, where SF was associated with increased TDS (β = 0.003, p = 0.01), PVF (β = 0.004, p = 0.03), and SVF (β = 0.004, p = 0.009) scores. In middle-aged subjects, SF was also associated with increased SVF scores (β = 0.005, p = 0.011). Lastly, in men, SF levels were negatively associated with R2*, a surrogate marker of brain iron content, in both the left frontal inferior opercular area (r = -0.41, p = 0.005) and the right frontal inferior opercular area (r = -0.44, p = 0.002). Conclusions: SF is significantly and positively associated with cognition. In older people with low SF levels, iron supplementation may be a promising therapy to improve cognition.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Moron-Font, Miriam
  • Clos-Sansalvador, Marta
  • Calle, Alexandra
  • Morancho Retana, Anna
  • Rosell Novel, Anna
  • Monguió-Tortajada, Marta
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
Ingeniería de tejido cardíaco; Exosomas; Infiltración, Enginyeria de teixits cardíacs; Exosomes; Infiltració, Cardiac tissue engineering; Exosomes; Infiltration, The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation., This work was supported in part by grants from Fundació la Marató de TV3 (201516-10, 201502-30), the PERIS (SLT002/16/00234) and SGR programmes (2017-SGR-301 REMAR Group, 2017-SGR-1427 and 2017-SGR-483 ICREC Group) from the Generalitat de Catalunya, the Spanish Ministry of Economy and Competitiveness-MICINN (SAF2017-84324-C2-1-R; PID2019-110137RB-I00; PID2019-107145RB-I00), Instituto de Salud Carlos III (PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, and ICI20/00135), ISCIII-REDinREN (RD16/0009 Feder Funds), Red de Terapia Celular-TerCel (RD16/0011/0006), CIBER Cardiovascular (CB16/11/00403) projects as a part of the Plan Nacional de I + D + I, and it was co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER), AGAUR (2019PROD00122), Sociedad Española de Cardiología, Societat Catalana de Cardiologia, PCMR[C] and EoI Collaborative Projects on Regenerative Medicine 2019, and Institut Català de Salut (ICS). PG is sponsored by the PERIS (SLT002/16/00209) from the Generalitat de Catalunya. AR is supported by the Miguel Servet program (CPII15/00003) and research grants (PI16/00981) from the Instituto de Salud Carlos III, and co-financed by the European Regional Development Fund. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

  • Garrido, A.
  • Hoyos Colell, Montserrat
  • Arnan, Montserrat
  • Vives Polo, Susana
  • Oñate, Guadalupe
  • Bataller Torralba, Alex
  • Salamero, Olga
Prognostic impact; Mutation; Acute myeloid leukemia, Impacte pronòstic; Mutació; Leucèmia mieloide aguda, Impacto pronóstico; Mutación; Leucemia mieloide aguda, The negative prognostic impact of internal tandem duplication of FLT3 (FLT3-ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML-NPM1) is restricted to those with a higher FLT3-ITD allelic ratio (FLT3high; ≥0.5) and considered negligible in those with a wild-type (FLT3WT)/low ITD ratio (FLT3low). Because the comutation of DNMT3A (DNMT3Amut) has been suggested to negatively influence prognosis in AML-NPM1, we analyzed the impact of DNMT3Amut in FLT3-ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML-NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3Amut status did not have a prognostic impact, with comparable overall survival (P = .2). Prognostic stratification established by FLT3-ITD (FLT3WT = FLT3low > FLT3high) was independent of DNMT3Amut status. Measurable residual disease (MRD) based on NPM1 quantitative polymerase chain reaction was available for 94 patients. DNMT3Amut was associated with a higher number of mutated NPM1 transcripts after induction (P = .012) and first consolidation (C1; P < .001). All DNMT3Amut patients were MRD+ after C1 (P < .001) and exhibited significant MRD persistence after C2 and C3 (MRD+ vs MRD−; P = .027 and P = .001, respectively). Finally, DNMT3Amut patients exhibited a trend toward greater risk of molecular relapse (P = .054). In conclusion, DNMT3Amut did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1 despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention., This work was supported in part by the Biomedical Research Institute (IIB Sant-Pau) and the José Carreras Leukemia Research Institute as well as grants from the Catalan Government (PERIS SLT002/16/0043 and AGAUR 2017 SGR 139) and the Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain (PI17/01246, PI20/01621 and CM20/00061).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

  • Bataller Torralba, Alex
  • Garrido, A.
  • Guijarro, Francisca
  • Oñate, Guadalupe
  • Díaz-Beyá, Marina
  • Arnan, Montserrat
  • Salamero, Olga
Risk stratification; Acute myeloid leukemia, Estratificació del risc; Leucèmia mieloide aguda, Estratificación de riesgo; Leucemia mieloide aguda, The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and management of acute myeloid leukemia (AML) have become fundamental guidelines to assess the prognosis and postremission therapy of patients. However, they have been retrospectively validated in few studies with patients included in different treatment protocols. We analyzed 861 patients included in the Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias-12 risk-adapted protocol, which indicates cytarabine-based consolidation for patients allocated to the ELN 2017 favorable-risk group, whereas it recommends allogeneic stem cell transplantation (alloSCT) as a postremission strategy for the ELN 2017 intermediate- and adverse-risk groups. We retrospectively classified patients according to the ELN 2017, with 327 (48%), 109 (16%), and 245 (36%) patients allocated to the favorable-, intermediate-, and adverse-risk group, respectively. The 2- and 5-year overall survival (OS) rates were 77% and 70% for favorable-risk patients, 52% and 46% for intermediate-risk patients, and 33% and 23% for adverse-risk patients, respectively. Furthermore, we identified a subgroup of patients within the adverse group (inv(3)/t(3;3), complex karyotype, and/or TP53 mutation/17p abnormality) with a particularly poor outcome, with a 2-year OS of 15%. Our study validates the ELN 2017 risk stratification in a large cohort of patients treated with an ELN-2017 risk-adapted protocol based on alloSCT after remission for nonfavorable ELN subgroups and identifies a genetic subset with a very poor outcome that warrants investigation of novel strategies., This study was supported (in part) by Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (ISCIII) grants PI16/01027, PI19/1476, and PI20/01621; Health Research and Innovation Strategic Plan (PERIS) grant SLT002/16/00433 and research group support SGR 1395 and SGR 1655 from Generalitat de Catalunya; resident award “Emili Letang” 2019 (Hospital Clínic de Barcelona); and “Beca de Investigación FEHH 2019” (Fundación Española de Hematologia y Hemoterapia).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

  • Wang, Yifan
  • Bernhardy, Andrea J.
  • Nacson, Joseph
  • Krais, John J.
  • Tan, Yin-Fei
  • Nicolas, Emmanuelle
  • Llop Guevara, Alba
  • Balmaña Gelpí, Judith
  • Serra Elizalde, Violeta
Resistència terapèutica contra el càncer; Càncer d'ovaris, Resistencia terapéutica al cáncer; Cáncer de ovarios, Cancer therapeutic resistance; Ovarian cancer, BRCA1 mutant carcinomas are sensitive to PARP inhibitor (PARPi) therapy; however, resistance arises. BRCA1 BRCT domain mutant proteins do not fold correctly and are subject to proteasomal degradation, resulting in PARPi sensitivity. In this study, we show that cell lines and patient-derived tumors, with highly disruptive BRCT domain mutations, have readily detectable BRCA1 protein expression, and are able to proliferate in the presence of PARPi. Peptide analyses reveal that chemo-resistant cancers contain residues encoded by BRCA1 intron 15. Mechanistically, cancers with BRCT domain mutations harbor BRCA1 gene breakpoints within or adjacent to Alu elements in intron 15; producing partial gene duplications, inversions and translocations, and terminating transcription prior to the mutation-containing BRCT domain. BRCA1 BRCT domain-deficient protein isoforms avoid mutation-induced proteasomal degradation, support homology-dependent DNA repair, and promote PARPi resistance. Taken together, Alu-mediated BRCA1 gene rearrangements are responsible for generating hypomorphic proteins, and may represent a biomarker of PARPi resistance., This work was supported by the US National Institutes of Health (NIH) Grants P50 CA083638 and 5P30 CA006927, as well as R01CA214799, Susan Komen CCRCR17499048, and OC130212 Department of Defense to N.J., and a Pilot Award and Nested Teal Postdoctoral Scholar supported Y.W. (OC140040). We thank Drs. Judith Balmaña, Cristina Saura and Joaquin Arribas for providing materials. PDXs were established thanks to the GHD-Pink program, the FERO Foundation and the Catalan Agency AGAUR [2017 SGR 540]. V.S. is supported by the Instituto de Salud Carlos III (CP14/00228) and ALG by a PERIS fellowship from the Departament de Salut, Generalitat de Catalunya (SLT002/16/00477). Clovis Oncology supplied rucaparib. We are grateful to FCCC Genomics, Cell Culture and Cell Sorting facilities. We thank Hsin Yao Tang at the Wistar Proteomics facility for help with mass spectrometry.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Vigilancia epidemiológica intensificada de arbovirosis: primer caso de dengue autóctono en Cataluña (España), zona Metropolitana Norte de Barcelona, 2018-2019, Intensified epidemiological surveillance of arbovirosis: First case of native dengue fever in Catalonia (Spain), Northern Metropolitan Area of Barcelona, 2018-2019

  • Valerio, Lluís
  • Roure, Silvia
  • Benitez Diaz, Rosa Maria
  • Fernández-Rivas, Gema
  • Rivaya, Belén
  • Expósito, Carme
  • Salvador Velez, Fernando M
Arbovirosis; Vigilància epidemiològica; Espanya, Arbovirosis; Vigilancia epidemiológica; España, Arbovirosis; Epidemiologic surveillance; Spain, Objetivo Valorar los resultados obtenidos por una red de vigilancia epidemiológica y asistencial de arbovirosis compuesta por médicos y profesionales de enfermería de hospital y atención primaria (AP) formados en su identificación, confirmación diagnóstica y manejo clínico. Emplazamiento Zona Sanitaria Metropolitana Norte de Barcelona (1.400.000 habitantes; Cataluña, España) durante un año natural. Participantes Diecisiete médicos (7 de AP y 10 hospitalarios) más 4 enfermeros/as de AP. Tipo de estudio Estudio observacional prospectivo. Mediciones principales Se definieron variables demográficas, epidemiológicas (caso autóctono/importado, sospechoso/probable/confirmado) y asistenciales (síntomas, perfil serológico, periodo virémico). Resultados De los 34 pacientes identificados cumplían criterios de estudio 26 (76,5%) casos; de ellos, se confirmó alguna arbovirosis en 14 (53,8%): 13 fiebres dengues más 1 chikungunya. No se registraron casos de fiebre de zika. Existían antecedentes de viaje a zonas endémicas (23; 88,4%), pero no en 3 casos (11,6%), en los que se consideró la posibilidad de una transmisión autóctona; de ellos, se confirmó un caso de dengue. La incidencia estimada de arbovirosis fue de 0,4 (IC 95%: 0,33-0,51) casos × 10.000 hab./año, que, comparada con la incidencia estimada en la misma área geográfica durante el periodo 2009-2013 (0,19 casos × 10.000 hab./año; IC 95%: 0,07-0,31), mostró un incremento significativo (p = 0,044). Los pacientes en periodo de viremia al momento de la primera visita médica fueron 11 (42,3%). Conclusiones Un programa de vigilancia epidemiológica intensificada definido a nivel de AP y hospitalario es capaz de detectar significativamente más casos de arbovirosis importadas y transmitidas autóctonamente. Posiblemente asistimos a un aumento en la incidencia de arbovirosis importadas, por lo que las medidas encaminadas a su identificación y confirmación deben reforzarse., Objective To evaluate the results obtained by a surveillance network on arbovirosis composed by doctors and nurses located at hospitals and Primary Care trained in their identification, diagnostic confirmation and clinical management. Location North Metropolitan Area of Barcelona (1,400,000 inhabitants; Catalonia; Spain) during a calendar year. Participants Seven Primary Care and 10 hospital physicians plus 4 Primary Care nurses. Type of study A prospective observational study. Main measurements Demographic, epidemiological (autochthonous/imported, suspect/probable/confirmed case) and healthcare variables (symptoms, serological profile, viral period) were defined. Results Of the 34 patients identified, 26 (76.5%) met study criteria. Among them, any arbovirosis was confirmed in 14 (53.8%): 13 dengue plus 1 chikungunya fever. There were no cases of Zika fever. There was a history of travel to endemic areas 23 (88.4%), but not in 3 cases (11.6%) in which the possibility of an indigenous transmission was considered; of them, a case of dengue was confirmed. The estimated incidence of arbovirosis was 0.4 (95% CI: 0.33-0.51) cases × 10,000 hab/year which, when compared to the estimated incidence in the same geographical area during the period 2009-2013 (0.19 cases × 10,000 hab/year; 95% CI: 0.07-0.31), a significant increase was found ( P = .044). Patients within viremia period at the time of their first medical visit were 11 (42.3%). Conclusions An intensified epidemiological surveillance program defined at Primary Care and hospital levels is able to detect significantly more cases of imported and autochthonous arbovirosis. Possibly we are witnessing an increase in the incidence of imported arbovirosis and, thus, measures aimed at their identification and confirmation should be reinforced., La Plataforma Integral para control de las arbovirosis en Cataluña (PICAT) es un proyecto realizado con el apoyo del Departamento de Salud de la Generalitat de Catalunya y ha sido financiada mediante una beca del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, cod. exp. SLT002/16/00466.